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1 General Introduction 
  





Chronic kidney disease (CKD) is defined as gradual loss of kidney function over a period of 
3 months to years (Al Khodor and Shatat 2017; Levey et al. 2005). With comorbidities such 
as cardiovascular disease and infectious diseases (Al Khodor and Shatat 2017; Levey et al. 
2005), CKD is a worldwide health issue affecting millions of individuals every year. According 
to a report in 2005 by the Japanese Society of Nephrology, approximately 13.3 million people 
in Japan have CKD (Imai et al. 2009).  
In Japan, one of the leading causes of CKD is immunoglobulin A nephropathy (IgAN) 
(Tomino 2016). IgAN is an idiopathic disease which means despite years of research and 
advancement in medical science, the definite cause of the disease is unknown. To address 
this gap in the existing research and thus, advance the development of medical science in 
curing IgAN, our current work explores the salivary microbiome of IgAN patients in a 
Japanese cohort. For a better understanding of our research motivation, objectives and 
hypotheses, in this chapter we provide you with a brief background of IgAN disease, followed 
by an introduction to human salivary microbiome and how these two topics might be linked 
to each other. The last section of this chapter describes the motivation behind the research, 
and the objectives of this study. 
1.1 Overview of IgA Nephropathy 
a. Clinical description 
IgAN is the most common and prevalent form of glomerulonephritis worldwide and was 
first classified in 1968 by Jean Berger and his co-author Nicole Hinglais (Berger and 
Hinglais 1968; D'Amico 1987; Gharavi et al. 2000; Schena 1990). This is why IgAN is also 
addressed as Berger’s disease. IgAN is clinically characterized by the mesangial 
deposition of immunoglobulin A (IgA) and immunoglobulin G (IgG) complexes in the 
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kidney glomeruli (Moriyama et al. 2014; Tashakkorinia et al. 2021). Upon classification, 
IgAN was thought to be a benign disease involving the kidneys and the immune system. 
However, several decade-long survival analytical studies revealed that around 40% of the 
patients diagnosed with IgAN progressed towards end-stage renal disease (ESRD) within 
20 years of their diagnosis (Alamartine et al. 1991; D'Amico 1988; Koyama et al. 1997; 
Moriyama 2019). Another retrospective study conducted from 1974 to 2011 at a single 
center in Japan concluded that with about 50% of the IgAN patients progressing towards 
ESRD within 30 years of their diagnosis, IgAN can no longer be classified as a benign 
disease (Moriyama et al. 2014).  
b. Types of IgA Nephropathy 
Broadly there are two types of IgAN – primary IgAN and secondary IgAN.  
The primary IgAN, which is often addressed as only IgAN, is the idiopathic form of disease. 
Simply put this translates to absence of any underlying ailment or disease as a starting 
point for IgAN in the patient. 
The secondary IgAN is when IgAN is diagnosed upon biopsy of patients suffering from 
other diseases (Obrișcă et al. 2019). However, despite such observations in clinical 
settings, there is no concordant definition of secondary IgAN in the scientific literature 
(Saha et al. 2018).  
• Secondary IgAN – when IgAN and the underlying ailment is presumed to share 
common pathogenesis (Obrișcă et al. 2019). Underlying ailments for secondary 
IgAN reported till date are liver diseases (cirrhosis, hepatitis C virus, non-alcoholic 
steatohepatitis), hepatitis B virus (HBV) infection, human immunodeficiency virus 
(HIV) infection, inflammatory bowel diseases (IBD), psoriasis (Ahuja et al. 1998; 
Beaufils et al. 1995; Filiopoulos et al. 2010; Koçak et al. 2012; Lai et al. 1989; 
McGuire et al. 2006; Obrișcă et al. 2019; Saha et al. 2018; Trimarchi et al. 2001). 
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• Associated IgAN – when the relationship between the pathogenesis of IgAN and 
the underlying disease is unclear or presumed to be coincidental (Obrișcă et al. 
2019). Associated IgAN is often discussed in relation to non-Hodgkin and Hodgkin 
lymphoma (Obrișcă et al. 2019; Saha et al. 2018). 
In literature, secondary IgAN and associated IgAN are often clubbed together as 
secondary IgAN.  
c. Symptoms and clinical manifestations in IgA Nephropathy 
Symptoms in IgAN patients vary from asymptomatic microscopic hematuria or proteinuria 
to severe hypertension due to kidney damage (Lai et al. 2016; Rodrigues et al. 2017). 
Two most common phenotypes of IgAN are asymptomatic hematuria and progressive 
CKD (Rodrigues et al. 2017). Most of the IgAN patients in the early stages exhibit 
asymptomatic hematuria with minimal proteinuria (i.e., <0.5g/d) and this is usually 
diagnosed by routine screening programs like urinalysis (Rodrigues et al. 2017; Yamagata 
et al. 2008). In IgAN patients with progressive CKD, symptoms usually occur in the order 
of moderate to severe proteinuria, followed by hypertension and a decline in kidney 
function (Yuzawa et al. 2015). Gross macroscopic hematuria paired with non-specific 
mucosal infection (synpharyngitic macrohematuria) is a classic clinical syndrome 
associated with first presentation of IgAN (Lai et al. 2016; Rodrigues et al. 2017). This 
type of clinical manifestation is less frequent, occurring in about 10%-15% of the patients 
and is more common in patients aged under 40 (Ibels and Györy 1994; Rodrigues et al. 
2017). In these patients, microscopic hematuria is associated with fluctuating proteinuria 
and in less than 30% of these patients, the proteinuria levels are more than 1g per day 
(Lai et al. 2016). Nephrotic syndrome, primarily characterized by edema and proteinuria, 
is a rare clinical manifestation observed in about 5% of the IgAN patients (Lai et al. 2016; 
Rodrigues et al. 2017). 
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According to Mayo Clinic repository (MayoClinic 2019), the signs and symptoms 
for IgAN are as follows: 
• Tea or Cola-colored urine caused by red blood cells discharged in the urine 
• Recurrent episodes of tea or Cola-colored urine during or after an infection in the body. 
• Swelling (edema) in limbs 
• Proteinuria or foamy urine due to protein discharge into the urine 
• Severe pain in one or both sides at the back below the ribs 
• High blood pressure 
• Compromised immune system 
d. Pathogenesis of the IgAN patients 
The pathogenesis of IgAN is described by multi-hit hypothesis. Briefly, the multi-hit 
hypothesis model can be broken down into four steps or “hits” (Lai et al. 2016; Rodrigues 
et al. 2017; Suzuki et al. 2011; Wyatt et al. 1995). The mechanism of IgAN pathogenesis 
according to multi-hit model is shown in Fig. 1. 
(1) Hit 1 is the production of galactose-deficient IgA1 or Gd-IgA1. 
(2) Recognition of these antibodies by circulating anti-Gd-IgA1 antibodies is the Hit 2. 
(3)  The antigen-antibody complex or immune complex formation is the Hit 3. This step 
is considered to be vital for nephritogenicity of the Gd-IgA1. 
(4) Deposition of these immune complexes in the kidney glomeruli and activation of 
inflammatory responses in the mesangial cells is the Hit 4. 
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Activated mesangial cells overproduce and release components of extracellular matrix, 
angiotensin II, aldosterone, proinflammatory and profibrotic cytokines and several growth 
factors which in turn mediate renal injury and tubulointerstitial damage (Amore et al. 2000; 
Lai 2012; Lai et al. 2016; Novak et al. 2012; Wyatt et al. 1995). The renal injury 
characterized by complement activation, expansion of mesangial matrix, podocyte injury, 
and increased glomerular permeability is depicted by clinical manifestations such as 
hypertension, proteinuria, hematuria and reduced kidney functioning (Amore et al. 2000; 
Lai 2012; Lai et al. 2016; Novak et al. 2012; Wyatt et al. 1995). Each of these steps in the 
Fig. 1. Main mechanisms involved in the pathogenesis of IgAN. IgAN, 
Immunoglobulin A Nephropathy. IC, Immune complex. Gd-IgA1, galactose-deficient 
Immunoglobulin A 1. (Adapted by permission from Oxford University Press. Clinical 
Kidney Journal. Rojas-Rivera, J et al. Rapidly progressive IgA nephropathy: a form of 
vasculitis or a complement-mediated disease? Copyright © 2021 Oxford University 
Press. 2015) 
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multi-hit model for IgAN pathogenesis is affected by a varied number of environmental 
and genetic factors, which in turn affect disease progression and susceptibility of IgAN in 
humans (Rodrigues et al. 2017).  
e. Diagnosis  
There is no specific laboratory test available for screening IgAN patients. While clinical 
assessments are used to determine the need for kidney biopsy, kidney biopsy or 
histopathological assessment is the confirmatory test for IgAN diagnosis.  
Urinalysis: Asymptomatic hematuria or proteinuria is the most common clinical 
manifestation in the IgAN patients (Yuzawa et al. 2015). The best way to detect this is 
by urinalysis.  A first voided (first morning) urine sample is examined using unstained 
bright-field microscope or phase contrast microscope (Lai et al. 2016). Renal injury 
and glomerular bleeding are detected by the presence of red blood cell casts and 
dysmorphic red blood cells in the urine sample under microscope (Lai et al. 2016). 
According to the Clinical Guidelines for IgAN version 3 by Japan nephrology society, 
persistent microscopic hematuria is an essential observation and intermittent or 
persistent proteinuria is a frequently associated observation in the urinalysis of IgAN 
patients (Yuzawa et al. 2015).  A timed urine collection and a spot urine protein to 
creatinine ratio measurement are different ways to quantify proteinuria (Lai et al. 2016). 
The Clinical Practice Guidelines for IgAN by Japan Nephrology Society recommends 
conducting at least 3 urinalyses of the subject before concluding the urinary 
abnormality (Yuzawa et al. 2015). The guidelines also instruct that at least 2 of these 
urinalyses should include analysis of the urinary sediment in addition to qualitative 
dipstick test (Yuzawa et al. 2015).  
Blood biochemical analysis: Despite the absence of IgAN specific blood based 
diagnostic test, elevated serum total IgA levels suggests IgAN when paired with other 
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findings such as microscopic or macroscopic hematuria and proteinuria (Lai et al. 
2016; Yuzawa et al. 2015). Additionally, an elevated levels of serum IgAN/C3 ratio is 
often used as a differential diagnostic tool for IgAN detection (Yuzawa et al. 2015). 
Large cohort study of white patients in the United States reported serum levels of Gd-
IgA1 as useful blood biomarker for diagnosing sporadic IgAN (Lai et al. 2016; Yuzawa 
et al. 2015).  
Secondary markers: According to the IgAN pathogenesis, high levels of IgA immune 
complexes are common in IgAN; however, this finding has limited diagnostic use on 
its own. Previous studies identified urinary cytokines and chemokines such as mono-
cyte chemoattractant protein 1 (MCP1; also known as CCL2), IL-6, IL-8 and epidermal 
growth factor as predictors of renal function outcome in IgAN (Lai et al. 2016; Stangou 
et al. 2009). GWAS of renal miRNA expression has identified a number of novel 
miRNAs related to IgAN pathogenesis (Lai et al. 2016; Szeto and Li 2014). For 
example, miR-148b is connected with production of Gd-IgA1 and is thus a potential 
biomarker of IgAN in the early stages of the disease(Szeto and Li 2014). Similarly, an 
antifibrotic miRNA, miR-29c can be a biomarker for diagnosing later stages of IgAN 
progression (Szeto and Li 2014). However, most of these secondary biomarkers are 
still at the research stage, which explains the lack of specific blood or urine test for 
IgAN diagnosis. 
Kidney function assessment: More than initial diagnosis, renal function assessment 
every 6 months is essential for monitoring the stage of disease progression. 
Endogenous creatinine clearance and/or estimated glomerular filtration rate (eGFR) 
are common parameters in the renal function assessment. Renal function at the 
baseline is considered to have prognostic implications (Lai et al. 2016).  Clinical 
outcome of patients with an eGFR less than 60 ml/min/1.73 m2 at the time of renal 
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biopsy is much worse than those with normal eGFR (90 -120 ml/min/1.73m2) at the 
baseline (Lai et al. 2016). In addition to the renal function, the degree of histological 
Fig. 2. Renal biopsy findings in a patient with IgA nephropathy. a | Light 
microscopy image of a normal glomerulus (Jones’ silver stain; 200× magnification). 
b | Light microscopy image of a glomerulus showing mild increase in the mesangial 
matrix and cellularity (arrow; Jones’ silver stain; 200× magnification). c | 
Immunofluorescence image of a glomerulus showing heavy granular staining of 
IgA in the mesangium (200× magnification). d | Transmission electron micrograph 
of the mesangium demonstrating electron-dense mesangial deposits (arrows; 
5,000× magnification). (Adapted by permission from Springer Nature. Nature 
Reviews Disease Primers. Lai, K., Tang, S., Schena, F. et al. IgA nephropathy. 
Copyright © 2021 Springer Nature Limited. 2016) 
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injury detected by pathological tests is of prognostic value in IgAN diagnosis. 
Kidney biopsy and pathological features: High serum IgA/C3 ratio, persistent 
microscopic hematuria paired with proteinuria, elevated levels of serum IgA, and 
macroscopic hematuria with mucosal infection are strong indicators of IgAN in clinical 
settings (Yuzawa et al. 2015). However, kidney biopsy is the gold standard for 
definitive diagnosis of IgAN (Lai et al. 2016; Suzuki 2019). Renal biopsy is also 
essential for assessment of disease progression and prognosis in IgAN patients and 
thus helps in long term patient management (Suzuki 2019; Yuzawa et al. 2015).  
The features of IgAN presented as seen by light microscopy of kidney biopsy 
specimens varies greatly among patients and even within individual samples (Wyatt 
and Julian 2013). The clinical presentation of IgAN in biopsy specimen ranges from 
mesangial cell proliferation (Fig. 2a,b) to crescentic lesions or advanced sclerosing 
appearance (Lai et al. 2016). The diagnostic hallmark of IgAN is presence of 
predominant IgA deposits (Fig. 2c) in the glomerular mesangium, with prevalent λ-light 
chains (Lai et al. 2016; Wyatt and Julian 2013). The IgA deposits are rarely monoclonal 
and often found in congregation with IgG, IgM or both (Lai et al. 2016; Wyatt and Julian 
2013). In addition to IgA deposits, some other histopathological features are noted in 
the biopsy specimens from IgAN patients using light microscopy. Increase in the 
mesangial matrix along with hypercellularity are common findings. Glomerular lesions 
including focal necrosis, segmental scarring and crescents in the Bowman’s capsule 
are also reported from IgAN renal biopsy specimens. Electron-dense material 
corresponding to the immune deposits are specifically located by immunofluorescence 
electron microscopy (Lai et al. 2016; Wyatt and Julian 2013). The deposits are 
commonly observed in the mesangium, adjacent to activated mesangial cells and 
occasionally in subendothelial areas of glomerular basement membranes associated 
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with proliferative lesions (Fig. 2d) (Lai et al. 2016; Wyatt and Julian 2013). In rare 
occasions, subepithelial deposits are also observed (Lai et al. 2016). Immune deposits 
are observed in other glomerular diseases such as lupus nephritis and Henoch- 
Schönlein purpura (Lai et al. 2016). Lupus nephritis and IgAN can be distinguished 
from each other using staining for the immunoglobulins (IgA, IgG and IgM) and staining 
for classic complement pathway proteins (C1q and C3) present in deposits, tubule 
reticular aggregates (interferon fingerprints) and the patient’s clinical history (Lai et al. 
2016). Renal pathology of Henoch–Schönlein purpura cannot be distinguished from 
IgAN except for a greater propensity to produce necrotizing crescentic 
glomerulonephritis (Lai et al. 2016).  
Despite the effectiveness in IgAN diagnosis, renal biopsy is not recommended by 
many clinical guidelines for patients with mild proteinuria or isolated hematuria which 
may in turn lead to poor prognosis of IgAN in the long run. Other reasons of infrequent 
renal biopsies may stem from procedural risk of this invasive tool or limitations of 
health insurance coverage (Suzuki 2019). The histopathological findings from renal 
biopsy is time point dependent and may be inconclusive when performed during the 
early stages of IgAN (Chauveau and Droz 1993; D'Amico 2004; Suzuki 2019). This 
could lead to poor prognosis in chronic IgAN patients (Suzuki 2019). 30%-40% of the 
IgAN patients with mild proteinuria and mild histological lesions at the time of kidney 
biopsy exhibit disease progression marked by rapidly progressing proteinuria 
(Donadio and Grande 2002; Imai and Miura 2012; Suzuki 2019; Szeto et al. 2001). 
Therefore, noninvasive disease biomarkers for diagnosis and assessment of real-time 
disease progression is the need of the hour (Suzuki 2019). 
f. Classification 
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There was a need for a global scoring system made up of limited number of 
pathologic parameters which is highly reproducible among pathologists, predictive of renal 
outcomes and which can be used to analyze and grade the kidney biopsy specimens for 
IgAN diagnosis. The Oxford classification is one of the first scoring system to receive a 
global consensus for it usage in IgAN diagnosis (Moriyama 2019). The Oxford 
Classification of IgAN consist of four pathologic parameters (MEST), which were 
independently associated with clinical outcome: mesangial proliferation (M), endocapillary 
proliferation (E), segmental sclerosis (S), and tubular atrophy and interstitial fibrosis (T) 
(Markowitz 2017; Rodrigues et al. 2017). Several studies have reported that pairing up 
Table 1. Updated Oxford Classification of IgAN and description of MEST-C criteria. 
M, Mesangial hypercellularity; C, crescents; E, endocapillary hypercellularity; s, segmental 
glomerulosclerosis; T, tubular, atrophy/interstitial fibrosis. (Reprinted with permission from 
Springer Nature. Nature Reviews Nephrology. Markowitz, G. Updated Oxford Classification 
of IgA nephropathy: a new MEST-C score. Copyright © 2021 Springer Nature Limited. 
2017) 
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the MEST score with clinical data collected at the time of biopsy (proteinuria, creatinine, 
mean arterial pressure) significantly improved the predictive accuracy in identifying 
patients at higher risk of poor prognosis (Barbour et al. 2016; Rodrigues et al. 2017). The 
study that developed the Oxford Classification of IgAN system recruited patients with 
proteinuria ≥0.5 g/d, eGFR ≥ 30 ml/min/1.73 m2 at renal biopsy, and at least 1 year of 
follow-up (Rodrigues et al. 2017). These criteria excluded patients with most rapidly 
progressing form of IgAN, which was characterized as crescentic forms of IgAN 
(Markowitz 2017). Crescents represent a severe form of renal injury in which cellular 
proliferation and infiltration of white blood cells lead to rupture of the glomerular basement 
membrane and successive extracapillary proliferation of parietal and visceral epithelial 
cells and intermixed mononuclear white blood cells within the Bowman’s capsule 
(Markowitz 2017). This proliferation confined by the rounded contour of the Bowman 
capsule looks like a crescent moon (Markowitz 2017). Various studies emphasized on the 
importance of including crescent in the MEST score system. Following the results from a 
2017 study, crescent (C) score was included in the Oxford Classification of IgAN and the 
updated classification system called MEST-C score system is presented with 
Table 2. Japanese Histological Grading Classification. Active lesion (A) indicates 
cellular crescent and fibrocellular crescent; chronic lesion (C) indicates global sclerosis, 
segmental sclerosis, fibrous crescent. (Reprinted from Tomino, Y. Diagnosis and treatment 
of patients with IgA nephropathy in Japan. Kidney Res Clin Pract. 2016;35(4):197-203. doi: 
10.1016/j.krcp.2016.09.001 Published under the terms of CC BY-NC-ND 4.0.) 
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corresponding definitions of the parameters in Table 1. In Japan, the third edition of the 
Clinical Practice Guidelines for IgA Nephropathy is also used for histological classification 
in addition to the Oxford Classification (Table 2) (Matsuo et al. 2011; Moriyama 2019; 
Tomino 2016; Yuzawa et al. 2015).  
g. Risk factors for IgA Nephropathy 
There are several risk factors associated with IgAN. Broadly these can be grouped into 
clinical findings and histological findings (Moriyama 2019). Risk factors associated with 
IgAN and ESRD are as follows (Moriyama 2019): 
• Clinical findings 
o Deteriorated renal function  
o Higher amount of urinary protein excretion  
o Hypertension  
o Sex (male)  
o Age (older, younger) 
o Hematuria (mild, severe, without macrohematuria) 
o Higher uric acid  
o Lower serum albumin or total protein  
o Dyslipidemia (higher total cholesterol, LDL-cholesterol, and triglyceride) 
o Obesity  
o Higher serum IgA or IgA/C3 
o Anemia 
• Histological findings 
o Active lesions 
▪ Cellular and fibrocellular crescent, endothelial hypercellularity, 
mesangial hypercellularity, tuft necrosis 
P a g e  | 15 
 
 
o Chronic lesions 
▪ Global sclerosis, segmental sclerosis, fibrous crescent, glomerular 
tuft adhesion to Bowman’s capsule, mesangial matrix increase, 
interstitial fibrosis and tubular atrophy  
o Depositions 
▪ IgG, IgA, IgM, C3, C4d 
h. Epidemiology of IgA Nephropathy  
Prevalence of IgAN varies with geography. Biopsy registry and dialysis registries are two 
key sources used in the epidemiological studies of IgAN. According to biopsy and organ 
replacement registries, Pacific Asian regions have higher incidence of IgAN(Rodrigues et 
al. 2017). Compared to only 1.3% autopsies of the deceased in Finland, lanthanic 
mesangial IgA deposits were observed in 15.6% of deceased donors in Japan (Rodrigues 
et al. 2017; Suzuki et al. 2003; Varis et al. 1993). Using biopsy registry data to understand 
the disease distribution according to geography and ethnicity will not always paint the real 
picture due to differences in the clinical practices like routine screening program vs clinical 
referrals (Rodrigues et al. 2017). Australia is the country with highest incidence rate of 
IgAN (105 cases pmp/y) followed by Japan (39-45 cases pmp/y) (Schena and Nistor 
2018). The prevalence of IgAN is often underestimated in low-income regions owing to 
differences in guidelines for performing kidney biopsies and access to quality health care 
(Lai et al. 2016). Efficiency of the health care system depends on the socioeconomic 
status. In developing countries, individuals with asymptomatic urinary abnormalities do 
not benefit from early referral to nephrologists since the public health care resources are 
largely dedicated to more severe clinical presentations such as nephrotic syndrome (Lai 
et al. 2016). On the other hand, in many developed countries in Asia, routine urine 
screening tests are conducted in schools which explains higher frequency of IgAN cases 
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in these countries (Cho et al. 2013; Imai et al. 2007; Lai et al. 2016). Additionally, in a 
country like Japan with rapidly decreasing number of children and young adults, IgAN, 
which more commonly affects these age groups, is a severe burden socially as well as 
economically(Schena and Nistor 2018).  
Ethnicity is one of the factors affecting the prevalence of IgAN across the globe. 
Several GWAS on IgAN identified genetic susceptibility loci associated with the disease 
and the prevalence of these risk alleles varied with ethnicity, with highest frequency in 
people with East Asian origin (Lai et al. 2016; Sallustio et al. 2019). Furthermore, meta-
analysis of GWAS reported a higher frequency of protective alleles in Europeans than in 
Asians, both in controls as well as IgAN patients (Yeo et al. 2019; Yeo et al. 2018b). 
Prevalence of IgAN also varies with age. Studies have reported a higher incidence rate in 
children and young adults (less than 30 years old) (Lai et al. 2016; Pontier and Patel 1994; 
Yokoyama et al. 2012). However, this frequency may also be influenced by routine 
urinalysis which is more common for children and young adults as compared to the elderly 
(more than 65 years of age) (Lai et al. 2016). Earlier studies indicated a male 
predominance in IgAN patients of Caucasian origin (Schena 1990). Additionally, 
according to the 2005 nationwide survey of IgAN in Japan by Ministry of Health, Labor 
and Welfare of Japan, male gender is one of the predictive factors associated with IgAN 
prognosis (Tomino 2016). 
i. Treatment and therapeutic strategies 
Japan has an established system of annual health check-ups, especially for children and 
young adults, which include urinalysis screening test and therefore, a varied range of 
stages of IgAN is observed and are managed using wide variety of treatments in Japanese 
population (Matsuzaki et al. 2013).However, there are no specific treatment regime for 
IgAN owed to its complex nature of pathogenesis varying across geographical regions 
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(Selvaskandan et al. 2019). There is a marked heterogeneity in the IgAN management 
practices adopted internationally but they can be typically grouped into supportive 
management, immunosuppression and tonsillectomy (Selvaskandan et al. 2019). The 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines list out treatment 
regimens for IgAN across the globe (KDIGO Clinical Practice Guideline for 
Glomerulonephritis Chapter 10: Immunoglobulin A nephropathy  2012) whereas clinical 
guidelines for IgAN (Version 3) are followed for IgAN management in Japan (Matsuo et 
al. 2011; Yuzawa et al. 2015). According to regional guidelines of Japan, corticosteroid 
therapy, steroid pulse therapy paired with tonsillectomy (TSP), non-steroidal 
immunosuppressants, antiplatelet agents, n-3 fatty acids (fish) oil are various types of 
therapeutic strategies recommended at different stages of IgAN progression (Matsuo et 
al. 2011; Yuzawa et al. 2015).  
Conventional therapies and supportive management: Both the guidelines (KDIGO 
and Japanese guidelines) recommend the use of renin-angiotensin system (RAS) 
inhibitors, such as an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin 
II-receptor blocker (ARB), for treating IgAN patients with proteinuria ≥ 1 g/day (Lai et al. 
2016; Selvaskandan et al. 2019). A meta-analysis of 11 randomized control trial (RCT) 
reported that ACE-I/ARBs succeeded in reducing proteinuria, lowering blood pressure 
and subsequently reducing the renal function decline rate (Selvaskandan et al. 2019). 
Interestingly, this observation still held true when 6 out of the 11 studies were removed 
from meta-analysis due to low Jadad score (Cheng et al. 2009; Selvaskandan et al. 2019). 
Studies suggest the combination of ACE-I and ARB for greater benefits (greater reduction 
in urinary protein levels, blood pressure levels and thus, better kidney outcome) in adult 
as well pediatric IgAN patients (KDIGO Clinical Practice Guideline for Glomerulonephritis 
Chapter 10: Immunoglobulin A nephropathy  2012; Russo et al. 1999; Yang et al. 2005). 
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It has also been noted that sodium restriction enhances the antiproteinuric effects of RAS-
I in IgAN management (Selvaskandan et al. 2019; Suzuki et al. 2009).A small cross-over 
study reported that low-sodium diets reduced levels of urinary proteins even in IgAN 
patients with normal blood pressure (Konishi et al. 2001; Selvaskandan et al. 2019). 
Japanese guidelines recommend limiting salt intake to 3-6g/day in order to lower risk of 
cardiovascular disease and progression to ESRD in IgAN patients (Yuzawa et al. 2015). 
A RCT noted that weight loss led to decrease in proteinuria in overweight primary IgAN 
patients (Kittiskulnam et al. 2014). Another study noted that overweight/obese patients 
were more likely to have high blood pressure, worse eGFR, proteinuria and greater 
prevalence of CKD stage 3 or higher (Rodrigues et al. 2017). Therefore, Japanese 
guidelines strongly recommends IgAN patients with BMI ≥ 25 to lose weight (Yuzawa et 
al. 2015). Studies have identified smoking as one of the risk factors in IgAN disease 
progression (Selvaskandan et al. 2019; Yamamoto et al. 2010). Additionally, in study 
cohorts across the globe, current and past smoking history is associated with renal 
dysfunction, increased proteinuria and albuminuria in IgAN patients (Yuzawa et al. 2015). 
Furthermore, smoking is also a consistent risk factor for upper respiratory tract diseases 
such as chronic obstructive disease (COPD), lung cancer, and cardiovascular ailments 
(Yuzawa et al. 2015). Given these evidences, Japanese guidelines strongly recommends 
IgAN patients to stop smoking (Yuzawa et al. 2015). Fish oil is rich in omega 3 fatty acids 
which have anti-inflammatory properties. It is hypothesized that fish oil may reduce 
inflammations in the kidney and thus provide a supportive care when used in combination 
of other therapies like RAS-I (Lai et al. 2016). Despite weak scientific evidences in support 
of beneficiary effects of fish oil in IgAN patients, both KDIGO and Japanese guidelines 
suggests its use in treating IgAN patients, especially those with persistent proteinuria even 
after optimized supportive management of the disease (KDIGO Clinical Practice Guideline 
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for Glomerulonephritis Chapter 10: Immunoglobulin A nephropathy  2012; Selvaskandan 
et al. 2019; Yuzawa et al. 2015). 
Immunosuppressive therapy: Various types of immunosuppressive agents are often 
prescribed to IgAN patients such as corticosteroids, cyclophosphamide, azathioprine and 
mycophenolate mofetil (Selvaskandan et al. 2019). Both KDIGO and Japanese guidelines 
suggest a treatment course of corticosteroids however the patients’ criteria is different for 
both guidelines. KDIGO suggests a 6-month long steroid therapy course for IgAN patients 
with persistent proteinuria of more than 1g/day and eGFR of more than 50 ml/min/1.73m2 
despite adequate ACEI or ARB usage and control for hypertension (KDIGO Clinical 
Practice Guideline for Glomerulonephritis Chapter 10: Immunoglobulin A nephropathy  
2012; Lai et al. 2016). Japanese guidelines recommend steroid therapy to IgAN patients 
with urinary protein more than 1g/day and eGFR more than 60ml min/1.73m2 despite 
supportive care (Lai et al. 2016). However, the use of corticosteroids for IgAN treatment 
often comes at the expense of more adverse events such as infections, weight gain, and 
disturbances in the glucose metabolism (Feehally 2017; Rauen et al. 2018; Selvaskandan 
et al. 2019). This was noted by STOP-IgAN study which also reported that higher rate of 
clinical remission is associated with corticosteroid therapy compared to supportive 
therapy (Feehally 2017; Rauen et al. 2018; Selvaskandan et al. 2019). Findings of RCTs 
suggest that corticosteroid intervention for a 6 month period may have a “legacy effect” 
with sustained benefits (like decline in the risk of progressive renal dysfunction) even after 
cessation of the treatment in the IgAN patients (Pozzi et al. 2004; Pozzi et al. 1999; 
Rodrigues et al. 2017).   
Tonsillectomy or Tonsillectomy with steroid-pulse therapy (TSP): Tonsillectomy is 
more commonly recommended by nephrologists in Asia as compared to Europe 
(Selvaskandan et al. 2019) Studies from Asian cohorts suggests an association between 
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reduction in urinary protein levels and tonsillectomy and highest benefits were noted when 
tonsillectomy was paired with corticosteroids (Kawamura et al. 2014; Komatsu et al. 2008; 
Matsumoto et al. 2018; Selvaskandan et al. 2019; Xie et al. 2003b). Retrospective studies 
on European cohorts found no benefit associated with tonsillectomy in IgAN patients 
(Selvaskandan et al. 2019). Given the lack of randomized trials about tonsillectomy of 
IgAN patients , KDIGO does not recommend tonsillectomy or TSP for IgAN management 
(KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 10: Immunoglobulin A 
nephropathy  2012). On the other hand, Japanese guidelines suggest tonsillectomy in the 
early stages of the disease irrespective of medical history of tonsilitis in the IgAN patient 
(Selvaskandan et al. 2019; Yuzawa et al. 2015). According to immunological studies, 
production of Gd-IgA1 is induced by mucosal infections and microbial antigen present in 
the tonsillar crypts are often associated with remission of IgAN after kidney transplantation 
(Lai et al. 2016). Thus by affecting the Hit 1 (production of Gd-IgA1) in IgAN pathogenesis 
model, tonsillectomy derails renal dysfunction which can be noted by improvement in 
urinary findings (Yuzawa et al. 2015).  
1.2 Overview of human salivary microbiome 
a. Definition  
Human body is home to trillions of microorganisms and genetic pool of all these microbes 
put together is known as human microbiome (Turnbaugh et al. 2007). The oral 
microbiome is defined as a collective of complex and diverse microbial communities living 
in the human oral cavity (Acharya et al. 2017a). According to human oral microbiome 
database (HOMD), the oral microbiome is one of the most diverse community of the 
human body and contains about 500-700 bacterial species (Acharya et al. 2017a; Chen 
et al. 2010; Huttenhower et al. 2012; Shaw et al. 2017; Wade 2013).  
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Saliva is sterile at the time of secretion from salivary glands into the oral cavity 
(Belstrom 2020). Salivary microbiome is the conglomeration of genetic material of the 
microbes that shed into the saliva from adherent epithelial cells of oral mucosa, dental 
plaque, tongue, throat and other distinct ecological niches of the oral cavity (Dawes 2003). 
Therefore, characterizing salivary microbiome will provide a deeper understanding of the 
workings of oral microbiome (Belstrom 2020; Shaw et al. 2017; Takeshita et al. 2016).  
b. Role of salivary microbiome in human health and disease  
Unlike gut microbiome, salivary microbiome composition is largely consistent with little 
variations across the globe (Nasidze et al. 2009; Shaw et al. 2017). The salivary 
microbiome structure established early in life is able to persist for several years (Shaw et 
al. 2017). Environmental factors such as lifestyle practices and living space also impacts 
the composition of salivary microbiome. For example, salivary microbiome of twins 
became increasingly less similar as they grew from babies to adults and lived in separate 
households (Stahringer et al. 2012). Instead of genetic makeup, cohabiting is one of the 
dominant factors that affect both salivary as well as gut microbiome composition (Shaw 
et al. 2017). This may help unravel the familial aggregation of diseases such as IBD 
(Nunes et al. 2011; Shaw et al. 2017) or CKD (Carlassara et al. 2021) that have an 
environmental component. Climate and diet are other environmental factors that affect 
the salivary microbiome composition (Belstrom 2020; De Filippis et al. 2014; Lassalle et 
al. 2018; Li et al. 2014a; Shaw et al. 2017). The diet patterns also affects the functionality 
of salivary microbiome (Lu et al. 2019). Salivary microbiota of tobacco smokers shifted 
from before drinking green tea to after drinking green tea and was marked by shifts in 
abundance of Streptococcus and Staphylococcus. The study inferred from these findings 
that salivary microbiota is involved in processing food extracts and affect carcinogenesis 
(Adami et al. 2018; Lu et al. 2019). Oral cavity is subject to frequent internal and external 
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perturbations as compared the gut mucosa (Marsh 2018). These ecological perturbations 
have made the salivary microbiome resilient to stress such as antibiotic therapy (Rosier 
et al. 2018; Shaw et al. 2017; Zaura et al. 2015).  
Early life development of salivary microbiome is influenced by ecological factors 
such as mode of delivery, duration of breastfeeding and antibiotic therapy and changes 
in the colonization pattern during this developmental stage (1st year of a baby’s life) may 
have long-term consequences for oral and systemic health (Belstrom 2020; Dzidic et al. 
2018). Salivary microbiome composition is also affected by age, with the most active 
window for increase in species richness being from 6 to 18 months (Lif Holgerson et al. 
2020). Interestingly, individuality in the salivary microbiota transformation materializes 
within the first few months of life(Lif Holgerson et al. 2020). Maturation and final 
homeostasis of salivary microbiome was influenced by determinants such as socio-
economic conditions, environmental and cultural factors, host biology and genetics(Lif 
Holgerson et al. 2020). The salivary microbiome attains diversity within 2 days after birth 
and remains in a continuous variable form up until 5 years (Lif Holgerson et al. 2020), and 
these can be paralleled with the rapid developmental changes as a baby grows to become 
a child. The salivary microbiome structure may also be affected by individual’s body-size 
and gender (Raju et al. 2019). The successive organization of the salivary microbiome is 
niche dependent and distinct in health and disease (Zenobia et al. 2021). Mucins and 
proline rich proteins in the saliva helps in biofilm formation as well as clearance of bacteria 
from oral surfaces (Freire et al. 2021; Zenobia et al. 2021). Initially the microbes interact 
with each other using quorum sensing pathways and adhere to the hard and soft tissue 
surfaces in the oral cavity. However host factors like cytokines regulate the biofilm 
formation to establish immune homeostasis(Zenobia et al. 2021).  
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1.3 Salivary microbiome and systemic diseases 
Salivary microbiota is closely associated with and sensitive to host physiological state. For 
example, circadian oscillations are observed in salivary microbiome which is correlated with 
the host circadian rhythm (Takayasu et al. 2017). Dysbiosis of salivary microbiome are 
linked with various oral and systemic diseases. The nature of dysbiosis in salivary 
microbiome is different in diseases involving the immune system, owing to the connection 
between immune homeostasis and microbiome (Acharya et al. 2017a). Chronic 
inflammatory disease states are correlated with burst of salivary opportunistic 
Grammaproteobacteria (Acharya et al. 2017a; Acharya et al. 2017b; Diaz et al. 2013; 
Schuurhuis et al. 2016). In cirrhosis patients with hepatic encephalopathy, salivary 
Enterobacteriaceae are negatively associated with anti-inflammatory cytokine IL-10 (Bajaj 
et al. 2015), whereas it is positively associated with proinflammatory IL-1β in healthy 
individuals (Acharya et al. 2017b). HIV disease status is associated with Haemophilus, 
Porphyromonas, Treponema, and Eubacterium (Kistler et al. 2015). Furthermore, there 
was a shift in salivary microbiome in HIV patients who underwent retroviral therapy, 
presented by increase in Prevotella, Fusobacterium, Capnocytophaga, Campylobacter and 
simultaneous decrease in Aggregatibacter (Acharya et al. 2017a; Li et al. 2014b). Increase 
in abundance of Prevotella is associated with pro-inflammatory Th-17 responses in chronic 
inflammatory disease cohort (Larsen 2017), IL-1β activity in healthy individuals (Acharya et 
al. 2017b) as well as in IBD patients (Said et al. 2014).  
On other end of immunological disease spectrum, similar patterns of dysbiosis in 
salivary microbiome is noted in autoimmune diseases (Acharya et al. 2017a). Lactobacillus 
salivarius is enriched in the rheumatoid arthritis patients (Zhang et al. 2015); similarly, 
higher abundance of Lactobacillus was noted in celiac disease (Tian et al. 2017).  
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From these findings we can infer that there is an intricate balance between host 
immune system and salivary microbiome. Therefore, characterizing the salivary 
microbiome specific to diseases may help in deeper understanding of disease 
pathogenesis and progression.  
1.4 Motivation, objectives and hypotheses 
a. Motivation 
With rapidly aging population and ever rising numbers of chronic dialysis patients (Masakane 
et al. 2018), IgAN is a major health burden upon the Japanese population. A confirmed 
diagnosis of the disease is obtained only after a highly-invasive procedure of renal biopsy 
(Tomino 2016). Keeping in mind the risk of performing a renal biopsy in the population such 
as the elderly, we understood the need to expedite the development of a non-invasive and 
efficient tool for IgAN diagnosis. 
Several genome-wide association studies (GWAS) on large cohorts reported that 
genetics only account for about 5% of the disease risk in IgAN (Sallustio et al. 2019). Thus, 
as we mentioned in section 1.1, various other factors are associated with the pathogenesis 
and maintenance of immune reactions in IgAN (Sallustio et al. 2019). IgAN patients often 
present gross hematuria in association with upper respiratory tract infections or 
gastrointestinal infections (Haas 2007; Park et al. 2020; Wyatt and Julian 2013; Wyatt et al. 
1995). Additionally, GWAS studies of IgAN patients identified several significant loci 
associated with the maintenance and functioning of the mucosal barrier (Kiryluk et al. 2014; 
Park et al. 2020). These findings indicate that mucosal immune system plays an important 
role in the IgAN pathogenesis (Sallustio et al. 2019). 
Given the co-evolution of the immune system and commensal microbiota, 
especially at the mucosal surfaces, microbiota is linked with maintenance of immune 
homeostasis and defense against pathogens (Bain and Cerovic 2020). The mucus layer 
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provides nutrients and a suitable platform for growth and sustenance of the commensal 
microbes, which in turn is the foundation of host-microbiota relationships (Bäckhed et al. 
2005; Li et al. 2015; Martin et al. 2012; Nakajima et al. 2018). This symbiotic relationship 
is clearly understood if we focus on the interactions between commensal microbiota and 
mucosal-associated lymphoid tissue (MALT). The microbiota is essential for the 
development of the MALT and in turn, MALT regulates the microbiota composition of 
mucosal surfaces like gut or oral cavity (Nakajima et al. 2018; Sallustio et al. 2019). IgA 
and more specifically, secretory IgA that originates from MALT plays an important role in 
maintaining the homeostasis at the mucosal surfaces(Li et al. 2020; Sallustio et al. 2019) . 
Studies have also reported that IgA secretion is induced and regulated by the commensal 
microbes (Macpherson and Harris 2004; Pabst et al. 2016). In humans, mucosal layer 
starts at the oral cavity and the inhabitants of oral mucosa, the salivary microbiome 
consisting of more than 200 species (Krishnan et al. 2017), plays indispensable roles in 
regulating and maintaining the mucosal immunity (Moutsopoulos and Konkel 2018). 
Changes in salivary microbiome in terms of composition and diversity reflects 
inflammatory responses and microbial dysbiosis in the gut (Bajaj et al. 2015; Abe et al. 
2018). Several studies have also noted that salivary microbiome is a potential source of 
diagnostic biomarkers for several immunological diseases such as rheumatoid arthritis 
(Chen et al. 2018), celiac disease (Francavilla et al. 2014), primary sclerosing cholangitis 
(Iwasawa et al. 2018), colorectal cancer (Flemer et al. 2018), pancreatic cancer (Coit et 
al. 2016; Torres et al. 2015) and CKD (Hu et al. 2018). Additionally, the simplicity and 
inexpensiveness of the sample collection procedure paired with its low risk factor are 
advantageous for profiling salivary microbiome of IgAN patients to discover microbial 
biomarkers for IgAN diagnosis (Hemadi et al. 2017). 
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According to current treatment guidelines for the early-stage primary IgAN patients 
in Japan, tonsillectomy monotherapy or tonsillectomy paired with steroid pulse therapy 
are the recommended therapeutic regimens (Nihei et al. 2017; Tomino 2016; Xie et al. 
2003a). The efficacy of these treatments can be attributed to the underlying immune 
reactions connecting tonsils with IgAN pathogenesis. As mentioned earlier, macroscopic 
hematuria in IgAN patients often coincides with upper respiratory tract infections, 
especially, tonsilitis (Park et al. 2020; Wang et al. 2012; Wyatt and Julian 2013). It was 
also noted that in the tonsils of the IgAN patients, there was a marked increase in 
polymeric IgA (pIgA) producing B-cells (Harper et al. 1995; Kodama et al. 2001; Meng et 
al. 2012) which are the flag bearers of IgAN pathogenesis.  Additionally, pathogenic 
bacteria associated with chronic tonsilitis (CT) and periodontitis were also found at the 
tonsillar crypts of IgAN patients (Jensen et al. 2013; Nagasawa et al. 2014; Watanabe et 
al. 2017). However, despite these evidences indicating an underlying connection between 
CT and IgAN pathogenesis, there has been no studies exploring the salivary microbiome 
associated with these diseases in comparison with each other. 
A study using transgenic mouse model of IgAN (designed to overexpress BAFF, a 
B-cell activation factor of the tumor necrosis factor (TNF) super family) revealed that IgA 
deposition in the kidney glomeruli was regulated by commensal microbiota (McCarthy et 
al. 2011). Inflammation in the gut and dysbiosis of gut microbiota is often considered as 
a source of inflammation in CKD (Han et al. 2016; Lau et al. 2015). In case of IgAN, the 
GWAS-identified risk loci for IgAN overlapped with those of IBD (Han et al. 2016; Sallustio 
et al. 2019). Swedish cohort-based study indicates that IgAN patients are at greater risk 
to incur IBD (Rehnberg et al. 2021). Based on these observation and hypotheses, several 
studies across Caucasian, Chinese and Korean populations attempted at exploring 
microbiome associated with IgAN. As expected, these studies highlighted a dysbiosis in 
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the gut(De Angelis et al. 2014; Dong et al. 2020; Hu et al. 2020), salivary(He et al. 2021b; 
Luan et al. 2019; Piccolo et al. 2015), periodontal (Cao et al. 2018) and tonsillar (Park et 
al. 2020) microbial communities. However, there has been no study till date that has 
compared the microbiome dysbiosis in IgAN with that in the IBD. 
b. Objectives and hypotheses 
Based on these motivations and identified gap in the literature, in this research project we 
used 16S rRNA gene sequence-based analysis to 
I. Compare the salivary microbiome composition of Japanese IgAN patients and age-, 
gender-matched Japanese healthy controls (HC). 
II. Compare the salivary microbiome composition of the Japanese IgAN patients and 
Japanese chronic tonsilitis (CT) patients. 
III. Compare the salivary microbiome composition of the Japanese IgAN patients and 
Japanese ulcerative colitis (UC) patients. 
Depending on these objectives, we hypothesized that the salivary microbiome of IgAN 
differed from the HC in terms of the composition and diversity. Similarly, we hypothesized 
that the salivary microbiome of IgAN also differed from the CT and UC patients in terms 
of the above-mentioned criteria. And lastly, we hypothesized that the salivary microbiome 
of the IgAN patients is a source of potential microbial biomarkers that can differentiate the 
IgAN from the HC as well as the CT and UC samples. In this thesis, Chapter 2 addresses 
with first objective and Chapter 3 addresses all the three objectives together. 
 
  














2 Comparison of Salivary Microbiome of 
Japanese IgA Nephropathy Patients and 
Healthy Controls   




Comparison of Salivary Microbiome of Japanese IgA Nephropathy 
Patients and Healthy Controls 
Abstract 
Background: With an incidence rate of 39-45 immunoglobulin A nephropathy (IgAN) 
cases per million population per year, Japan is ranked second in the world for IgAN 
prevalence. Being an idiopathic disease, IgAN is poorly understood and the 
development of diagnostic methods independent of renal biopsy had been slow. 
Genome wide association studies have identified several risk loci in IgAN pathogenesis 
to be associated with regulation of mucosal immunity. Salivary microbiome is a key 
player in the maintenance of immune homeostasis. In recent years, dysbiosis of salivary 
microbiome has been associated with oral as well as systemic diseases like arthritis, 
autism spectrum disorder, cancer, inflammatory bowel disease, and chronic kidney 
disease. This study aimed to investigate the salivary microbiome profile of IgAN patients 
in comparison with age-, gender-matched healthy controls (HC) in Japanese population. 
Methods: Saliva was collected from 43 IgAN patients and 50 age- and gender matched 
HC. The hypervariable V1–V2 regions of 16S rRNA gene were purified from all the 
samples and amplified using 27Fmod and 338R primers. The salivary microbial profile 
of IgAN and HC samples were investigated by using high-throughput 454-
pyrosequencing technology and bioinformatic analyses pipelines. Statistical analyses 
were conducted on R software.  We used Linear discriminant analysis effect size 
(LEfSe) tool and R-based Area under curve-random forest (AUC-RF) package to identify 
microbial biomarkers for differentiating IgAN from HC. 
Results: Alpha diversity parameters for richness and diversity (Observed Operational 
Taxonomic Units, Chao1, Shannon) were significantly lower in the IgAN than HC 
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samples (p<0.05, wilcoxon test). At the phylum level, Bacteroidetes significantly 
decreased whereas Proteobacteria significantly increased in abundance in IgAN 
samples compared with HC samples. Using LEfSe followed by AUC-RF, we were able 
to identify a group of 7 genera (Staphylococcus, Prevotella, Neisseria, 
Peptostreptococcus, Corynebacterium, Stomatobaculum and Veillonella) to differentiate 
IgAN from HC, with area under curve of 0.90. Additionally, there was a significant 
difference between IgAN male and HC male samples in terms of the microbiome 
structure and composition. A similar difference was also observed between IgAN female 
and HC female samples.  
Conclusion: 
There is a significant dysbiosis in salivary microbiome of IgAN patients. Salivary 
microbiome is potential source of biomarkers for development of effective and non-
invasive diagnostic tool for IgAN diagnosis and association of microbiome and gender 
in the context of IgAN patients should be explored in future studies. To our best 
knowledge, this is the first report of salivary microbiome profile of Japanese IgAN 
patients. 
Keywords: salivary microbiome; IgA nephropathy; oral microbiota; kidney disease; 
random forest algorithm. 
2.1 Introduction 
Oral mucosal barrier is the site of first encounters with a cornucopia of immunological 
triggers such as transient or commensal microbiota, dietary or airborne antigens and 
food (Moutsopoulos and Konkel 2018). Therefore, homeostasis of the oral mucosa is 
vital for maintenance of human health (Wilharm et al. 2019). At the barrier sites, one of 
the vital tasks of the local immune system is to balance between effective immune 
surveillance without spiking inflammatory response and tolerate local resident 
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microbiota (Moutsopoulos and Konkel 2018). Therefore, the oral epithelial cells and oral 
microbiota are in a continuous flux with each other to regulate the local and systemic 
homeostasis (Wilharm et al. 2019). Oral microbiome consists of diverse community of 
microbiota, compared to other barrier sites (Huttenhower et al. 2012; Moutsopoulos and 
Konkel 2018). The human microbiome is closely associated with mucosal immunity 
including Th-17 response and mucosal IgA-regulated immunity (Zenobia et al. 2021). 
Oral cavity is often overlooked in terms of mucosal immunity; however, it houses the 
oral microbiome which interacts with the immune landscape and regulates local and 
systemic homeostasis (Wilharm et al. 2019; Zenobia et al. 2021). The salivary 
microbiome is considered as the representative of the oral microbiome as the microbiota 
adhering to niches on various intraoral surfaces sheds into the saliva (Duan et al. 2020). 
Changes in salivary microbiome in terms of composition and diversity reflects 
inflammatory responses and microbial dysbiosis in the gut (Bajaj et al. 2015; Abe et al. 
2018). Several studies have also noted that salivary microbiome is a potential source 
of diagnostic biomarkers for several immunological diseases such as rheumatoid 
arthritis (Chen et al. 2018), celiac disease (Francavilla et al. 2014), primary sclerosing 
cholangitis (Iwasawa et al. 2018), colorectal cancer (Flemer et al. 2018), pancreatic 
cancer (Coit et al. 2016; Torres et al. 2015) and CKD (Hu et al. 2018). Additionally, the 
simplicity and inexpensiveness of the sample collection procedure paired with its low 
risk factor are advantageous for profiling salivary microbiome(Hemadi et al. 2017). 
IgAN patients often present gross hematuria in association with upper respiratory 
tract infections or gastrointestinal infections (Haas 2007; Park et al. 2020; Wyatt and 
Julian 2013; Wyatt et al. 1995). Additionally, GWAS studies of IgAN patients identified 
several significant loci associated with the maintenance and functioning of the mucosal 
barrier (Kiryluk et al. 2014; Park et al. 2020). These findings indicate that mucosal 
P a g e  | 32 
 
 
immune system plays an important role in the IgAN pathogenesis (Sallustio et al. 2019). 
A study using transgenic mouse model of IgAN (designed to overexpress BAFF, a B-
cell activation factor of the tumor necrosis factor (TNF) super family) revealed that IgA 
deposition in the kidney glomeruli was regulated by commensal microbiota (McCarthy 
et al. 2011). Inflammation in the gut and dysbiosis of gut microbiota is often considered 
as a source of inflammation in CKD (Han et al. 2016; Lau et al. 2015). Recent studies 
reported dysbiosis in salivary microbiota in CKD patients(Hu et al. 2018). Studies also 
identified a rise in number of periodontal pathogens in ESRD patients(Araújo et al. 2015; 
Schmalz et al. 2016) and a decline in oral health along with salivary microbiome 
dysbiosis in ESRD patients undergoing hemodialysis (Duan et al. 2020). With this 
background, several studies across the world attempted at exploring microbiome 
associated with IgAN. As expected, these studies highlighted a dysbiosis in the gut(De 
Angelis et al. 2014; Dong et al. 2020; Hu et al. 2020), salivary(He et al. 2021b; Luan et 
al. 2019; Piccolo et al. 2015), periodontal (Cao et al. 2018) and tonsillar (Park et al. 
2020) microbial communities. Two Japanese cohort studies focused on exploring tonsil 
microbiome of IgAN patients in comparison with recurrent tonsilitis, tonsillar hyperplasia 
(Watanabe et al. 2017) and chronic tonsilitis(Nagasawa et al. 2014). However, there 
has been no study till date that explored the salivary microbiome profile of IgAN patients 
in comparison with healthy individuals in Japanese population. 
In the current study, we performed 16S rRNA gene sequence-based analysis of 
the salivary microbiome of IgAN and healthy subjects in a Japanese cohort. Using 
random forest models, we identified a set of potential microbial biomarkers that can 
differentiate IgAN from other diseases and healthy individuals. According to the Ministry 
of Health, Labor, and Welfare 2005 survey in Japan, the male gender is one of the 
predictive factors of IgAN (Tomino 2016). Thus, we also explored the gender-specific 
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association of the salivary microbiome for IgAN patients by grouping the dataset based 
on genders prior to analysis. We found a significant difference in the salivary 
microbiome structure between IgAN and healthy subjects based on gender-grouping.  
2.2 Methods 
a. Sample collection and DNA extraction 
The study was approved by the ethics committees of Azabu University (029, 14 March 
2013) and RIKEN (H30-4, 29 August 2019). Saliva samples were collected from 43 
IgAN patients (median age 39) and 50 age and sex-matched healthy controls (the HC , 
median age 37.5) were recruited for this study (Table 3). IgAN patients collected their 
saliva prior to their tonsillectomy surgery. Any subject with history of oral disease, 
gastrointestinal or hepatobiliary surgery and antimicrobial usage within the past three 
months of the recruitment date were excluded from the study. Informed consents were 
obtained from the subjects before sampling and the study participants were instructed 
Demography IgAN (n=43) HC (n=50) 
Age, years, median (IQR) 39(20.5) 37.5(8) 
Male 20 36 
Female 23 14 
 
Median age in terms of years is shown for each group along with IQRin parentheses. 
Small IQR values represent data points that are spreadcloser to the median. IgAN, 
Immunoglobulin A nephropathy; CT, chronic tonsillitis; UC, ulcerative colitis; HC, 
healthy control; IQR, interquartile range. 
Table 3. Study subject demographics of IgAN and HC group 
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to restrain from eating or drinking for 2 hours prior to sampling. The saliva samples 
were transported to the laboratory at 4°C within 24 hours of collection. Upon reaching 
the laboratory, the samples were immediately frozen using liquid nitrogen and stored 
at -80°C until further downstream analysis. 
 The DNA extraction from these salivary samples was performed as described 
previously (Morita et al. 2007; Said et al. 2014). 1ml of saliva was centrifuged at 3,300g 
for 10 mins at 4°C. The resulting bacterial cell pellets were then suspended in 10mM 
Tris–HCl/10mM EDTA buffer and incubated with 15mg/ml lysozyme (Sigma-Aldrich 
Co. LLC) for 1 h at 37°C. Purified achromopeptidase (Wako Pure Chemical Industries, 
Ltd.) was added to the samples at a final concentration of 2000 units/ml before 
incubating the samples for an additional 30 mins at 37°C. The suspension was treated 
with 1% (wt/vol) sodium dodecyl sulphate (SDS) and 1 mg/ml proteinase K (Merck 
Japan) and incubated for 1h at 55°C. The resultant lysate was treated with phenol: 
chloroform: isoamyl alcohol (25:24:1) (Life Technologies Japan, Ltd.) and centrifuged 
at 3,300g for 10mins at 4°C. To precipitate the microbial DNA, 1/10 volume of 3M 
sodium acetate (pH= 4.5) and 2 volumes ethanol (Wako Pure Chemical Industries, 
Ltd.) was added to the supernatant. The suspension was centrifuged at 3,300g for 
15mins at 4°C and the resulting DNA pellets were rinsed with 75% ethanol, dried and 
dissolved in 10mM Tris–HCl/1mM EDTA (TE) buffer. For purification, the DNA 
samples were treated with 1 mg/ml RNase A (Wako Pure Chemical Industries, Ltd.) 
at 37°C for 30 min and precipitated by adding equal volumes of 20% polyethylene 
glycol solution (PEG6000-2.5MNaCl). These were centrifuged at 8,060g at 4°C and 
double-rinsed with 75% ethanol before drying the pellets. The dried pellets were then 
dissolved in TE buffer and stored at -20°C until polymerase chain reaction (PCR) steps 
followed by sequencing. 
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b. 16S rRNA amplicon library preparation and sequencing  
The salivary microbial DNA was sequenced using the 454 GS FLX Titanium or 454 
GS Junior system (Roche Applied Science, Indianapolis, IN) according to the 
manufacturer’s instructions (Said et al. 2014; Tsuda et al. 2015). Prior to the 
sequencing the 16S rRNA amplicon libraries were prepared by PCR amplification of 
the V1-V2 region of the 16S rRNA gene. For the PCR amplification, barcoded 27Fmod 
(5′-AGRGTTTGATYMTGGCTCAG-3′) and 338R (5′-TGCTGCCTCCCGTAGGAGT-
3′) primers were used(Kim et al. 2013).  
The protocol for PCR amplification was same as previously described (Tsuda 
et al. 2015). Briefly, 50 μl of PCR mix is composed of 10mM Tris-HCl (pH 8.3), 50mM 
KCl, and 1.5mM MgCl2 in the presence of 250 μM dNTP, 1 U Ex Taq polymerase 
(TakaraBio, Kyoto, Japan), forward and reverse primers (0.2 μM) and ~ 20 ng template 
DNA. At the thermal cycler, the PCR protocol consisted of initial denaturation at 96 °C 
for 2 min, followed by 25 cycles of denaturation at 96 °C for 30 s, annealing at 55 °C 
for 45 s, and extension at 72 °C for 1 min, a final extension at 72 °C and hold at 4 °C 
on a 9700 PCR system (Life Technologies Japan, Tokyo, Japan).  
The resultant PCR amplicons were then purified by AMPure XP magnetic 
purification beads (Beckman Coulter, Brea, CA, USA) and quantification using the 
Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies Japan). Equal amounts of 
the PCR amplicons were pooled and used for the 16S rRNA sequencing.  
c. Data analysis 
The raw sequences were analyzed using a predesigned pipeline for analysis of 454 
pyrosequencing data of the 16S rRNA gene V1-V2 region, as reported previously(Kim 
et al. 2013). Reads lacking both universal primers, low-quality reads (with an average 
quality score ≤ 25) and possible chimeric reads together accounted for 44-46% of total 
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reads and were excluded from the downstream analysis (Table 4). After filtering, 2300 
reads per sample were chosen randomly from the remaining high-quality reads for 
further analysis. The selected reads were sorted on the basis of their average quality 
score and grouped into OTUs using the UCLUST algorithm with 96% identity as 














1124798(100) 619041(55) 499955(44.4) 2258(0.2) 7864(0.7) 
Note: The number in the parentheses indicate the ratio in percentage to the total 
read number. 
 
similarity searching against RDP, CORE and NCBI genome databases using the 
GLSEARCH program. For taxonomic assignments at the phylum, genus and species 
levels, 70%, 94% and 96% sequence similarity thresholds were used, respectively. 
 We used Chi-squared test on the gender data across groups for gender-
matching the samples. Similarly, for age-matching, we used the one-way ANOVA test 
on the demographic data of the samples. Beta-diversity was assessed by using the 
UniFrac distance metric (Lozupone et al. 2011) followed by the principal coordinate 
analysis (PCoA) to visualize the overall microbiome structure of the saliva samples. 
We used The permutational multivariate analysis of variance (PERMANOVA) to find 
the significance of beta-diversity between the groups, and the corresponding p-values 
Table 4. Statistics of 16S V1-V2 pyrosequencing of salivary microbiome 
samples of IgAN and HC groups 
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were adjusted for multiple testing using Benjamin-Hochberg (BH) correction method. 
We assessed within-sample diversity or alpha diversity in terms of microbial richness 
and microbial diversity. In this assessment, the observed OTU number and Chao1 
index were the measures to quantify microbial richness whereas Shannon’s index 
quantified the microbial diversity of the samples. To check the statistical significance 
of the relative abundance of individual taxa, we used the Wilcoxon-test with BH 
correction for multiple comparisons for the data at different taxonomic levels, namely, 
OTU, phylum, and genus.  
This protocol was also used for revealing gender-specific microbiome 
association in the study groups. Briefly, we first grouped the complete dataset into 
male and female sample. UniFrac weighted and unweighted metrics corresponding to 
this dataset was assessed using PERMANOVA in order to evaluate existence of 
gender-effect. Statistically significant groups (p-value < 0.05, Wilcoxon test) were 
further investigated in terms of microbial diversity as well as taxonomic profile of 
microbiome, specific to male and female samples in the groups. 
To identify differentially abundant taxa between IgAN and HC groups at the 
genus and OTU levels, we used Linear Discriminate Analysis (LDA) effect size (LEfSe) 
tool (http://huttenhower.sph.harvard.edu/lefse/) on the galaxy server 
(https://huttenhower.sph.harvard.edu/galaxy/). LEfSe identifies the features (in our 
case, taxa) which are most likely to explain differences between the groups in a 
dataset. For this LEfSe uses the non-parametric Kruskal-Wallis test and unpaired 
Wilcoxon rank sum test to evaluate the statistical significance of the features and pairs 
this with LDA method to estimate the effect relevance of each feature/taxa among the 
groups (Segata et al. 2011). For this study, LEfSe analysis was carried out with default 
parameters, i.e., alpha value was set to 0.05 for statistical analyses, non-negative 
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threshold for the logarithmic LDA score was set to 2 and strategy for multi-class 
analysis was set to all-against-all (more stringent).  
To identify a group of taxa among the selected biomarkers from the previous 
step (LEfSe analysis) which can act as potential biomarkers and classify IgAN from 
HC group, we used Area Under Curve-Random Forest (AUC-RF) (version 1.1) (Calle 
et al. 2011) package. To generate random forest (RF) models using AUC-RF we used 
the protocol previously described (Iwasawa et al. 2018). Brielfy, RF was built, using all 
the variables selected by LEfSe tool and here the variables are ranked in terms of their 
importance (which is depicted by the mean decrease Gini score). Subsequently, 5% 
of the least important features were eliminated and RF was built with the remaining 
variables. The area under curve (AUC) was calculated for each of the RF models and 
was based on the out-of-the-bag (OOB) predictions. The best model was the RF model 
with the best AUC value. The performance of the best model was confirmed by 
evaluating the mean AUC of a 10-fold cross-validation repeated 20 times using the 
AUC-RF (Calle et al. 2011) package. The AUC-RF based analyses were performed 
using the R (v3.6.1) within RStudio environment (v1.2.5019). 
d. Data availability 
The high-quality 16S V1-V2 sequences used in this study for downstream analysis 
were deposited on the DDBJ/GenBank/EMBL database (accession no. DRA002611, 
DRA002617, and DRA002618(Tsuda et al. 2015) and DRA011285).  
2.3 Results 
a. Summary of 454 reads 
We obtained a total of 1,124,798 high-quality 16S reads from the two groups by using 
454 GS FLX Titanium platform (Table 4) (Roche Applied Science, Indianapolis, IN). 
After removing low quality and possibly chimera reads, we obtained a total of 619,041 
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reads from 93 samples. Of them, we randomly selected 2300 reads per sample 
(213,900 reads from 93 samples), and further analyzed them using the pipeline for 
454 barcoded pyrosequencing of 16S amplicons in order to minimize overestimation 
of species richness in the clustering due to intrinsic sequencing error (Kim et al. 2013). 
The average Good’s coverage index(Good 1953; Singleton et al. 2001) of the 2300 
reads per sample was 0.97 (values ranging from 0.94 to 0.99), indicating a high degree 
of coverage. Hence, the sequence data was sufficient for analysis in the current study. 
b. Differences in alpha and beta diversity of salivary microbiota of HC and IgAN groups 
Fig. 3. Alpha diversity in IgAN and HC subjects. Samples from 43 IgAN (blue), 
and 50 HC (purple) subjects are shown.  (A) The observed and Chao1-estimated 
OTU numbers, and the Shannon index of salivary microbiome from the two groups. 
* p-value <0.05; ** p-value < 0.01; *** p-value <0.001 based on Wilcox test. OTU, 
operational taxonomic unit. 
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The salivary microbiome of IgAN and HC samples were compared based on their 
alpha (Fig. 3) and beta diversity (Fig. 4). Alpha diversity estimates the variation of 
microbiome within a sample and is often denoted in terms of richness and diversity. In 
this study microbiome richness was estimated in terms of number of observed OTUs 
and Chao1 index. The number of observed OTUs as well as the Chao1 index in the 
Fig. 4. Beta diversity in IgAN and HC subjects. Each dot represents a scaled 
measure of the composition of a given sample color coded by groups with blue dots 
code for IgAN and purple dots code for HC samples. (A) Weighted UniFrac –PCoA 
and (B) Unweighted UniFrac – PCoA of the salivary microbiome from the two groups. 
PCoA, principal coordinate analysis. 
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IgAN samples were significantly lower than the HC samples (p= 1.06E-05 and 2.81E-
07, respectively; Fig. 3). Shannon index, which takes into account both the richness 
and evenness of the microbiome and thus indicates within-sample diversity, was 
significantly decreased in the IgAN patients as compared to the HC (p= 9.66E-05, Fig. 
3).  
Between-samples diversity is depicted as the beta diversity which explains the 
variations of microbial communities between the samples. In this study, sequence-
based distances or UniFrac distance metrics are used to estimate the beta-diversity 
of the dataset. Unweighted UniFrac metric is entirely based on the sequence distances 
only whereas the weighted UniFrac metric includes both the sequence distance and 
abundance information(Lozupone and Knight 2005). PCoA of the unweighted and 
weighted UniFrac distance metrics of our dataset is shown in the Fig. 4. In the 
unweighted plot, the largest principal coordinates were 11.53% and 5.26% of total 
variation, respectively, while they were 31.33% and 20.27%, respectively, in the 
weighted plot. The PCoA based on the unweighted UniFrac distance metric showed 
that many of the IgAN samples segregated from the HC sample Fig. 4B. 
PERMANOVA shows that the IgAN samples significantly differed from the HC samples 







0.07 0.001 0.03 0.001
p-values <0.05 are in bold.
Category
Weighted UniFrac Unweighted UniFracNo. of 
Subjects
Table 5. Permutational multivariate analysis of variance (PERMANOVA) in 
salivary microbiome samples among two groups—IgAN and HC. 
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c. Variations in the salivary microbiome taxonomic profiles between the two groups 
We taxonomically assigned the 213,900 reads to 2,784 OTUs according to the 
phylotypes in the public microbial 16S rRNA gene databases. The phyla with relative 
mean abundances of more than 0.1% across both the groups (IgAN and HC) and thus 
accounting for 99.8% of total abundances were Firmicutes, Bacteroidetes, 
Proteobacteria, Actinobacteria, Fusobacteria, Candidatus Saccharibacteria (TM7), 
and Streptophyta. The relative mean abundances of Bacteroidetes and Fusobacteria 
were significantly lower in the IgAN compared to the HC samples (p= 0.0002 and 
0.0361, respectively). On the other hand, the relative mean abundance of 
Fig. 5. Phylum level fold-change between IgAN and HC samples. For each 
phylum, fold-change is calculated by dividing (mean relative abundance) % in IgAN 
by (mean relative abundance) % in HC. The (mean relative abundance) % in HC is 
given in parentheses besides corresponding phyla. * p-value <0.05; ** p-value < 0.01; 
*** p-value <0.001 based on Wilcox test. 
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Proteobacteria was significantly higher (p = 0.0004) in the IgAN patients than the HC 
Fig. 6. Differential taxa between IgAN and HC derived using LEfSe. Histogram 
of LDA score indicating the effective size and ranking of each differentially 
abundant (A) OTU and (B) genus is shown here. LDA>2 threshold was used for 
LEfSe analysis. LEfSe, Linear discriminant analysis (LDA) Effect Size; IgAN, 
Immunoglobulin A Nephropathy; HC, Healthy Control; OTU, operational taxonomic 
unit. 
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(Fig. 5).  The ratio of relative mean abundances of Firmicutes to Bacteroidetes was 
higher in the IgAN as compared to the HC. On the other hand, the Firmicutes to 
Proteobacteria ratio was lower in the IgAN as compared to the HC samples. 
The taxonomic assignment at the genus level identified 270 bacterial genera, 
of which 48 genera had a relative mean abundance of more than 0.1%, accounting for 
97.8% of the total abundance. Among these 48 genera, 21 genera varied significantly 
in terms of relative mean abundance between the two groups. Streptococcus, 
Neisseria, Rothia, Haemophilus and Turicibacter were significantly more abundance 
in the IgAN patients than the HC (p = 0.0382, 0.0001, 0.0169, 0.0431, and 0.0285, 
respectively). On the other hand, Prevotella, Veillonella, Alloprevotella, Cutibacterium, 
Megasphaera, Atopobium, Campylobacter, Eubacterium, Corynebacterium, 
Solobacterium, Peptostreptococcus, Staphylococcus, Enhydrobacter, Peptococcus, 
and Dialister were significantly depleted in abundance in the IgAN samples compared 
to the HC samples (p = 0.0003, 0.0004, 0.0277, 0.0002, 0.0040, 0.0380, 0.0178, 
0.0256, 0.0096, 0.0083, 0.0011, 2.3295E-07, 0.0002, 0.0004, 0.0325, and 0.0342, 
respectively).  
 To further evaluate salivary microbiome differences among patients with IgAN 
and healthy subjects (HC), the LEfSe method was employed to identify significant 
discriminative features between the two groups (with logarithmic LDA score threshold 
>2). From LEfSe analysis, we were able to identify 32 differential taxa at the OTU level 
and 22 differential taxa at the genus level between IgAN and HC samples (Fig. 6). 
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To determine the potential value of the identified microbial biomarkers to 
Fig. 7. Random Forest (RF) analysis of the salivary microbiota of IgAN and HC 
groups using AUC-RF package at OTU and genus level. Best RF models 
(comparison based on combination of best mean area under curve (AUC) value) was 
obtained. The corresponding AUC curve with Kopt is shown for (A)Genus and (B)OTU 
levels. (C), (D) The selected features of best RF models to differentiate IgAN from HC 
are shown; the features are ranked as highest Mean Decrease Gini score (top-most 
taxa on each plot) to lowest Mean decrease Gini score (last taxa on each plot). Kopt, 
optimal number of features to distinguish between the two groups under comparison. 
OTU, operational taxonomic unit. 
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clinically differentiate the IgAN from the HC samples, we generated RF models using 
the AUC-RF package. We generated models for two taxa levels (genus and OTU). 
We used the AUC of the receiver operative curve (ROC), that was in turn based 
upon the out-of-bag (OOB) error rate, to find the combination of multiple taxa from 
the 22 differential genera selected by the LefSe tool which can contribute in 
Fig. 8. Genus level variables from Random Forest (RF) analysis of the 
salivary microbiota using AUC-RF package. The relative abundance of taxa 
selected by AUC-RF are shown here. Seven genera selected for IgAN vs HC 
model* p-value <0.05; ** p-value < 0.01; *** p-value <0.001 based on Wilcox test 
with Benjamin-Hochberg correction. IgAN=blue, and HC=purple. IgAN, 
Immunoglobulin A Nephropathy; HC, Healthy Control; OTU, operational taxonomic 
unit. 
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discriminating IgAN group from the HC group. The model with best AUC value at the 
genus level was observed for 7 genera between IgAN and HC samples (Fig. 7B). 
These 7 genera (Staphylococcus, Prevotella, Neisseria, Peptostreptococcus, 
Corynebacterium, Veillonella and Stomatobaculum), thus, contributed in 
Fig. 9. OTU level variables from Random Forest (RF) analysis of the salivary 
microbiota using AUC-RF package. The relative abundance of taxa selected by 
AUC-RF are shown here. Eight OTUs were selected for IgAN vs HC model. The 
corresponding species and percentage of identity for the OTUs are given in the 
parentheses. * p-value <0.05; ** p-value < 0.01; *** p-value <0.001 based on Wilcox 
test with Benjamin-Hochberg correction. IgAN=blue, and HC=purple. IgAN, 
Immunoglobulin A Nephropathy; HC, Healthy Control; OTU, operational taxonomic 
unit. 
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distinguishing the IgAN from the HC samples. Out of 7 genera, only Neisseria was 
significantly more abundant in the IgAN patients than the HC (p = 8.77E-05) (Fig. 8. 
Genus level variables from Random Forest (RF) analysis of the salivary 
microbiota using AUC-RF package. The relative abundance of taxa selected by 
AUC-RF are shown here. Seven genera selected for IgAN vs HC model* p-value 
<0.05; ** p-value < 0.01; *** p-value <0.001 based on Wilcox test with Benjamin-
Hochberg correction. IgAN=blue, and HC=purple. IgAN, Immunoglobulin A 
Nephropathy; HC, Healthy Control; OTU, operational taxonomic unit.). On the other 
hand, Staphylococcus, Prevotella, Peptostreptococcus, Corynebacterium, Veillonella 
and Stomatobaculum were significantly less abundant in the IgAN samples than the 
HC samples (p = 2.33E-07, 0.0003, 0.0011, 0.0096, 0.0002, and 0.0004, 
respectively) (Fig. 8). We confirmed the results by 10-fold cross-validation of AUC-
RF model repeated 20 times to obtain the mean AUC of 0.903 for IgAN vs HC. 
 At the OTU level, we used the 32 differential OTUs selected by the LefSe tool 
to build the RF model. The models with best AUC values had 8 OTUs between the 
IgAN and HC samples (Fig. 7A). Out of 8 OTUs, only OTU00002 (100% identity with 
Neisseria perflava) was significantly more abundant in IgAN patients than the HC . On 
the contrary, remaining 7 OTUs, namely, OTU00011 (100% identity with Veillonella 
atypica), OTU00065 (99.67% identity with Leptotrichia sp. oral clone FP036), 
OTU00059 (98.77% identity with Lachnospiraceae bacterium oral taxon 500), 
OTU00022 (100% identity with Prevotella nanceiensis), OTU00050 (99.71% identity 
with Peptostreptococcus stomatis), OTU00013 (100% identity with Prevotella pallens) 
and OTU00075 (100% identity with Staphylococcus saccharolyticus), were 
significantly less abundant in the IgAN samples than the HC samples ( p = 
0.000240349, 8.17E-05, 9.46E-05, 0.0117, 0.0014, 4.26E-05 and 9.90E-07, 
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respectively) (Fig. 9). The mean AUC of the 10-fold cross-validation repeated 20 times 
was 0.86 between the IgAN and HC. 
d. Gender-specific microbiome association 
To check whether there is any underlying gender-specific association of the salivary 
microbiome, we performed a PERMANOVA test where the samples were grouped 
according to their genders. PERMANOVA test showed a significant difference 
between male and female samples in the IgAN group for weighted UniFrac metric and 
Table 7. Permutational multivariate analysis of variance (PERMANOVA) in 
salivary microbiome samples in the two groups to check gender effect. p-
value <0.05 are bold and underlined. 
 
Table 6. Permutational multivariate analysis of variance (PERMANOVA) in 
salivary microbiome samples in the two groups, namely IgAN and HC, 
grouped by gender. The adjusted p-values were adjusted for multiple testing by 
Benjamin-Hochberg method. p-value <0.05 are bold and underlined. 
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in the HC group for unweighted UniFrac metric only (Table 6). The observed OTU 
Fig. 10. Alpha and beta diversity in IgAN male, HC male, IgAN female and HC female 
subjects. Samples from 20 IgAN male, 36 HC male, 23 IgAN female and 14 HC female 
subjects are shown.  (A) The observed and Chao1-estimated OTU numbers, and the 
Shannon index of salivary microbiome from the four groups. * p-value <0.05; ** p-value < 
0.01; *** p-value <0.001 based on Wilcox test. (B) Unweighted UniFrac –PCoA and (C) 
weighted UniFrac –PCoA of the salivary microbiome from the four groups (IgAN=blue, and 
HC=purple). IgAN, Immunoglobulin A Nephropathy; CT, Chronic Tonsillitis; UC, Ulcerative 
Colitis; HC, Healthy Control; OTU, operational taxonomic unit; PCoA, principal coordinate 
analysis. 
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numbers of the IgAN male and IgAN female samples were significantly lower than HC 
Fig. 11. Unique Gender-associated genera with significant difference between the 
IgAN and HC groups. (A) 12 genera with more than 0.1% mean relative abundance and 
p-value < 0.05 between IgAN male and HC male groups are shown. (B) 5 genera with 
more than 0.1% mean relative abundance and p-value <0.05 between IgAN Female and 
HC male are shown. 
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male and HC female samples, respectively (p = 0.0010, and 0.04, respectively) (Fig. 
10A). Similarly, the chao1-estimated OTU numbers of the IgAN male and IgAN female 
samples were significantly lower than HC male and HC female samples, respectively 
(p= 0.0002 and 0.003, respectively) (Fig. 10B). Alpha diversity, indicated by the 
Shannon index, showed a significant difference between IgAN female and HC female 
samples (p = 0.005) but not between IgAN male and HC male samples (Fig. 10A). 
The PCoA based on unweighted UniFrac distance metric segregated IgAN male and 
IgAN female samples from HC male and HC female samples, respectively (Fig. 10B). 
There was a similar sample segregation trend between IgAN male and HC male, and 
IgAN female and HC female samples in PCoA plots based on weighted UniFrac 
distance metrics (Fig. 10B). Additionally, there was a significant difference between 
IgAN male and HC male samples for both weighted and unweighted UniFrac metrics 
(Table 7). We observed a similar scenario in PERMANOVA between IgAN female and 
HC female samples (Table 7). 
At the taxonomic composition, there was no phylogenetic demarcation between 
taxa that were differentially abundant in two gender-based analysis. At the phylum 
level, Bacteroidetes was significantly less abundant in IgAN male group than the HC 
male group, and Candidatus Saccharibacteria (TM7) was significantly less abundant 
in IgAN female group than HC female group. However, phylum Proteobacteria is 
significantly higher in IgAN male and IgAN female samples than the HC male and HC 
female samples, respectively. At the genus level, 12 genera (Neisseria, Rothia, 
Oribacterium, Turicibacter, Campylobacter, Peptostreptococcus, Romboutsia, 
Stomatobaculum, Enhydrobacter, Peptococcus, Acinetobacter, and Dialister) with 
more than 0.1% mean relative abundance were significantly higher in IgAN male 
samples than HC male samples. Three genera (Atopobium, Corynebacterium and 
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Micrococcus), with more than 0.1% mean relative abundance, were significantly 
decreased while Streptococcus genus significantly increased in IgAN female samples 
as compared with HC female samples (Fig. 11).  
2.4 Discussion 
Mucosal immunity has a symbiotic relationship with the microbiome. GWAS studies 
have indicated that several risk loci involved in IgAN pathogenesis is associated with 
mucosal immunity (Sallustio et al. 2019). Additionally, a transgenic murine model for 
IgAN didn’t exhibit any IgA deposits in kidney glomeruli in the absence of commensal 
microbiota, thus highlighting a connection between microbiome and IgAN pathogenesis 
(McCarthy et al. 2011; Sallustio et al. 2019). There have been reports about the gut, 
tonsil, periodontal and salivary microbiota associated with IgAN (Cao et al. 2018; De 
Angelis et al. 2014; Dong et al. 2020; Hu et al. 2020; Luan et al. 2019; Nagasawa et al. 
2014; Park et al. 2020; Piccolo et al. 2015; Watanabe et al. 2017). However, despite 
Japan being the second highest in the world in terms of incidence and frequency of 
IgAN (Schena and Nistor 2018), the IgAN associated microbiota studies for the 
Japanese cohort are limited. Our present study represents the characterization of 
salivary microbiome of patients with IgAN in comparison with healthy subjects. To the 
best of our knowledge, this is the first study to characterize salivary microbiome profile 
of Japanese IgAN patients.   
In this study, we observed altered salivary microbial composition in the IgAN 
patients as compared to the healthy subjects, indicated by the lower species richness 
and microbial diversity in the IgAN patients’ salivary microbiota. Similarly, salivary 
microbial richness and diversity were lower but not significant (P>0.05) in IgAN than HC 
in the Caucasian population(Piccolo et al. 2015) whereas a Chinese population based 
study of IgAN salivary microbiota did not report any significant difference(Luan et al. 
P a g e  | 54 
 
 
2019). Another oral microbiome of IgAN patients from Han Chinese ancestry reported 
a decrease in Chao1 diversity index in IgAN group compared to health group; however, 
the difference was not statistically significant (p>0.05)(He et al. 2021a). In fecal 
microbiome studies associated with IgAN, few studies reported similar findings of lower 
microbial richness (De Angelis et al. 2014; Hu et al. 2020) and diversity(De Angelis et 
al. 2014) in IgAN compared to HC, whereas another study did not find any significant 
difference(Dong et al. 2020). The observed differences might be rooted in the variability 
of study design, like using different hypervariable regions for 16S rRNA sequencing, 
using different sequencing platforms, sample size, or ethnicity differences. In our study, 
statistical analysis of the phylogeny-based weighted and unweighted UniFrac metrics 
shows that the observed dysbiosis is associated with differences in the presence or 
absence of the microbial taxa as well as their abundance in the population. Therefore, 
as seen in Caucasian(De Angelis et al. 2014; Piccolo et al. 2015) and Chinese(Dong et 
al. 2020; He et al. 2021a; Luan et al. 2019) population studies, our study demonstrates 
microbial dysbiosis in IgAN patients as compared to the healthy subjects. A detailed 
and larger population-based study with collaborative research across globe using same 
protocol from subject recruitment to sample processing and analysis is required for 
more concrete understanding of IgAN microbiome. 
There were differences at the taxonomic level between the IgAN and HC 
samples. The phylum Firmicutes dominated all the samples and was most abundant in 
the IgAN, following previous studies on fecal and salivary microbiota studies of IgAN 
patients (De Angelis et al. 2014; Hu et al. 2020; Luan et al. 2019). However, the 
difference between the mean relative abundance of Firmicutes in IgAN and HC group 
was not statistically significant (p>0.05) and this observation also matches with previous 
IgAN salivary microbiome studies (Luan et al. 2019; Piccolo et al. 2015).  The 
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Firmicutes/Proteobacteria ratio was lower in the IgAN group as compared to the HC 
groups. This ratio agrees with the previously reported salivary microbiota study on the 
Caucasian population (Piccolo et al. 2015) and periodontal microbiome study on the 
Asian population (Cao et al. 2018) but is in contrast with the salivary microbiota study 
in Chinese cohort (Luan et al. 2019).  
The significant differences between IgAN and HC samples in terms of microbial 
taxa prompted us to investigate the selected biomarkers for discriminating IgAN group 
from the healthy controls. In our study, a combination of salivary taxa separated IgAN 
from healthy individuals with AUC of 0.86 and 0.90 at OTU and genus levels, 
respectively. A Chinese cohort study reported separation of IgAN from HC with 
predictive accuracy up to 80% upon using salivary microbial OTUs in combination with 
biochemical characteristics (Luan et al. 2019). These results indicate that salivary 
microbiome derived biomarkers can be used for predictive diagnosis of IgAN from 
healthy population.  
Staphylococcus is one of the genera that differentiates IgAN from HC samples. 
This genus significantly decreased in abundance in IgAN samples compared to the HC. 
Staphylococcus genera is often represented by pathogenic species such as 
Staphylococcus aureus which are known to cause postoperative wound infection, food 
poisoning, septicemia, endocarditis, and toxic shock syndrome (Kluytmans et al. 1997; 
Koyama et al. 2004). Studies have indicated that S. aureus cell antigen is associated 
with IgAN pathogenesis(Koyama et al. 2004). However, Staphylococcus is also a 
commensal microbiota in the oral cavity (Lamm 1997). Further research is needed to 
reveal members of Staphylococcus genera which contribute in IgAN pathogenesis. 
Neisseria was also one of the contributors in distinguishing IgAN from healthy 
individuals. This genus is enriched in the IgAN group than healthy groups, similar to the 
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findings of prior studies (He et al. 2021a; Piccolo et al. 2015). Also, at the OTU level, 
some OTUs belonging to the Neisseria genus were among the selected taxa for 
differentiating IgAN from the HC samples and they were significantly enriched in IgAN 
patients. Previous salivary microbiome studies report the co-occurrence of Neisseria 
and Haemophilus in salivary ecosystem (De Angelis et al. 2014; Takeshita et al. 2016). 
Salivary community type comprising of Neisseria, Haemophilus, Gemella, 
Porphyromonas, and Streptococcus mitis along with reduced phylogenetic diversity was 
associated with better periodontal health (Takeshita et al. 2016). A salivary microbiome 
study of IBD patients reported that elevated salivary IgA levels were correlated with 
lower abundance of Neisseria, Haemophilus, Gemella and Streptococcus (Said et al. 
2014). On the other hand, salivary microbiome study of IgAN patients reported that 
Haemophilus was positively correlated with levels of serum IgA(He et al. 2021a). 
According to scientific literature, salivary and serum IgA levels are elevated in IgAN 
patients and they are positively correlated (Yamabe et al. 1987). In our study, 
abundance of Neisseria, Haemophilus, Gemella and Streptococcus genera increased 
in the IgAN patients. The difference in the relationship between abundance of these 
genera and salivary IgA levels can be attributed to difference in the disease 
pathogenesis of IgAN and IBD. However, given the lack of data corresponding to 
salivary IgA levels of the IgAN patients in our study, the underlying relationship of 
salivary IgA and microbiome in light of these two diseases has a scope of future 
research. 
Prevotella also contributed in differentiating IgAN patients from HC. A study that 
used Projection to Latent Structure (PLS) models for discriminant analysis reported that 
Prevotella was among the top 5 genera that differentiated between IgAN and HC 
samples (He et al. 2021a). In line with previous reports(Cao et al. 2018; Luan et al. 
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2019; Piccolo et al. 2015), there was significant enrichment of Prevotella in HC than 
IgAN samples. Though OTU clustering methods in our study is not sufficient for species 
level assignment, we found OTUs assigned to Prevotella pallens with 100% identity 
which were among the selected taxa for distinguishing IgAN patients from HC and 
similar to Italian cohort study, these were significantly enriched in HC than IgAN patients 
(Piccolo et al. 2015).  The Chinese fecal microbiome study comparing the IgAN patients 
with membranous nephropathy patients, and healthy controls noted a positive 
correlation between Prevotella and a higher serum albumin level (Dong et al. 2020). 
Serum albumin plays an essential role in reducing oxidative stress in the mesangial 
cells by attenuating the reactive oxygen species like hydrogen peroxide, thereby 
lowering the risk of IgAN progression towards ESRD (Kawai et al. 2018). From this, we 
can infer that Prevotella genera has a protective role in the salivary and gut ecosystem, 
and a decline in its abundance may facilitate systemic disease progression like IgAN. 
Under Firmicutes phyla, Streptococcus is the predominant genera, and is more 
abundant in the IgAN group (p= 0.0382). In previous reports, Streptococcus was 
enriched in the subgingival microbiome of chronic periodontitis patients with IgAN (Cao 
et al. 2018) and is also one of the core members of tonsillar crypt microbiome (Jensen 
et al. 2013). 16S rDNA reads of Streptococcaeae family increased in the fecal 
microbiome of IgAN patients with persistent proteinuria (De Angelis et al. 2014). Another 
study reported an increase in the cell surface collagen-binding Cnm protein of 
Streptococcus mutans in tonsillar specimens of IgAN patients compared to chronic 
tonsilitis patients (Ito et al. 2019). This study also reported an association between the 
presence of Cnm-positive S. mutans strain with greater severity of symptoms in IgAN 
patients, marked by higher proteinuria and lower serum albumin levels (Ito et al. 2019). 
In our study, we found the mean relative abundance of S. mutans was higher in IgAN 
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than HC samples. These evidences along with findings such as presence streptococcal 
proteins in the renal tissues from IgAN patients (Schmitt et al. 2010) indicate that 
bacterial causal agents of focal tonsillar infection, like Streptococcus, can be associated 
with IgAN pathogenesis.  
Several OTUs belonging to Haemophilus genus varied significantly between the 
IgAN and HC groups. Some members of Hemophilus genus, like H. parahaemolyticus, 
are commensal microflora in the upper respiratory tract, and literature suggests these 
are to be considered as opportunistic pathogens capable of causing invasive and 
severe diseases (Le Floch et al. 2013). H. parahaemolyticus belongs to the H. 
parainfluenzae group and is one of the few species in Haemophilus genera like H. 
influenzae, which produces IgA1 protease that attributes to its pathogenicity in human 
host (Norskov-Lauritsen 2014). Piccolo et al. reported an increase of H. parainfluenzae 
in salivary microbiota of IgAN patients with the lowest proteinuria (Piccolo et al. 2015). 
In our study, H. parahaemolyticus and H. parainfluenzae are more abundant in the 
salivary microbiome of the IgAN patients. Authors recommending the use of H. 
influenzae derived IgA protease for IgAN treatment state that the lack of mesangial IgA1 
specificity of the H. influenzae derived IgA protease limits its immediate application for 
IgAN therapy (Eitner and Floege 2008). These observations suggest that some 
members of Hemophilus genera contribute to the early stages of IgAN pathogenesis. 
Further research based on these associative members might contribute towards a 
better understanding of the progression of IgAN and thus expedite the therapeutic 
applications. 
While some epidemiological studies observed a male predominance in North 
American and Western European populations(Barratt and Feehally 2014; Sukcharoen 
et al. 2020), others show an equal distribution of IgAN incidence between genders in 
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the Asian population(Cheng et al. 2013; Feehally and Barratt 2015; Lee et al. 2012).  A 
single-center study in Japan showed that primary glomerulonephritis showed higher 
frequency in men as compared to women(Moriyama et al. 2010). In microbiome studies 
gender may act as a confounding factor as some show a significant difference between 
male and female microbiome(Minty et al. 2020; Raju et al. 2019). Thus, upon exploring 
existence of gender-associated microbiota in our cohort we found that unlike previous 
study on a cohort of Hans Chinese origin(He et al. 2021a), microbial richness of the 
IgAN male and IgAN female groups was significantly lower than corresponding HC male 
and HC female groups (Fig. 10). We also found that some genera had significant 
difference of abundance only between HC and IgAN males (Fig. 11A), whereas some 
others differed only between HC and IgAN females (Fig. 11B).  Similarly, oral 
microbiome study of IgAN patients from Chinese Han ancestry reported several genera 
with potential to discriminate between IgAN and HC samples in terms of gender(He et 
al. 2021a). These observations suggest that microbiota may play a role in the gender-
associated risk of IgAN disease progression and, further research in this field is 
essential.  
The current study has some limitations. Firstly, our study included non-uniform 
sample size across the groups. The imbalance in dataset was not statistically significant 
and did not affect the microbiome analysis. Disease predictive modeling is affected by 
an imbalanced dataset; however, the AUC-RF package uses a random forest classifier 
for modeling and the random forest classifier is relatively robust when dealing with an 
imbalanced dataset(Dittman et al. 2015). Secondly, data associated with stage of 
disease for IgAN patients is not available for clinical metadata correlation analysis. 
However, since in Japan, tonsillectomy is recommended and effective in the early 
stages IgAN (Hotta et al. 2001) and the IgAN patients in the current study collected the 
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saliva sample before their tonsillectomy surgery, it implies that patients were in the early 
stage of the disease. Lastly, our study design is limited by the lack of clinical data 
reporting the serum or salivary IgA levels in the IgAN patients. As secretory IgA plays 
important role in IgAN pathogenesis, there is a scope for future microbiome study 
exploring the relationship between the secretory IgA levels and predominant microbiota 
associated with IgAN. 
In conclusion, our findings from the current study, where we explored the 
variations in salivary microbiome profiles of IgAN patients, and HC, indicate that the 
salivary microbiome is a potential biomarker source to develop a non-invasive 
diagnostic tool for IgAN. However, the biological role of the microbial biomarkers 
identified in this study in the pathogenesis and disease progression of IgAN is a scope 
of further research. 
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Comparison of Salivary Microbiome of Japanese IgA Nephropathy 
Patients versus Chronic Tonsillitis Patients, Ulcerative Colitis 
Patients and Healthy Controls 
Abstract 
Background: In Japan, IgA nephropathy (IgAN) is one of the leading causes of chronic 
kidney disease, with 50% of the cases progressing to end stage renal disease. 
Understanding about the origin and maintenance of IgAN has limited the development 
of a diagnostic tool independent of renal biopsy. The salivary microbiome is a rich source 
of biomarkers for systemic diseases. In this study, we primarily aimed to investigate the 
salivary microbiome as a tool for the non-invasive diagnosis of IgAN. IgAN has been 
reported to be triggered by upper-respiratory tract and gastrointestinal infections. 
Recent studies reported that patients with IgAN are more likely to incur inflammatory 
bowel diseases. Researchers have also established that chronic inflammation of tonsils 
triggered the recurrence of IgAN. Therefore, this study also aimed at investigating 
salivary microbiome profile of IgAN patients in comparison with mucosal diseases like 
chronic tonsillitis and ulcerative colitis. 
Methods: Saliva was collected from 43 IgAN patients (IgAN), 50 healthy controls (HC), 
20 chronic tonsilitis (CT) patients and 22 ulcerative colitis (UC) patients. The 
hypervariable V1–V2 regions of 16S rRNA gene were purified from all the samples and 
amplified using 27Fmod and 338R primers. The salivary microbial profile of all the 
samples were investigated by using high-throughput 454-pyrosequencing technology 
and bioinformatic analyses pipelines. Statistical analyses were conducted on R software.  
We used Linear discriminant analysis effect size (LEfSe) tool and R-based Area Under 
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Curve-Random Forest (AUC-RF) package to identify microbial biomarkers for 
differentiating IgAN from mucosal diseases (CT and UC) and HC. 
Results: We noted a significant difference in microbial diversity and richness between 
IgAN patients and HC. IgAN and CT differed significantly in terms of both microbial 
diversity and richness whereas there was no significant difference in terms of alpha 
diversity between IgAN and UC. PERMANOVA of UniFrac distance metrics to quantify 
the beta-diversity, we found that when compared with the HC samples, the IgAN 
samples presented lower degree of dysbiosis than the other two disease groups (CT 
and UC). Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, 
Candidatus Saccharibacteria (TM7), and Streptophyta were the major phyla with relative 
mean abundances of more than 0.1% across all the groups (IgAN, CT, UC and HC) and 
accounted for 99.8% of the total abundances. Combining the genera selected by the 
random forest algorithm, we were able to distinguish the IgAN from the HC samples with 
the area under the curve (AUC) of 0.90, from the UC samples with the AUC of 0.88, and 
from the CT samples with AUC of 0.70. Additionally, genus Neisseria was common 
among the selected genera that contributed in distinguishing the IgAN samples from HC, 
CT and UC samples.  
Conclusion: 
There is a significant dysbiosis in salivary microbiome of IgAN patients. IgAN can be 
differentiated from related mucosal disease using biomarkers derived from the salivary 
microbiome. Therefore, salivary microbiome is a potential source of biomarkers for 
development of effective and non-invasive diagnostic tool for IgAN diagnosis. 
Keywords: salivary microbiome; IgA nephropathy; oral microbiota; kidney disease; 
random forest algorithm. 




Chronic kidney disease (CKD) is a worldwide health issue affecting millions of 
individuals every year. According to the Japanese Society of Nephrology report in 2005, 
approximately 13.3 million people in Japan have CKD (Imai et al. 2009). In Japan, 
Immunoglobulin A nephropathy (IgAN) has been identified as one of the leading causes 
of CKD (Tomino 2016). IgAN also carries the reputation of being the most common form 
of primary glomerulonephritis reported globally (D'Amico 1987; Schena 1990). With 
50% of IgAN patients progressing to end-stage renal disease (ESRD)(Moriyama et al. 
2014), IgAN is a substantial health burden, especially in Japan. Japan is the home to 
the world’s most rapidly aging population (Chen et al. 2019) and has witnessed an 
annual rise in the number of patients undergoing dialysis (Masakane et al. 2018). Even 
after more than 50 years since its first classification, the confirmed diagnosis of IgAN is 
only by kidney biopsy (Tomino 2016), which is an invasive diagnostic tool and 
possesses greater risk, especially for the elderly. Thus, research studies aiming to 
develop a non-invasive but effective diagnostic tool for IgAN is the need of the hour. 
IgAN is an idiopathic disease, as indicated by the multi-hit hypothesis (Suzuki et 
al. 2011). Clinical diagnosis of IgAN includes detection of the differently glycosylated 
polymeric IgA1 (pIgA1) immune complex deposits in the kidney glomeruli by 
histopathology, along with microscopic or macroscopic hematuria and proteinuria by 
urinalysis (Sallustio et al. 2019). However, the trigger or maintenance of these immune 
reactions is still mostly unexplored. Genome-wide association studies (GWAS) on large 
patient cohorts have discovered loci that only account for about 5% of the disease risk 
in IgAN (Sallustio et al. 2019). Thus, apart from genetics, various other environmental 
factors (Sallustio et al. 2019) are thought to be associated with IgAN progression and 
pathogenesis. Among these, mucosal immunity is an essential factor in IgAN 
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pathogenesis as upper respiratory tract microflora is associated with recurrent 
macroscopic hematuria (Sallustio et al. 2019). The microbiota plays a vital role in the 
development of mucosal-associated lymphoid tissue (MALT), and in turn, MALT 
regulates the microbiota composition (Nakajima et al. 2018; Sallustio et al. 2019). IgA 
primarily originates from MALT, and GWAS  of IgAN identified several risk loci involved 
in maintaining mucosal immunity (Sallustio et al. 2019). Oral mucosa is the gateway to 
the human body, and the salivary microbiome plays a crucial role in oral mucosal 
immunity (Moutsopoulos and Konkel 2018). Salivary microbiome dysbiosis often 
reflects inflammatory responses and microbiome changes in the gut (Abe et al. 2018; 
Bajaj et al. 2015). Members of the salivary microbiome are potential diagnostic 
biomarkers for immunological diseases such as rheumatoid arthritis (Chen et al. 2018), 
primary sclerosing cholangitis (Iwasawa et al. 2018), and pancreatic cancer (Coit et al. 
2016; Torres et al. 2015). Also, saliva collection and storage are non-invasive, 
inexpensive, and pertain to lower risk (Hemadi et al. 2017). These factors can be 
advantageous in conducting salivary microbial profiling in IgAN patients to find non-
invasive microbial biomarkers for effective low-risk diagnostics of IgAN.  
The GWAS also revealed common risk loci between IgAN and IBD like Crohn’s 
disease(CD) or ulcerative colitis(UC) (Sallustio et al. 2019). A Swedish population-
based study reported that patients with IgA nephropathy were more likely to incur IBD 
(Rehnberg et al. 2021). The same study revealed that IgAN patients have 2.6 times 
higher risk of UC than those without IgAN (Rehnberg et al. 2021). A transgenic murine 
model of IgAN highlighted an essential dependence of signals from commensal 
microbiota for kidney IgA deposition in IgAN pathogenesis (McCarthy et al. 2011). Few 
studies have reported a change in the gut (De Angelis et al. 2014; Dong et al. 2020; Hu 
et al. 2020), salivary (He et al. 2021a; Luan et al. 2019; Piccolo et al. 2015), 
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periodontal(Cao et al. 2018) and tonsillar (Park et al. 2020) microbiota composition in 
IgAN patients from Caucasian and Asian origin. However, none of these studies have 
explored the underlying microbiome changes in IgAN versus IBD. To better understand 
the common underlying mechanisms in IgAN and IBD pathogenesis and to find out the 
reason behind co-occurrence of IgAN and IBD, we aimed to explore the microbiome 
profile associated with IgAN and UC in comparison to each other. 
In Japan, tonsillectomy monotherapy or tonsillectomy paired with steroid pulse 
therapy is one of the most effective therapeutic regimens for early-stage primary IgAN 
patients (Nihei et al. 2017; Xie et al. 2003a). The reason behind the efficacy of this 
treatment is rooted in the association of focal tonsillar infection and a rise in pIgA 
secreting plasma cells in tonsils of IgAN patients (Meng et al. 2012). At the molecular 
level, galactose deficient IgA1 (Gd-IgA1) is one of the key players in the IgAN 
pathogenesis and its production is linked with overexpression of toll-like receptor 9 
(TLR9) in the tonsils, especially after upper respiratory tract infections like tonsilitis 
(Moriyama et al. 2020). Activated TLR-9 leads to production of APRIL (a proliferation-
inducing ligand) and BAFF (B cell activating factors from the TNF super family), which 
in turn activates B lymphocytes to generate Gd-IgA1 producing plasma cells (Moriyama 
et al. 2020; Suzuki 2019; Suzuki et al. 2011). Therefore, tonsillectomy cuts off the 
primary step in the Gd-IgA1 production and prevents disease progression and severity 
in IgAN(Moriyama et al. 2020). IgAN is also called synpharyngitic glomerulonephritis as 
often the onset of the disease is triggered by upper respiratory tract infection (Rodrigues 
et al. 2017).  Some studies reported pathogenic bacteria, commonly associated with 
chronic tonsillitis (CT) and periodontitis, to be present in tonsillar crypts of IgAN patients 
(Jensen et al. 2013; Nagasawa et al. 2014; Watanabe et al. 2017). Despite the previous 
reports indicating periodontal pathogens involved in IgAN pathogenesis, there have 
P a g e  | 67 
 
 
been no studies exploring the salivary microbiome profile of IgAN in comparison with 
CT patients. 
In the current study, we performed 16S rRNA gene sequence-based analysis of 
the salivary microbiome of IgAN, UC, and CT patients and healthy subjects in a 
Japanese cohort. In our attempt to distinguish IgAN from other mucosal diseases (UC 
and CT), we identified a set of potential microbial biomarkers that can differentiate IgAN 
from other diseases and healthy individuals. According to the Ministry of Health, Labor, 
and Welfare 2005 survey in Japan, the male gender is one of the predictive factors of 
IgAN (Tomino 2016). Also, according to previous reports, gender may incur an effect 
on microbiome composition (He et al. 2021a). Thus, we also explored the gender-
specific association of the salivary microbiome for IgAN patients. 
3.2 Methods 
a. Sample collection and DNA extraction 
The study was approved by the ethics committees of Azabu University (029, 14 March 
2013), Osaka university (2413, 29 September 2014), and RIKEN (H30-4, 29 August 
2019). Any subject with history of oral disease, gastrointestinal or hepatobiliary surgery 
and antimicrobial usage within the past three months of the recruitment date were 
excluded from the study. Informed consents were obtained from the subjects before 
sampling and the study participants were instructed to restrain from eating or drinking 
for 2 hours prior to sampling. Depending on the inclusion and exclusion criteria of the 
study, saliva samples were collected from 43 IgAN patients (median age 39), 20 CT 
patients (median age 34.5), 33 UC patients (median age 47) and 65 HC (median age 
37). After age and gender matching, 11 UC samples and 15 HC samples were 
removed from the current study which led to the median age for the UC samples to be 
44.5 and for the HC samples to be 37.5 (Table 8). Please note that the subjects in the 
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IgAN and HC cohorts are the same as the ones included in the first part of the study 
presented in Chapter 2. IgAN and CT patients collected their saliva prior to their 
tonsillectomy surgery (Table 8).  
The saliva samples were transported to the laboratory at 4°C within 24 hours 
of collection. Upon reaching the laboratory the samples were immediately frozen using 
liquid nitrogen and stored at -80°C until further downstream analysis. The DNA 
extraction from these salivary samples was performed as described previously (Morita 
et al. 2007; Said et al. 2014). 1ml of saliva was centrifuged at 3,300g for 10 mins at 
4°C. The resulting bacterial cell pellets were then suspended in 10mM Tris–HCl/10mM 
EDTA buffer and incubated with 15mg/ml lysozyme (Sigma-Aldrich Co. LLC) for 1 h 
at 37°C. Purified achromopeptidase (Wako Pure Chemical Industries, Ltd.) was added 
to the samples at a final concentration of 2000 units/ml before incubating the samples 
for an additional 30 mins at 37°C. The suspension was treated with 1% (wt/vol) sodium 
dodecyl sulphate (SDS) and 1 mg/ml proteinase K (Merck Japan) and incubated for 
1h at 55°C. The resultant lysate was treated with phenol: chloroform: isoamyl alcohol 
Demography IgAN (n=43) CT (n=20) UC (n=22) HC (n=50)
Age, years, median(IQR) 39(20.5) 34.5(14.5) 44.5(7.75) 37.5(8)
Male 20 13 11 36
Female 23 7 11 14
IQR:Inter-quartile range.
Table 8. Demography of the subjects included in four different groups – IgAN, 
CT, UC and HC. Median age in terms of years is shown for each group along with IQR 
enclosed in parentheses. Small IQR value represents data points to be spread closer 
to median. IgAN, Immunoglobulin A Nephropathy; CT, Chronic Tonsillitis; UC, 
Ulcerative Colitis; HC, Healthy Control; IQR, interquartile range. 
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(25:24:1) (Life Technologies Japan, Ltd.) and centrifuged at 3,300g for 10mins at 4°C. 
To precipitate the microbial DNA, 1/10 volume of 3M sodium acetate (pH= 4.5) and 2 
volumes ethanol (Wako Pure Chemical Industries, Ltd.) was added to the supernatant. 
The suspension was centrifuged at 3,300g for 15mins at 4°C and the resulting DNA 
pellets were rinsed with 75% ethanol, dried and dissolved in 10mM Tris–HCl/1mM 
EDTA (TE) buffer. For purification, the DNA samples were treated with 1 mg/ml RNase 
A (Wako Pure Chemical Industries, Ltd.) at 37°C for 30 min and precipitated by adding 
equal volumes of 20% polyethylene glycol solution (PEG6000-2.5MNaCl). These were 
centrifuged at 8,060g at 4°C and double-rinsed with 75% ethanol before drying the 
pellets. The dried pellets were then dissolved in TE buffer and stored at -20°C until 
polymerase chain reaction (PCR) steps followed by sequencing. 
b. 16S rRNA amplicon library preparation and sequencing  
The salivary microbial DNA was sequenced using the 454 GS FLX Titanium or 454 
GS Junior system (Roche Applied Science, Indianapolis, IN) according to the 
manufacturer’s instructions (Said et al. 2014; Tsuda et al. 2015). Prior to the 
sequencing the 16S rRNA amplicon libraries were prepared by PCR amplification of 
the V1-V2 region of the 16S rRNA gene. For the PCR amplification, barcoded 27Fmod 
(5′-AGRGTTTGATYMTGGCTCAG-3′) and 338R (5′-TGCTGCCTCCCGTAGGAGT-
3′) primers were used(Kim et al. 2013).  
The protocol for PCR amplification was same as previously described (Tsuda 
et al. 2015). Briefly, 50 μl of PCR mix is composed of 10mM Tris-HCl (pH 8.3), 50mM 
KCl, and 1.5mM MgCl2 in the presence of 250 μM dNTP, 1 U Ex Taq polymerase 
(TakaraBio, Kyoto, Japan), forward and reverse primers (0.2 μM) and ~ 20 ng template 
DNA. At the thermal cycler, the PCR protocol consisted of initial denaturation at 96 °C 
for 2 min, followed by 25 cycles of denaturation at 96 °C for 30 s, annealing at 55 °C 
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for 45 s, and extension at 72 °C for 1 min, a final extension at 72 °C and hold at 4 °C 
on a 9700 PCR system (Life Technologies Japan, Tokyo, Japan).  
The resultant PCR amplicons were then purified by AMPure XP magnetic 
purification beads (Beckman Coulter, Brea, CA, USA) and quantification using the 
Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies Japan). Equal amounts of 
the PCR amplicons were pooled and used for the 16S rRNA sequencing.  
c. Data analysis 
The raw sequences were analyzed using a predesigned pipeline for analysis of 454 
pyrosequencing data of the 16S rRNA gene V1-V2 region, as reported previously(Kim 
et al. 2013). Reads lacking both universal primers, low-quality reads (with an average 
quality score ≤ 25) and possible chimeric reads together accounted for 48-49% of total 
reads and were excluded from the downstream analysis (Table 9). After filtering, 2300 
reads per sample were chosen randomly from the remaining high-quality reads for 
further analysis. The selected reads were sorted on the basis of their average quality 
score and grouped into OTUs using the UCLUST algorithm with 96% identity as 
threshold (Said et al. 2014). We conducted taxonomic assignments for each OTU by 
similarity searching against RDP, CORE and NCBI genome databases using the 
Table 9. Statistics of 16S V1-V2 pyrosequencing of salivary microbiome 
samples 
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GLSEARCH program. For taxonomic assignments at the phylum, genus and species 
levels, 70%, 94% and 96% sequence similarity thresholds were used, respectively. 
 We used Chi-squared test on the gender data across groups for gender-
matching the samples. Similarly, for age-matching, we used the one-way ANOVA test 
on the demographic data of the samples. Beta-diversity was assessed by using the 
UniFrac distance metric (Lozupone et al. 2011) followed by PCoA to visualize the 
overall microbiome structure of the saliva samples. We used PERMANOVA to find the 
significance of beta-diversity between the groups, and the corresponding p-values 
were adjusted for multiple testing using Benjamin-Hochberg (BH) correction method. 
We assessed within-sample diversity or alpha diversity in terms of microbial richness 
and microbial diversity. In this assessment, the observed OTU number and Chao1 
index were the measures to quantify microbial richness whereas Shannon’s index 
quantified the microbial diversity of the samples. To check the statistical significance 
of the relative abundance of individual taxa, we used the Wilcoxon-test with BH 
correction for multiple comparisons for the data at different taxonomic levels, namely, 
OTU, phylum, and genus.  
This protocol was also used for revealing gender-specific microbiome 
association in the study groups. Briefly, we first grouped the complete dataset into 
male and female sample. UniFrac weighted and unweighted metrics corresponding to 
this dataset was assessed using PERMANOVA in order to evaluate existence of 
gender-effect. Statistically significant groups (p-value < 0.05, Wilcoxon test) were 
further investigated in terms of microbial diversity as well as taxonomic profile of 
microbiome, specific to male and female samples in the groups. 
 To identify differentially abundant taxa between IgAN, CT, UC and HC groups 
at the genus and OTU levels, we used LEfSe tool 
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(http://huttenhower.sph.harvard.edu/lefse/) on the galaxy server 
(https://huttenhower.sph.harvard.edu/galaxy/). LEfSe identifies the features (in our 
case, taxa) which are most likely to explain differences between the groups in a 
dataset. For this LEfSe uses the non-parametric Kruskal-Wallis test and unpaired 
Wilcoxon rank sum test to evaluate the statistical significance of the features and pairs 
this with LDA method to estimate the effect relevance of each feature/taxa among the 
groups (Segata et al. 2011). For this study, LEfSe analysis was carried out with default 
parameters, i.e., alpha value was set to 0.05 for statistical analyses, non-negative 
threshold for the logarithmic LDA score was set to 2 and strategy for multi-class 
analysis was set to all-against-all (more stringent).  
To identify a group of taxa among the selected biomarkers from the previous 
step (LEfSe analysis) which can act as potential biomarkers and classify IgAN from 
HC samples as well as other patients’ samples (UC and CT), we used Area Under 
Cuver-Random Forest (AUC-RF) (version 1.1) (Calle et al. 2011) package. To 
generate RF models using AUC-RF we used the protocol previously described 
(Iwasawa et al. 2018). Brielfy, RF was built, using all the variables selected by LEfSe 
tool and here the variables are ranked in terms of their importance (which is depicted 
by the mean decrease Gini score). Subsequently, 5% of the least important features 
were eliminated and RF was built with the remaining variables. The AUC was 
calculated for each of the RF models and was based on the OOB predictions. The 
best model was the RF model with the best AUC value. The performance of the best 
model was confirmed by evaluating the mean AUC of a 10-fold cross-validation 
repeated 20 times using the AUC-RF (Calle et al. 2011) package. The AUC-RF based 
analyses were performed using the R (v3.6.1) within RStudio environment (v1.2.5019). 
d. Data availability 
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The high-quality 16S V1-V2 sequences used in this study for downstream analysis 
were deposited on the DDBJ/GenBank/EMBL database (accession no. DRA002611, 
DRA002617, and DRA002618 (Tsuda et al. 2015), DRA011285 and DRA011286). 
Additionally, this chapter of the thesis is published as a research paper titled 
“Dysbiosis in the Salivary Microbiome Associated with IgA Nephropathy —A Japanese 
Cohort Study” (Khasnobish et al. 2021).  
3.3 Results 
a. Summary of 454 reads 
We obtained a total of 1,576,683 high-quality 16S reads from the four groups by using 
454 GS FLX Titanium platform (Roche Applied Science, Indianapolis, IN) (Table 9). 
After removing low quality and possibly chimera reads, we obtained a total of 809,607 
reads from 135 samples. Of them, we randomly selected 2300 reads per sample 
(310,500 reads from 135 samples), and further analyzed them using the pipeline for 
454 barcoded pyrosequencing of 16S amplicons in order to minimize overestimation 
of species richness in the clustering due to intrinsic sequencing error (Kim et al. 2013). 
The average Good’s coverage index (Good 1953; Singleton et al. 2001) of the 2300 
reads per sample was 0.97 (values ranging from 0.94 to 0.99), indicating a high degree 
of coverage. Hence, the sequence data was sufficient for analysis in the current study. 
b. Differences in alpha and beta diversity of salivary microbiota of IgAN, CT, UC and HC 
groups 
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The salivary microbiome of the IgAN samples was compared with the CT, UC and HC 
samples based on their alpha and beta diversities. Richness and diversity are the two 
most commonly used indices under alpha diversity. For this study, richness was 
estimated in terms of number of observed OTUs and Chao1 index whereas diversity 
Fig. 12. Alpha and beta diversity in IgAN, CT, UC and HC subjects. Samples from 43 
IgAN (blue), 20 CT (red), 22 UC (green) and 50 HC (purple) subjects are shown.  (A) The 
observed and Chao1-estimated OTU numbers, and the Shannon index of salivary 
microbiome from the four groups. * p-value <0.05; ** p-value < 0.01; *** p-value <0.001 
based on Wilcox test with Benjamin-Hochberg correction. (B) Weighted UniFrac–PCoA 
and (C) Unweighted UniFrac–PCoA of the salivary microbiome from the four groups. 
OTU, operational taxonomic unit; PCoA, principal coordinate analysis; IgAN, 
Immunoglobulin A Nephropathy; CT, Chronic Tonsillitis; UC, Ulcerative Colitis; HC, 
Healthy Controls. 
P a g e  | 75 
 
 
was estimated in terms of Shannon index. Similar to the findings in the last chapter, 
we observed a significant decrease in the number of observed OTUs as well as the 
Chao1 index in the IgAN samples than the HC samples (p = 5.31E-05 and 1.40E-06, 
respectively). The number of observed OTUs in the IgAN samples was significantly 
higher than the CT samples (p = 0.04407) (Fig. 12A). There was no significant 
difference between the IgAN and the UC samples in terms of the observed OTU 
numbers (Fig. 12A). The Chao1-estimated OTU numbers of the IgAN, CT, and UC 
samples were significantly lower than that of the HC samples (p= 1.40E-06, 6.79E-07, 
and 0.00459, respectively) (Fig. 12A). There was no significant difference between 
the IgAN samples and the UC samples in terms of the Chao1-estimated OTU numbers 
(p>0.05). Similarly, the Chao1-estimated OTU numbers of the CT was lower than the 
IgAN samples but the difference was not statistically significant (p>0.05). Shannon 
index, representing the within-sample microbial diversity, was significantly different 




Weighted UniFrac  Unweighted UniFrac 
R2 Adjusted p-value R2 
Adjusted p-
value 
CT vs HC 
CT: 20 
HC: 50 
0.06 0.006 0.06 0.001 
IgAN vs CT 
IgAN: 43 
CT: 20 
0.02 0.217 0.03 0.003 
IgAN vs HC 
IgAN: 43 
HC: 50 
0.07 0.003 0.03 0.001 
CT vs UC 
CT: 20 
UC: 22 
0.04 0.179 0.04 0.002 
UC vs HC 
UC: 22 
HC: 50 
0.04 0.043 0.05 0.001 
IgAN vs UC 
IgAN: 43 
UC: 22 
0.06 0.003 0.04 0.001 
The adjusted p-values were adjusted for multiple testing by Benjamin-Hochberg 
method. p-value <0.05 are in bold. 
 
Table 10. Permutational multivariate analysis of variance (PERMANOVA) in 
salivary microbiome samples among the four groups – IgAN, CT, UC and HC. 
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index was significantly lower in the IgAN, CT, and UC samples than the HC samples 
(p= 0.00048, 4.34E-08, and 0.01055, respectively). Among the patient samples, the 
Shannon index of the CT was significantly lower than the IgAN and UC samples (p= 
0.02099 and 0.01763, respectively) (Fig. 12A).   
Beta diversity, also known as between-sample diversity, is used to explain the 
variations in the microbiome structure between the samples. In our study we used 
weighted and unweighted UniFrac metrics to determine the beta diversity between 
IgAN, CT, UC and HC samples. PCoA of the unweighted and weighted UniFrac 
distance metrics of our dataset is shown in the (Fig. 12B, C).  In the unweighted plot, 
the largest principal coordinates were 11.53% and 5.26% of total variation, 
respectively, while they were 30.33% and 20.27%, respectively, in the weighted plot. 
PCoA based on the unweighted UniFrac distance metric showed that many of the 
IgAN, CT, and UC samples were segregated from HC samples (Fig. 12B). According 
to the PERMANOVA, the IgAN and CT samples exhibited a significant difference 
based on the unweighted UniFrac metric (p<0.01) but there was no significant 
difference between the groups depending on the weighted UniFrac metric (Table 10). 
Additionally, the PERMANOVA results also indicate that the IgAN samples differed 
significantly from both HC and UC samples based on unweighted (p <0.01) as well as 
weighted (p< 0.01) UniFrac metrics, respectively (Table 10). When compared with the 
HC, the IgAN samples presented lower degree of dysbiosis than the CT and UC 
samples. This was evident from the R2 values from the PERMANOVA on to 
unweighted UniFrac metrics (R2 value= 0.03 (IgAN vs HC); 0.06 (CT vs HC); 0.05 (UC 
vs HC); Table 10). 
c. Variations in the salivary microbiome taxonomic profiles between the two groups 
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Next, 310,500 reads from 135 samples were taxonomically assigned to 2782 OTUs 
using the phylotypes in the public microbial 16S rRNA gene databases. The major 
phyla with relative mean abundances of more than 0.1% across all the groups (IgAN, 
CT, UC and HC) accounted for 99.8% of the total abundances and consisted of 
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, Candidatus 
Saccharibacteria (TM7), and Streptophyta. Firmicutes was the major phyla across all 
groups, with highest mean relative abundance in the IgAN samples but there was no 
significant difference in terms of mean relative abundance of Firmicutes amongst the 
groups (p>0.05). Bacteroidetes was significantly less abundant (p = 0.0014), whereas 
Proteobacteria was significantly more abundant (p = 0.0021) in the IgAN samples than 
the HC samples. The relative mean abundance of Actinobacteria was significantly 
higher in the UC samples than the IgAN and HC samples (p = 0.0256 and 0.0085, 
respectively). Candidatus Sachharibacteria (TM7) was significantly less abundant in 
the CT samples than the IgAN and HC samples (p = 0.0074 and 3.75909E-05, 
respectively). Given the higher relative mean abundances of Firmicutes corresponding 
with lower relative mean abundances of Bacteroidetes in the disease groups (IgAN, 
CT and UC), the Firmicutes/Bacteroidetes ratio was higher in the disease samples 
than the HC samples. However, the Firmicutes/Proteobacteria ratio was lower in the 
disease samples than the HC samples.  
 The taxonomic assignment at the genus level identified 270 bacterial genera. 
51 out of these 270 genera had a relative mean abundance of more than 0.1% and 
accounted for 97.8% of the total abundance. Streptococcus was the highest in 
abundance in the IgAN samples followed by CT, UC and HC samples, but there was 
no significant difference amongst the groups in terms of its mean relative abundance. 
Neisseria was significantly more abundant in the IgAN samples than the HC and UC 
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samples (p = 0.0005 and 0.0032, respectively), whereas Prevotella, Megasphaera, 
and Solobacterium were significantly less abundant in the IgAN samples compared to 
the HC and UC samples (p = 0.0019, 0.0335, 0.0241, 0.0261, 0.0417 and 0.0391, 
respectively). Stomatobaculum was significantly more abundant in the IgAN samples 
than the CT and UC samples (p= 0.0385 and 0.005, respectively). However, 
Stomatobaculum significantly depleted in abundance in the IgAN samples as 
compared to the HC samples (p = 0.0008). Similarly, the abundance of 
Peptostreptococcus in the IgAN samples was significantly lower when compared to 
the HC samples (p = 0.0044) but significantly higher when compared to the CT 
samples (p = 0.0431). Peptococcus was significantly more abundant whereas 
Schaalia was significantly less abundant in the IgAN samples than the CT samples 
(p= 0.0361 and 0.0147, respectively).  Schaalia was also lower in abundance in the 
IgAN samples than the UC samples (p = 0.0017). Actinomyces and Selenomonas 
were significantly less abundant, whereas Gemella was significantly more abundant 
in IgAN samples than the UC samples (p = 0.0020, 0.0006, and 0.0098, respectively). 
 Additionally, there were some similar patterns regarding genus abundance in 
the patient samples (IgAN, CT and UC) compared to the HC samples. 
Stomatobaculum, Staphylococcus, Cutibacterium, and Peptostreptococcus 
significantly decreased in abundance in all the patient samples (IgAN, UC, and CT) as 
compared with the HC samples (respective p-values < 0.05). Similarly, the genera, 
namely, Veillonella, Solobacterium, and Corynebacterium, showed a significant 
decrease in abundance in the IgAN and the CT samples than the HC samples 
(respective p-values < 0.05). The mean relative abundance of Enhydrobacter genera 
was significantly lower in the IgAN and the UC samples than the HC samples (p = 
0.0021, and 0.0457, respectively).  
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To further evaluate the salivary microbiome differences among patients with IgAN, CT, 
Fig. 13. Common differential features between IgAN and remaining three groups 
(CT, UC and HC) from LefSe analysis. With threshold LDA score >2, differentially 
abundant taxa were identified between IgAN vs CT, IgAN vs UC and IgAN vs HC 
groups. The four common taxa at the OTU level are shown in here. Individual red bars 
represent relative abundance of the taxa in a sample. LefSe, Linear discriminant 
analysis (LDA) effect size; IgAN, Immunoglobulin A Nephropathy; CT, Chronic 
Tonsillitis; UC, Ulcerative Colitis; HC, Healthy Controls. 
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UC, and the healthy subjects (HC), the LEfSe method was used to identify significant 
Fig. 14. Random Forest (RF) analysis of the salivary microbiota of the four groups 
using AUC-RF package at OTU level. Best RF models (comparison based on 
combination of best mean area under curve (AUC) value) was obtained at (a) Genus 
and (b) OTU level. The selected features of best RF models for (c) IgAN-HC, (d)IgAN-
CT and (e)IgAN-UC comparisons are shown. Kopt = optimal number of features to 
distinguish between the two groups under comparison; IgAN, Immunoglobulin A 
Nephropathy; CT, Chronic Tonsillitis; UC, Ulcerative Colitis; HC, Healthy Controls. 
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discriminative features between the groups. With the logarithmic LDA score threshold 
set at 2, at the OTU level, we identified 19, 33, and 36 differential taxa between IgAN 
and CT, IgAN and UC, and IgAN and HC samples, respectively (Fig. S1). Among these, 
four taxa, namely, OTU00113 (99.68% similarity with Haemophilus parahaemolyticus), 
OTU00237 (98.76% similarity with Stomatobaculum longum), OTU00251 (99.04% 
similarity with Actinomyces sp. ICM47) and OTU00050 (99.71% similarity with 
Peptostreptococcus stomatis) were common differential features between IgAN and 
remaining three groups (CT, UC and HC) (Fig. 13). 
To determine the potential value of the identified microbial biomarkers to 
clinically differentiate the IgAN group from disease (CT and UC) and the HC samples, 
we generated random forest (RF) models using the AUC-RF package. We generated 
models for two taxa levels (genus and OTU) (Table 11). We used the AUC of the 
receiver operative curve (ROC), that was in turn based upon the OOB error rate, to 
Category 
cvAUC 
OTU Level Genus Level 
IgAN vs HC 0.88 0.90 
IgAN vs CT 0.62 0.707 
IgAN vs UC 0.88 0.851 
The mean AUCs (cvAUC) of the 10-fold cross validation process repeated 
20 times using the best RF model in the AUC-RF package are shown here. 
cvAUC, mean area under curve from 20 repetitive 10-fold cross validation of 
random forest model; RF, Random Forest. 
 1 
Table 11. The mean area under curve for salivary microbiome samples 
among the IgAN, CT, UC and HC groups. 
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find the combination of multiple taxa from the 30 genera selected by the LefSe tool as 
Fig. 15. Genus level variables from Random Forest (RF) analysis of the salivary 
microbiota using AUC-RF package. The mean relative abundance of taxa selected by 
AUC-RF are shown here.(A)Six unique genera selected for IgAN vs HC model; (B) One 
unique genera selected for IgAN vs CT model; and (C)Common genera selected for IgAN 
vs HC and IgAN vs CT model . * p-value <0.05; ** p-value < 0.01; *** p-value <0.001 
based on Wilcox test with Benjamin-Hochberg correction. IgAN=blue, CT=red, and 
HC=purple. IgAN, Immunoglobulin A Nephropathy; CT, Chronic Tonsillitis; HC, Healthy 
Control; OTU, operational taxonomic unit. 
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potential features which can contribute in differentiating IgAN group from the rest. The 
models with best AUC values at the genus level were observed for 7, 2, and 3 genera 
between the IgAN and HC, the IgAN and CT, and the IgAN and UC samples, 
respectively (Fig. 14A). Among these selected genera, Neisseria was a common 
contributor for distinguishing the IgAN samples from HC, CT, and UC samples, and 
Schaalia was a common contributor for distinguishing the IgAN samples from CT and 
UC samples (Fig. 15C). Neisseria was significantly higher in abundance in the IgAN 
than the HC and the UC samples (p= 0.0005, and 0.0032 respectively), whereas there 
was no significant difference in terms of its abundance between IgAN and CT samples. 
Schaalia was significantly less abundant in the IgAN samples than the CT and UC 
samples (p = 0.01 and 0.002, respectively) (Fig. 15B). Out of 7 genera, 6 
(Staphylococcus, Prevotella, Peptostreptococcus, Corynebacterium, Veillonella and 
Stomatobaculum) solely contributed to distinguishing the IgAN samples from the HC 
samples (Fig. 15). Out of the 3 genera, genus Selenomonas only contributed to 
distinguishing the IgAN samples from the UC samples. We confirmed the results by 
10-fold cross-validation of the AUC-RF models repeated 20 times and obtained the 
mean AUCs, which were 0.90 between the IgAN and HC samples, 0.707 between the 
IgAN and CT samples, and 0.851 between the IgAN and UC samples (Table 11).  
At the OTU level, we used 66 differential OTUs selected by the LefSe tool to 
build the RF model. The models with best AUC values had 9, 15, and 12 OTUs 
between the IgAN and HC samples, the IgAN and CT, and the IgAN and UC samples, 
respectively (Fig. 14B). Out of these OTUs, OTU00002 (100% similarity with Neisseria 
perflava) and OTU00050 (99.71% identity with Peptostreptococcus stomatis) were 
common contributors in distinguishing the IgAN samples from the healthy (HC) as well 
as patient samples (CT, and UC). OTU00002 (100% similarity with Neisseria perflava) 
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was significantly higher in abundance in the IgAN samples than the HC and UC 
samples (p= 0.0002 and 0.0060, respectively), but the difference between its 
abundance in the IgAN and CT samples was not significant (p > 0.05). UC and HC 
samples had significantly higher whereas the CT samples had a significantly lower 
abundance of the OTU, OTU00050 (99.71% identity with Peptostreptococcus 
stomatis), than the IgAN samples (p = 0.02, 0.01, and 0.03, respectively). Four OTUS, 
OTU00312 (98.7% similarity with Schaalia meyeri), OTU00251 (99.04% similarity with 
Actinomyces sp. ICM47), OTU00011 (100% similarity with Veillonella atypica), and 
OTU00031 (100% similarity with Oribacterium sinus) were the common contributors 
in distinguishing the IgAN group from the other two disease (CT and UC) samples. 
OTU00312 (98.7% similarity with Schaalia meyeri) was significantly lower in 
abundance in the IgAN samples as compared to CT and UC samples (p = 0.005 and 
0.005, respectively). While OTU00251 (99.04% similarity with Actinomyces sp. 
ICM47) had significantly lower abundance, OTU00031 (100% similarity with 
Oribacterium sinus) had significantly higher abundance in the IgAN samples than UC 
group (p = 0.0005 and 0.04, respectively). There was no significant difference between 
IgAN and the other two disease groups in terms of the abundance of OTU00011 (100% 
similarity with Veillonella atypica). The mean AUC of the 10-fold cross-validation 
repeated 20 times for the best AUC-RF models was 0.88 between the IgAN and HC 
samples, 0.62 between the IgAN and CT samples, and 0.88 between the IgAN and 
UC samples (Table 11). 
d. Gender-specific microbiome association 
P a g e  | 85 
 
 
As we observed in the previous chapter there was an underlying gender-specific 
microbiome structure in IgAN and HC samples. Therefore, we aimed to check whether 
any such structure presents itself when we are comparing the four samples – IgAN, 
CT, UC and HC in terms of the gender distribution amongst the samples. To check 
whether there is any underlying gender-specific association of the salivary microbiome, 
we performed a PERMANOVA test where the samples were grouped according to 
their genders. PERMANOVA test showed a significant difference between male and 
female groups with respect to weighted and unweighted UniFrac metrics irrespective 
of the disease-state grouping (Table 12). Upon further analyzing the dataset group-
wise, there was a significant difference between male and female samples in the IgAN 
samples for weighted UniFrac metric and in the HC samples for unweighted UniFrac 
metric only (Table 12). However, the CT and UC samples didn’t exhibit any gender-
specific microbiome structure. These findings match our findings in the previous 
Table 12. Permutational multivariate analysis of variance (PERMANOVA) in 
salivary microbiome samples in the four groups to check gender effect. The 
adjusted p-values were adjusted for multiple testing by Benjamin-Hochberg method. 
p-value <0.05 are in bold. 
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chapter which accounts for detailed gender-specific microbiome structure in the IgAN 
and HC samples. 
3.4 Discussion 
The human microbiome is closely associated with mucosal immunity, and there have 
been reports about the gut, tonsil, periodontal and salivary microbiota associated with 
IgAN (Cao et al. 2018; De Angelis et al. 2014; Dong et al. 2020; Hu et al. 2020; Luan et 
al. 2019; Nagasawa et al. 2014; Park et al. 2020; Piccolo et al. 2015; Watanabe et al. 
2017). However, despite Japan being the second highest in the world in terms of 
incidence and frequency of IgAN (Schena and Nistor 2018), the IgAN associated 
microbiota studies for the Japanese cohort are limited. Our present study represents 
the characterization of salivary microbiome of patients with IgAN in comparison with 
patients with CT and UC, and healthy subjects. To the best of our knowledge, this is the 
first study to characterize salivary microbiome of Japanese IgAN patients.   
In this study, we observed altered salivary microbial composition in the IgAN 
patients as compared to the healthy subjects, indicated by the lower species richness 
and microbial diversity in the IgAN patients’ salivary microbiota. Similar trend was 
observed in salivary microbiome composition of CT and UC patients. Similarly, salivary 
microbial richness and diversity were lower but not significant (P>0.05) in IgAN than HC 
in the Caucasian population(Piccolo et al. 2015) whereas a Chinese population based 
study of IgAN salivary microbiota did not report any significant difference(Luan et al. 
2019). In fecal microbiome studies associated with IgAN, few studies reported similar 
findings of lower microbial richness(De Angelis et al. 2014; Hu et al. 2020) and 
diversity(De Angelis et al. 2014) in IgAN compared to HC, whereas another study did 
not find any significant difference(Dong et al. 2020). The observed differences might be 
rooted in the variability of study design, like using different hypervariable regions for 
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16S rRNA sequencing, using different sequencing platforms, sample size, or ethnicity 
differences. Statistical analysis of the phylogeny-based weighted and unweighted 
UniFrac metrics shows that the observed dysbiosis is associated with differences in the 
presence or absence of the microbial taxa as well as their abundance in the population. 
Therefore, as seen in Caucasian(De Angelis et al. 2014; Piccolo et al. 2015) and 
Chinese(Dong et al. 2020; Luan et al. 2019) population studies, our study demonstrates 
microbial dysbiosis in IgAN patients. From PERMANOVA analysis of unweighted 
UniFrac distance metrics, IgAN and CT samples differ significantly only in terms of 
microbial taxa composition. In contrast, both the membership and abundance of the 
microbial taxa contribute to a significant difference between IgAN and UC samples.  
Thus, we can infer that the CT and IgAN samples's overall microbial population is similar. 
However, as this is the first instance of comparing salivary microbiome of IgAN, CT and 
UC patients, a detailed and larger population-based study exploring relationships 
among these diseases in terms of microbiome is required for more concrete 
understanding. 
There were differences at the taxonomic level between the IgAN and the rest of 
the samples. The phylum Firmicutes dominated all the samples and was most abundant 
in the IgAN, following previous studies on fecal and salivary microbiota studies of IgAN 
patients(De Angelis et al. 2014; Hu et al. 2020; Luan et al. 2019). The 
Firmicutes/Proteobacteria ratio was lower in the IgAN group as compared to the HC 
samples. This ratio agrees with the previously reported salivary microbiota study on the 
Caucasian population (Piccolo et al. 2015) and periodontal microbiome study on the 
Asian population(Cao et al. 2018) but is in contrast with the salivary microbiota study in 
Chinese cohort(Luan et al. 2019).  
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Our study reported an increase in Firmicutes/Bacteroides ratio in the UC group 
compared to the HC group, which is similar to the findings of a few gut microbiome 
studies (Kabeerdoss et al. 2015; Xun et al. 2018). Also, being in line with a meta-
analysis study of the gut microbiota composition in IBD (Walters et al. 2014) and salivary 
microbiome ecotypes associated with UC (Xun et al. 2018), we observed a significant 
enrichment of Phyla Actinobacteria in the UC group as compared to IgAN and HC. This 
confirms that abnormal physiological state is associated with microbial dysbiosis in gut 
inflammatory diseases (Xun et al. 2018).  
The significant differences between IgAN group and the remaining three groups 
(CT, UC and HC) in terms of microbial taxa prompted us to investigate the selected 
biomarkers for discriminating IgAN samples from other diseases as well as healthy 
controls. In our study, a combination of salivary taxa separated IgAN from healthy 
individuals with AUC of 0.88 and 0.90 at OTU and genus levels, respectively. A Chinese 
cohort study reported separation of IgAN from HC with predictive accuracy up to 80% 
upon using salivary microbial OTUs in combination with biochemical characteristics 
(Luan et al. 2019). These results indicate that salivary microbiome derived biomarkers 
can be used for predictive diagnosis of IgAN from healthy population.  
Neisseria was a common contributor in distinguishing IgAN from healthy 
individuals and CT patients. This genus is enriched in the IgAN samples when 
compared with the disease as well as healthy samples, similar to the findings of a 
previous study(Piccolo et al. 2015). Also, at the OTU level, some OTUs belonging to 
the Neisseria genus were among the selected taxa for differentiating IgAN from the UC 
samples and they were significantly enriched in IgAN patients. Previous salivary 
microbiome studies report the co-occurrence of Neisseria and Haemophilus in salivary 
ecosystem(De Angelis et al. 2014; Takeshita et al. 2016). Salivary community type 
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comprising of Neisseria, Haemophilus, Gemella, Porphyromonas, and Streptococcus 
mitis along with reduced phylogenetic diversity was associated with better periodontal 
health(Takeshita et al. 2016). A salivary microbiome study of IBD patients reported that 
elevated salivary IgA levels were correlated with lower abundance of Neisseria, 
Haemophilus, Gemella and Streptococcus (Said et al. 2014). Salivary IgA levels are 
elevated in IgAN patients according to scientific literature (Yamabe et al. 1987). In our 
study, abundance of Neisseria, Haemophilus, Gemella and Streptococcus genera 
increased in the IgAN patients. Therefore, we can infer that abundance of Neisseria, 
Haemophilus, Gemella and Streptococcus genera are not directly associated with 
salivary IgA response in IgAN pathogenesis. This can be attributed to difference in the 
disease pathogenesis of IgAN and IBD. However, as this is the first instance of 
comparison between IgAN and UC associated salivary microbiome and given the lack 
of data corresponding to salivary IgA levels of the IgAN patients in our study, the 
underlying relationship of salivary IgA and microbiome in light of these two diseases 
has a scope of future research. 
Some of the OTUs belonging to the genus Gemella differentiated IgAN from UC 
samples (Fig. S1(B)). Unlike previous study results (Piccolo et al. 2015), this taxa was 
relatively more abundant in IgAN patients than UC and HC samples. Such differences 
in IgAN salivary microbiome across population supports the heterogeneity of IgAN 
pathology across different ethnicities (Yeo et al. 2018a).  
Prevotella is one of the selected genera that contributes to differentiating IgAN 
patients from healthy controls. In line with previous reports(Cao et al. 2018; Luan et al. 
2019; Piccolo et al. 2015), there was significant enrichment of Prevotella in HC than 
IgAN samples. The Chinese fecal microbiome study comparing the IgAN patients, 
membranous nephropathy patients, and healthy controls noted a positive correlation 
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between Prevotella and a higher serum albumin level. Serum albumin plays an essential 
role in reducing oxidative stress in the mesangial cells by attenuating the reactive 
oxygen species like hydrogen peroxide, thereby lowering the risk of IgAN progression 
towards ESRD (Kawai et al. 2018). From this, we can infer that Prevotella genera has 
a protective role in the salivary and gut ecosystem, and a decline in its abundance may 
facilitate systemic disease progression like IgAN. 
Though OTU clustering methods in our study is not sufficient for species level 
assignment, we found several OTUs assigned to Prevotella melaninogenica species, 
with more than 99% identity, which were among the selected taxa for distinguishing 
IgAN patients from UC patients and these were significantly enriched in UC patients 
than IgAN patients. Even though P. melaninogenica is identified as a member of the 
Japanese salivary core microbiome (Takeshita et al. 2016), various studies have 
associated P. melaninogenica with oral and systemic diseases (Brook 1995; Kondo et 
al. 2018; Sibley et al. 2011). In blood mononuclear cells of IgAN patients (Chang and Li 
2020; Saito et al. 2016) and in dendritic cells of IBD patients (Crohn’s disease and 
UC)(Hug et al. 2018), the TLR2 expression increases. Since P. melaninogenica 
reportedly stimulates cytokine response via TLR2 pathways (Kondo et al. 2018), it has 
the potential to contribute to the progression of inflammatory disorders like UC and IgAN. 
On the other hand, the depletion of CD4+ T cells correlated with an increase of P. 
melaninogenica in salivary microbiota of HIV patients (Lewy et al. 2019). Thus, lower 
abundance of P. melaninogenica in IgAN patients in our study implied the autoimmune 
nature of IgAN, and further investigation is needed to clarify the role of this genera in T 
helper cell imbalance in IgAN. 
Under Firmicutes phyla, Streptococcus is the predominant genera, with highest 
abundance in the CT samples, followed by the IgAN samples. In previous reports, 
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Streptococcus was enriched in the subgingival microbiome of chronic periodontitis 
patients with IgAN (Cao et al. 2018) and is also one of the core members of tonsillar 
crypt microbiome (Jensen et al. 2013). 16S rDNA reads of Streptococcaeae family 
increased in the fecal microbiome of IgAN patients with persistent proteinuria(De 
Angelis et al. 2014). Another study reported an increase in the cell surface collagen-
binding Cnm protein of Streptococcus mutans in tonsillar specimens of IgAN patients 
compared to CT patients (Ito et al. 2019). This study also reported an association 
between the presence of Cnm-positive S. mutans strain with greater severity of 
symptoms in IgAN patients, marked by higher proteinuria and lower serum albumin 
levels(Ito et al. 2019). In our study, we found the mean relative abundance of S. mutans 
was higher in IgAN than CT samples (though p>0.05). These evidences along with 
findings such as presence streptococcal proteins in the renal tissues from IgAN patients 
(Schmitt et al. 2010) indicate that bacterial causal agents of focal tonsillar infection, 
like Streptococcus, can be associated with IgAN pathogenesis.  
Several OTUs belonging to Haemophilus genus vary significantly only between 
the IgAN and UC samples. Some members of Hemophilus genus, like H. 
parahaemolyticus, are commensal microflora in the upper respiratory tract, and 
literature suggests these are to be considered as opportunistic pathogens capable of 
causing invasive and severe diseases (Le Floch et al. 2013). H. parahaemolyticus 
belongs to the H. parainfluenzae samples and is one of the few species in Haemophilus 
genera like H. influenzae, producing IgA1 protease that attributes to its pathogenicity in 
its human host (Norskov-Lauritsen 2014). Piccolo et al. reported an increase of H. 
parainfluenzae in salivary microbiota of IgAN patients with the lowest 
proteinuria(Piccolo et al. 2015). Authors recommending the use of H. influenzae derived 
IgA protease for IgAN treatment state that lack of mesangial IgA1 specificity of the H. 
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influenzae derived IgA protease limits its immediate application for IgAN therapy (Eitner 
and Floege 2008). These observations suggest that some members 
of Hemophilus genera contribute to the early stages of IgAN pathogenesis. Further 
research based on these associative members might contribute towards a better 
understanding of the progression of IgAN and thus expedite the therapeutic applications. 
 In this study the microbial diversity and richness of salivary microbiome 
decreased significantly in UC patients compared to HC. This was in contrast to previous 
studies that reported no significant difference between these two groups in terms of 
richness or diversity(Said et al. 2014; Xun et al. 2018). Also, unlike the previous 
reports(Xun et al. 2018), Firmicutes/Bacteroidetes ratio decreased in UC samples 
compared to HC samples. Like previous reports(Said et al. 2014; Xun et al. 2018), 
Oribacterium decreased significantly in UC than HC. While our study and another 
study(Xun et al. 2018) reported enrichment of Streptococcus in UC patient’s salivary 
microbiome, Said et al. (2014) reported a depletion of this genus in UC patients. 
Moreover, unlike the previous report (Said et al. 2014), in our study Veillonella was less 
abundant in UC samples than HC samples. We also noted a decrease in abundance of 
Prevotella in UC samples (though P>0.05). This was in line with the Chinese cohort 
study (Xun et al. 2018) where they reported a significant depletion in Prevotella in UC 
samples. However, Said et al. (2014) reported an increase in abundance of this genus 
in UC samples. The contrast in the observations between our study and previous study 
can be attributed to multiple factors like study design, sample size, and genetic history 
of the study subjects.  
  While some epidemiological studies observed a male predominance in North 
American and Western European populations(Barratt and Feehally 2014; Sukcharoen 
et al. 2020), others show an equal distribution of IgAN incidence between genders in 
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the Asian population(Cheng et al. 2013; Feehally and Barratt 2015; Lee et al. 2012).  A 
single-center study in Japan showed that primary glomerulonephritis showed higher 
frequency in men as compared to women(Moriyama et al. 2010). In microbiome studies 
gender may act as a confounding factor as some show a significant difference between 
male and female microbiome(Minty et al. 2020; Raju et al. 2019). Thus, upon exploring 
existence of gender-associated microbiota in our cohort we found that unlike previous 
study on a cohort of Hans Chinese origin(He et al. 2021a), microbial richness of the 
IgAN male and IgAN female groups was significantly lower than corresponding HC male 
and HC female groups (Fig. 10). We also found that some genera had significant 
difference of abundance only between HC and IgAN males (Fig. 11A), whereas some 
others differed only between HC and IgAN females (Fig. 11B).  These observations 
suggest that microbiota may play a role in the gender-associated risk of IgAN disease 
progression and, further research in this field is essential.  
The current study has some limitations. Firstly, our study included small and non-
uniform sample size across the groups. The imbalance in dataset was not statistically 
significant and did not affect the microbiome analysis. Disease predictive modeling is 
affected by an imbalanced dataset; however, the random forest classifier is relatively 
robust when dealing with an imbalanced dataset(Dittman et al. 2015) and the AUC-RF 
package uses a random forest classifier for modeling. Secondly, data associated with 
stage of disease for IgAN patients is not available for clinical metadata correlation 
analysis. However, since tonsillectomy is recommended and effective in the early 
stages IgAN(Hotta et al. 2001) and the IgAN patients in the current study collected the 
saliva sample before their tonsillectomy surgery, it implies that patients were in the early 
stage of the disease. Lastly, our study design is limited by the lack of clinical data 
reporting the serum or salivary IgA levels in the IgAN patients. As secretory IgA plays 
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important role in IgAN pathogenesis, there is a scope for future microbiome study 
exploring the relationship between the secretory IgA levels and predominant microbiota 
associated with IgAN. 
In conclusion, our findings from the current study, where we explored the 
variations in salivary microbiome profiles of IgAN patients, UC patients, CT patients and 
HC, indicate that the salivary microbiome is a potential biomarker source to develop a 
non-invasive diagnostic tool for IgAN. However, the biological role of the microbial 
biomarkers identified in this study in the pathogenesis and disease progression of IgAN 
is a scope of further research. 
  

















CKD is a worldwide health issue affecting millions of individuals every year. According 
to the Japanese Society of Nephrology report in 2005, approximately 13.3 million people 
in Japan have CKD(Imai et al. 2009). IgAN has been identified as one of the leading 
causes of CKD in Japanese population (Tomino 2016). With an incidence rate of 39-45 
IgAN cases per million population per year and 50% of these patients progressing to 
ESRD (Moriyama et al. 2014), Japan is second highest in the world in terms of IgAN 
prevalence. Japan is the home to world’s most rapidly aging population (Chen et al. 
2019) and with annually rising numbers of dialysis patients (Masakane et al. 2018), 
IgAN is a significant health burden on the Japanese population. Even after more than 
50 years since its first classification, underlying mechanisms of IgAN pathogenesis is 
poorly understood and the development of diagnostic methods independent of renal 
biopsy has been slow. IgA primarily originates from MALT, and GWAS of IgAN identified 
several risk loci involved in maintaining mucosal immunity (Sallustio et al. 2019). The 
salivary microbiome plays crucial roles in regulating mucosal immunity for local and 
systemic homeostasis (Moutsopoulos and Konkel 2018). Members of the salivary 
microbiome are potential diagnostic biomarkers for immunological diseases such as 
rheumatoid arthritis (Chen et al. 2018), primary sclerosing cholangitis (Iwasawa et al. 
2018), pancreatic cancer (Coit et al. 2016; Torres et al. 2015) and CKD (Hu et al. 2018). 
Interestingly, the GWAS revealed common risk loci between IgAN and IBD (UC or CD) 
(Sallustio et al. 2019). IgAN patients have 2.6 times higher risk of UC than those without 
IgAN (Rehnberg et al. 2021). Some studies detected pathogenic bacteria, commonly 
associated with CT and periodontitis, in tonsillar crypts of IgAN patients (Jensen et al. 
2013; Nagasawa et al. 2014; Watanabe et al. 2017). According to the Ministry of Health, 
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Labor, and Welfare 2005 survey in Japan, the male gender is one of the predictive 
factors of IgAN (Tomino 2016). Also, according to previous reports, gender may incur 
an effect on microbiome composition (He et al. 2021a). Thus, we also explored the 
gender-specific association of the salivary microbiome for IgAN patients. 
To address the gaps in IgAN research, this study aimed to investigate the 
salivary microbiome profile of IgAN patients in comparison with that of age-, gender-
matched healthy individuals in Japanese population. Second objective of this research 
study was to compare the salivary microbiome profile of IgAN patients with related 
mucosal diseases like CT and UC. Lastly, we aimed to investigate the salivary 
microbiome as a tool for the non-invasive diagnosis of IgAN.  
The first study aimed to compare the salivary microbiome profile of IgAN patients 
with that of HC in a Japanese cohort. Saliva was collected from 43 IgAN patients and 
50 age- and gender matched HC. The hypervariable V1–V2 regions of 16S rRNA gene 
were purified from all the samples and amplified using 27Fmod and 338R primers. The 
salivary microbial profile of IgAN and HC samples were investigated by using high-
throughput 454-pyrosequencing technology and bioinformatic analyses pipelines. 
Statistical analyses were conducted on R software.  We used Linear discriminant 
analysis effect size (LEfSe) tool and R-based AUC-RF package to identify microbial 
biomarkers for differentiating IgAN from HC. Alpha diversity parameters for richness 
and diversity (Observed Operational Taxonomic Units, Chao1, Shannon) were 
significantly lower in than HC samples (p<0.05, wilcoxon test). At the phylum level, 
Bacteroidetes significantly decreased whereas Proteobacteria significantly increased in 
abundance in IgAN samples compared with HC samples. Using LEfSe followed by 
AUC-RF, we were able to identify a group of 7 genera (Staphylococcus, Prevotella, 
Neisseria, Peptostreptococcus, Corynebacterium, Stomatobaculum and Veillonella) to 
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differentiate IgAN from HC samples, with area under curve of 0.90. Additionally, there 
was a significant difference between IgAN male and HC male samples in terms of the 
microbiome structure and composition. A similar difference was also observed between 
IgAN female and HC female samples. There is a significant dysbiosis in salivary 
microbiome of IgAN patients. Salivary microbiome is potential source of biomarkers for 
development of effective and non-invasive diagnostic tool for IgAN diagnosis and 
association of microbiome and gender in the context of IgAN patients should be 
explored in future studies. To our best knowledge, this is the first report of salivary 
microbiome profile of Japanese IgAN patients. 
The second study aimed to explore the salivary microbiome profile of IgAN 
patients in comparison with salivary microbiome profiles of chronic tonsilitis patients, 
ulcerative colitis patients and healthy controls. Saliva was collected from 43 IgAN 
patients (IgAN), 50 healthy controls (HC), 20 chronic tonsilitis patients (CT) and 22 
ulcerative colitis patients (UC). The hypervariable V1–V2 regions of 16S rRNA gene 
were purified from all the samples and amplified using 27Fmod and 338R primers. The 
salivary microbial profile of all the samples were investigated by using high-throughput 
454-pyrosequencing technology and bioinformatic analyses pipelines. Statistical 
analyses were conducted on R software.  We used LEfSe tool and R-based AUC-RF 
package to identify microbial biomarkers for differentiating IgAN from mucosal diseases 
(CT and UC) and HC. We noted a significant difference in microbial diversity and 
richness between IgAN patients and HC. IgAN and CT differed significantly in terms of 
both microbial diversity and richness whereas there was no significant difference in 
terms of alpha diversity between IgAN and UC. PERMANOVA of UniFrac distance 
metrics to quantify the beta-diversity, we found that when compared with the HC 
samples, the IgAN samples presented lower degree of dysbiosis than the other two 
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disease groups (CT and UC). Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, 
Fusobacteria, Candidatus Saccharibacteria (TM7), and Streptophyta were the major 
phyla with relative mean abundances of more than 0.1% across all the groups (IgAN, 
CT, UC and HC) and accounted for 99.8% of the total abundances. Combining the 
genera selected by the random forest algorithm, we were able to distinguish the IgAN 
from the HC samples with the area under the curve (AUC) of 0.90, from the UC samples 
with the AUC of 0.88, and from the CT samples with AUC of 0.70. Additionally, genus 
Neisseria was common among the selected genera that contributed in distinguishing 
the IgAN samples from HC, CT and UC samples. IgAN can be differentiated from 
related mucosal disease using biomarkers derived from the salivary microbiome. 
Therefore, salivary microbiome is a potential source of biomarkers for development of 
effective and non-invasive diagnostic tool for IgAN diagnosis. 
  





















‘Gratitude can transform common days into thanksgivings, turn routine jobs into joy and 
change ordinary opportunity into blessings.’ 
Having an opportunity to pave the path towards a doctoral degree in a foreign land would 
have been nothing but a dream if not for the people who walked with me throughout this 
journey. I want to take this opportunity to pay my honest gratitude to all those who constantly 
strived to get the best out of me. 
         First and foremost, I would like to extend my sincere thanks to my supervisor, Prof. 
Hidetoshi Morita for his valuable guidance, and cooperation. I am grateful to my co-
supervisors, Assoc. Prof. Kensuke Arakawa and Prof. Naoki Nishino for their inspiring 
support and helpful advice throughout the tenure of my Ph.D. research. Under their unique 
guidance, I trained to become an independent researcher. 
         Talent wins games, but teamwork and intelligence win championships. I would like to 
take this opportunity to express my heartfelt gratitude to fellow researchers and students of 
the Laboratory of Animal Applied Microbiology for assistance, encouragement, and their 
priceless company which made my journey memorable. In this regard, I extend my sincere 
appreciation to my friend and lab mate, Junliang Zhao for being my constant support system 
during the research tenure. 
The success of the journey often depends on the quality of the start. In this regard, I 
am indebted to my senior, Dr. Tien Thi Thuy Nguyen, who molded my confidence and guided 
me as I started my journey as a research student under her guidance. 
         I would like to thank all the staff of the Graduate School of Environmental and Life 
Science, Okayama University for their cooperation during this research work. I would also 
like to thank the Japanese government, specifically the Ministry of Education, Culture, Sports, 
P a g e  | 102 
 
 
Science and Technology (Monbukagakusho (MEXT)) for the financial aid that ensured a 
stress-free living in Japan as a foreign researcher. 
Great teamwork is the only way we create the breakthroughs that define our careers. 
It is an honor to express my sincere appreciation to Prof. Masahira Hattori for accepting me 
into his laboratory as part of the IMS RIKEN internship program. His feedback elevated the 
quality of this research and inspired the young researcher in me. I would also like to thank Dr. 
Wataru Suda and Dr. Lena Takayasu of Laboratory of Microbiome Science, IMS RIKEN, 
Japan for their intense technical guidance, moral support, and constant encouragement to 
go that extra mile for excellence. I am immensely grateful to all the members of the Laboratory 
of Microbiome Science, IMS RIKEN, Japan as our enriching discussions have sustained my 
love for research. 
This thesis is a gratuity, symbolizing my gratitude to all the people close to me for 
having their faith in me despite experiencing all my tantrums. Thanks to Nouha Tekiki, Majd 
Sami Barham, Hager Mansour, Areej Z Sakkour, Hannaneh Ahmadi, Ghmkin Hassan, Herik 
Acosta, Shivakshi Sulekh, and Sayaka Kondo for their unwavering support in my life in Japan. 
I am thankful to my host family, Nakazato family, for making me feel at home away from home. 
I’m extremely grateful to Shahbaz Ahmed for being my constant source of strength. I would 
also like to thank my friends from India – Dr. Prerona Dutta, Suparna Chakraborty, Purnima 
Kovuri, Ashmita Saha, Kripa Gupta, Debodip Saha, Ria Dhar, Siddhartha Ranjan Pradhan, 
Dibyayan Deb, and Santanu Das – for having cheered me throughout my endeavor of 
doctoral studies. 
Last but not least I want to convey my sincere gratitude to my family who always 
endowed me with their love, affection, care, and trust. I owe everything to my parents, Mrs. 
Kabita Khasnobish and Mr. Anutosh Khasnobish, who gave me the strength to achieve my 
dreams. My sister, Anwesha Khasnobish, has always been my best and toughest critic whose 
P a g e  | 103 
 
 
support is an inevitable part of my life. My niece, Archisha Mukhopadhyay, gave me the extra 
dose of energy and curiosity to finish my last lap of the doctoral journey. 




























Abe K., Takahashi A., Fujita M., Imaizumi H., Hayashi M., Okai K., Ohira H. (2018) 
Dysbiosis of oral microbiota and its association with salivary immunological 
biomarkers in autoimmune liver disease. PLoS One 13 (7):e0198757. 
doi:10.1371/journal.pone.0198757 
Acharya A., Chan Y., Kheur S., Jin L. J., Watt R. M., Mattheos N. (2017a) Salivary 
microbiome in non-oral disease: A summary of evidence and commentary. Arch Oral 
Biol 83:169-173. doi:10.1016/j.archoralbio.2017.07.019 
Acharya A., Chan Y., Kheur S., Kheur M., Gopalakrishnan D., Watt R., Mattheos N. 
(2017b) Salivary microbiome of an urban Indian cohort and patterns linked to 
subclinical inflammation. Oral Diseases 23 (7):926-940. 
doi:https://doi.org/10.1111/odi.12676 
Adami G. R., Tangney C. C., Tang J. L., Zhou Y., Ghaffari S., Naqib A., Sinha S., Green 
S. J., Schwartz J. L. (2018) Effects of green tea on miRNA and microbiome of oral 
epithelium. Scientific Reports 8 (1):5873. doi:10.1038/s41598-018-22994-3 
Ahuja T. S., Funtanilla M., de Groot J. J., Velasco A., Badalamenti J., Wilson S. (1998) 
IgA nephropathy in psoriasis. Am J Nephrol 18 (5):425-429. doi:10.1159/000013388 
Al Khodor S., Shatat I. F. (2017) Gut microbiome and kidney disease: a bidirectional 
relationship. Pediatr Nephrol 32 (6):921-931. doi:10.1007/s00467-016-3392-7 
Alamartine E., Sabatier J. C., Guerin C., Berliet J. M., Berthoux F. (1991) Prognostic 
factors in mesangial IgA glomerulonephritis: an extensive study with univariate and 
multivariate analyses. Am J Kidney Dis 18 (1):12-19. doi:10.1016/s0272-
6386(12)80284-8 
Amore A., Conti G., Cirina P., Peruzzi L., Alpa M., Bussolino F., Coppo R. (2000) 
Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of 
P a g e  | 106 
 
 
vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis 36 
(6):1242-1252. doi:10.1053/ajkd.2000.19840 
Araújo M. V., Hong B. Y., Fava P. L., Khan S., Burleson J. A., Fares G., Samson W., 
Strausbaugh L. D., Diaz P. I., Ioannidou E. (2015) End stage renal disease as a 
modifier of the periodontal microbiome. BMC Nephrol 16:80. doi:10.1186/s12882-015-
0081-x 
Bäckhed F., Ley R. E., Sonnenburg J. L., Peterson D. A., Gordon J. I. (2005) Host-
Bacterial Mutualism in the Human Intestine. Science 307 (5717):1915-1920. 
doi:10.1126/science.1104816 
Bain C. C., Cerovic V. (2020) Interactions of the microbiota with the mucosal immune system. 
Clinical & Experimental Immunology 199 (1):9-11. doi:10.1111/cei.13400 
Bajaj J. S., Betrapally N. S., Hylemon P. B., Heuman D. M., Daita K., White M. B., Unser 
A., Thacker L. R., Sanyal A. J., Kang D. J., Sikaroodi M., Gillevet P. M. (2015) 
Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic 
encephalopathy. Hepatology 62 (4):1260-1271. doi:https://doi.org/10.1002/hep.27819 
Barbour S. J., Espino-Hernandez G., Reich H. N., Coppo R., Roberts I. S., Feehally J., 
Herzenberg A. M., Cattran D. C. (2016) The MEST score provides earlier risk 
prediction in lgA nephropathy. Kidney Int 89 (1):167-175. doi:10.1038/ki.2015.322 
Barratt J., Feehally J. (2014) 20 - Immunoglobulin A Nephropathy and Related Disorders. 
In: Gilbert SJ, Weiner DE (eds) National Kidney Foundation Primer on Kidney 
Diseases (Sixth Edition). W.B. Saunders, Philadelphia, pp 185-192. 
doi:https://doi.org/10.1016/B978-1-4557-4617-0.00020-0 
Beaufils H., Jouanneau C., Katlama C., Sazdovitch V., Hauw J. J. (1995) HIV-associated 
IgA nephropathy—A post-mortem study. Nephrology Dialysis Transplantation 10 
(1):35-38. doi:10.1093/oxfordjournals.ndt.a090849 
P a g e  | 107 
 
 
Belstrom D. (2020) The salivary microbiota in health and disease. J Oral Microbiol 12 
(1):1723975. doi:10.1080/20002297.2020.1723975 
Berger J., Hinglais N. (1968) [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) 74 
(9):694-695 
Brook I. (1995) Prevotella and Porphyromonas infections in children. Journal of Medical 
Microbiology 42 (5):340-347. doi:https://doi.org/10.1099/00222615-42-5-340 
Calle M. L., Urrea V., Boulesteix A. L., Malats N. (2011) AUC-RF: a new strategy for 
genomic profiling with random forest. Hum Hered 72 (2):121-132. 
doi:10.1159/000330778 
Cao Y., Qiao M., Tian Z., Yu Y., Xu B., Lao W., Ma X., Li W. (2018) Comparative Analyses 
of Subgingival Microbiome in Chronic Periodontitis Patients with and Without IgA 
Nephropathy by High Throughput 16S rRNA Sequencing. Cell Physiol Biochem 47 
(2):774-783. doi:10.1159/000490029 
Carlassara L., Zanoni F., Gharavi A. G. (2021) Familial Aggregation of CKD: Gene or 
Environment? American Journal of Kidney Diseases 77 (6):861-862. 
doi:10.1053/j.ajkd.2020.12.010 
Chang S., Li X.-K. (2020) The Role of Immune Modulation in Pathogenesis of IgA 
Nephropathy. Frontiers in Medicine 7 (92). doi:10.3389/fmed.2020.00092 
Chauveau D., Droz D. (1993) Follow-up evaluation of the first patients with IgA nephropathy 
described at Necker Hospital. Contrib Nephrol 104:1-5. doi:10.1159/000422388 
Chen B., Zhao Y., Li S., Yang L., Wang H., Wang T., Bin S., Gai Z., Heng X., Zhang C., 
Yang J., Zhang L. (2018) Variations in oral microbiome profiles in rheumatoid arthritis 
and osteoarthritis with potential biomarkers for arthritis screening. Sci Rep 8 (1):17126. 
doi:10.1038/s41598-018-35473-6 
P a g e  | 108 
 
 
Chen R., Xu P., Song P., Wang M., He J. (2019) China has faster pace than Japan in 
population aging in next 25 years. BioScience Trends 13 (4):287-291. 
doi:10.5582/bst.2019.01213 
Chen T., Yu W. H., Izard J., Baranova O. V., Lakshmanan A., Dewhirst F. E. (2010) The 
Human Oral Microbiome Database: a web accessible resource for investigating oral 
microbe taxonomic and genomic information. Database (Oxford) 2010:baq013. 
doi:10.1093/database/baq013 
Cheng G. Y., Liu D. W., Zhang N., Tang L., Zhao Z. Z., Liu Z. S. (2013) Clinical and 
prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study 
of 348 cases with a mean 5-year follow-up. Clin Nephrol 80 (1):40-46. 
doi:10.5414/cn107813 
Cheng J., Zhang W., Zhang X. H., He Q., Tao X. J., Chen J. H. (2009) ACEI/ARB therapy 
for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 
63 (6):880-888. doi:10.1111/j.1742-1241.2009.02038.x 
Cho B. S., Hahn W. H., Cheong H. I., Lim I., Ko C. W., Kim S. Y., Lee D. Y., Ha T. S., Suh 
J. S. (2013) A nationwide study of mass urine screening tests on Korean school 
children and implications for chronic kidney disease management. Clin Exp Nephrol 
17 (2):205-210. doi:10.1007/s10157-012-0672-9 
Coit P., Mumcu G., Ture-Ozdemir F., Unal A. U., Alpar U., Bostanci N., Ergun T., 
Direskeneli H., Sawalha A. H. (2016) Sequencing of 16S rRNA reveals a distinct 
salivary microbiome signature in Behçet's disease. Clin Immunol 169:28-35. 
doi:10.1016/j.clim.2016.06.002 
D'Amico G. (1987) The commonest glomerulonephritis in the world: IgA nephropathy. Q J 
Med 64 (245):709-727 
P a g e  | 109 
 
 
D'Amico G. (1988) Clinical features and natural history in adults with IgA nephropathy. Am 
J Kidney Dis 12 (5):353-357. doi:10.1016/s0272-6386(88)80023-4 
D'Amico G. (2004) Natural history of idiopathic IgA nephropathy and factors predictive of 
disease outcome. Semin Nephrol 24 (3):179-196. 
doi:10.1016/j.semnephrol.2004.01.001 
Dawes C. (2003) Estimates, from salivary analyses, of the turnover time of the oral mucosal 
epithelium in humans and the number of bacteria in an edentulous mouth. Arch Oral 
Biol 48 (5):329-336. doi:10.1016/s0003-9969(03)00014-1 
De Angelis M., Montemurno E., Piccolo M., Vannini L., Lauriero G., Maranzano V., Gozzi 
G., Serrazanetti D., Dalfino G., Gobbetti M., Gesualdo L. (2014) Microbiota and 
metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 9 
(6):e99006. doi:10.1371/journal.pone.0099006 
De Filippis F., Vannini L., La Storia A., Laghi L., Piombino P., Stellato G., Serrazanetti 
D. I., Gozzi G., Turroni S., Ferrocino I., Lazzi C., Di Cagno R., Gobbetti M., Ercolini 
D. (2014) The same microbiota and a potentially discriminant metabolome in the saliva 
of omnivore, ovo-lacto-vegetarian and Vegan individuals. PLoS One 9 (11):e112373. 
doi:10.1371/journal.pone.0112373 
Diaz P. I., Hong B.-Y., Frias-Lopez J., Dupuy A. K., Angeloni M., Abusleme L., Terzi E., 
Ioannidou E., Strausbaugh L. D., Dongari-Bagtzoglou A. (2013) Transplantation-
Associated Long-Term Immunosuppression Promotes Oral Colonization by Potentially 
Opportunistic Pathogens without Impacting Other Members of the Salivary Bacteriome. 
Clinical and Vaccine Immunology 20 (6):920-930. doi:doi:10.1128/CVI.00734-12 
Dittman D. J., Khoshgoftaar T. M., Napolitano A. The Effect of Data Sampling When Using 
Random Forest on Imbalanced Bioinformatics Data. In: 2015 IEEE International 
P a g e  | 110 
 
 
Conference on Information Reuse and Integration, 13-15 Aug. 2015 2015. pp 457-463. 
doi:10.1109/IRI.2015.76 
Donadio J. V., Grande J. P. (2002) IgA nephropathy. N Engl J Med 347 (10):738-748. 
doi:10.1056/NEJMra020109 
Dong R., Bai M., Zhao J., Wang D., Ning X., Sun S. (2020) A Comparative Study of the Gut 
Microbiota Associated With Immunoglobulin a Nephropathy and Membranous 
Nephropathy. Front Cell Infect Microbiol 10:557368. doi:10.3389/fcimb.2020.557368 
Duan X., Chen X., Gupta M., Seriwatanachai D., Xue H., Xiong Q., Xu T., Li D., Mo A., 
Tang X., Zhou X., Li Y., Yuan Q. (2020) Salivary microbiome in patients undergoing 
hemodialysis and its associations with the duration of the dialysis. BMC Nephrology 
21 (1):414. doi:10.1186/s12882-020-02009-y 
Dzidic M., Collado M. C., Abrahamsson T., Artacho A., Stensson M., Jenmalm M. C., 
Mira A. (2018) Oral microbiome development during childhood: an ecological 
succession influenced by postnatal factors and associated with tooth decay. Isme j 12 
(9):2292-2306. doi:10.1038/s41396-018-0204-z 
Eitner F., Floege J. (2008) Bacterial protease for the treatment of IgA nephropathy. Nephrol 
Dial Transplant 23 (7):2173-2175. doi:10.1093/ndt/gfn155 
Feehally J. (2017) Immunosuppression in IgA Nephropathy: Guideline Medicine Versus 
Personalized Medicine. Semin Nephrol 37 (5):464-477. 
doi:10.1016/j.semnephrol.2017.05.019 
Feehally J., Barratt J. (2015) The Genetics of IgA Nephropathy: An Overview from Western 
Countries. Kidney Dis (Basel) 1 (1):33-41. doi:10.1159/000381738 
Filiopoulos V., Trompouki S., Hadjiyannakos D., Paraskevakou H., Kamperoglou D., 
Vlassopoulos D. (2010) IgA nephropathy in association with Crohn's disease: a case 
P a g e  | 111 
 
 
report and brief review of the literature. Ren Fail 32 (4):523-527. 
doi:10.3109/08860221003710554 
Flemer B., Warren R. D., Barrett M. P., Cisek K., Das A., Jeffery I. B., Hurley E., 
O‘Riordain M., Shanahan F., O‘Toole P. W. (2018) The oral microbiota in colorectal 
cancer is distinctive and predictive. Gut 67 (8):1454-1463. doi:10.1136/gutjnl-2017-
314814 
Francavilla R., Ercolini D., Piccolo M., Vannini L., Siragusa S., De Filippis F., De 
Pasquale I., Di Cagno R., Di Toma M., Gozzi G., Serrazanetti D. I., De Angelis M., 
Gobbetti M. (2014) Salivary microbiota and metabolome associated with celiac 
disease. Appl Environ Microbiol 80 (11):3416-3425. doi:10.1128/aem.00362-14 
Freire M., Nelson K. E., Edlund A. (2021) The Oral Host&#x2013;Microbial Interactome: An 
Ecological Chronometer of Health? Trends in Microbiology 29 (6):551-561. 
doi:10.1016/j.tim.2020.11.004 
Gharavi A. G., Yan Y., Scolari F., Schena F. P., Frasca G. M., Ghiggeri G. M., Cooper K., 
Amoroso A., Viola B. F., Battini G., Caridi G., Canova C., Farhi A., Subramanian 
V., Nelson-Williams C., Woodford S., Julian B. A., Wyatt R. J., Lifton R. P. (2000) 
IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. 
Nat Genet 26 (3):354-357. doi:10.1038/81677 
Good I. J. (1953) The population frequences of species and the estimation of population 
parameters. Biometrika 40 (3-4):237-264. doi:10.1093/biomet/40.3-4.237 
Haas M. (2007) IgA nephropathy and Henoch-Schönlein purpura nephritis. Heptinstall's 
Pathology of the Kidney:423-486 
Han L., Fang X., He Y., Ruan X. Z. (2016) ISN Forefronts Symposium 2015: 
IgA Nephropathy, the Gut Microbiota, and Gut−Kidney Crosstalk. Kidney International 
Reports 1 (3):189-196. doi:10.1016/j.ekir.2016.08.002 
P a g e  | 112 
 
 
Harper S. J., Allen A. C., Bene M.-C., Pringle J. H., Faure G., Lauder I., Feehally J. (1995) 
Increased dimeric IgA-producing B cells in tonsils in IgA nephropathy determined by 
in situ hybridization for J chain mRNA. Clinical & Experimental Immunology 101 
(3):442-448. doi:https://doi.org/10.1111/j.1365-2249.1995.tb03132.x 
He J.-W., Zhou X.-J., Hou P., Wang Y.-N., Gan T., Li Y., Liu Y., Liu L.-J., Shi S.-F., Zhu 
L., Lv J.-C., Zhang H. (2021a) Potential Roles of Oral Microbiota in the Pathogenesis 
of Immunoglobin A Nephropathy. Frontiers in Cellular and Infection Microbiology 11 
(260). doi:10.3389/fcimb.2021.652837 
He J., Zhou X.-j., Hou P., Wang Y.-N., Gan T., Liu Y., Lijun L., Shi S.-F., Zhu L., lv J. 
(2021b) Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A 
Nephropathy. Frontiers in Cellular and Infection Microbiology 11:652837. 
doi:10.3389/fcimb.2021.652837 
Hemadi A. S., Huang R., Zhou Y., Zou J. (2017) Salivary proteins and microbiota as 
biomarkers for early childhood caries risk assessment. International Journal of Oral 
Science 9 (11):e1-e1. doi:10.1038/ijos.2017.35 
Hotta O., Miyazaki M., Furuta T., Tomioka S., Chiba S., Horigome I., Abe K., Taguma Y. 
(2001) Tonsillectomy and steroid pulse therapy significantly impact on clinical 
remission in patients with IgA nephropathy. Am J Kidney Dis 38 (4):736-743. 
doi:10.1053/ajkd.2001.27690 
Hu J., Iragavarapu S., Nadkarni G. N., Huang R., Erazo M., Bao X., Verghese D., Coca 
S., Ahmed M. K., Peter I. (2018) Location-Specific Oral Microbiome Possesses 
Features Associated With CKD. Kidney Int Rep 3 (1):193-204. 
doi:10.1016/j.ekir.2017.08.018 
P a g e  | 113 
 
 
Hu X., Du J., Xie Y., Huang Q., Xiao Y., Chen J., Yan S., Gong Z., Ouyang S. (2020) Fecal 
microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-
sectional study. BMC Nephrol 21 (1):97. doi:10.1186/s12882-020-01741-9 
Hug H., Mohajeri M. H., La Fata G. (2018) Toll-Like Receptors: Regulators of the Immune 
Response in the Human Gut. Nutrients 10 (2). doi:10.3390/nu10020203 
Huttenhower C., Gevers D., Knight R., Abubucker S., Badger J. H., Chinwalla A. T., 
Creasy H. H., Earl A. M., FitzGerald M. G., Fulton R. S., Giglio M. G., Hallsworth-
Pepin K., Lobos E. A., Madupu R., Magrini V., Martin J. C., Mitreva M., Muzny D. 
M., Sodergren E. J., Versalovic J., Wollam A. M., Worley K. C., Wortman J. R., 
Young S. K., Zeng Q., Aagaard K. M., Abolude O. O., Allen-Vercoe E., Alm E. J., 
Alvarado L., Andersen G. L., Anderson S., Appelbaum E., Arachchi H. M., 
Armitage G., Arze C. A., Ayvaz T., Baker C. C., Begg L., Belachew T., Bhonagiri 
V., Bihan M., Blaser M. J., Bloom T., Bonazzi V., Paul Brooks J., Buck G. A., 
Buhay C. J., Busam D. A., Campbell J. L., Canon S. R., Cantarel B. L., Chain P. 
S. G., Chen I. M. A., Chen L., Chhibba S., Chu K., Ciulla D. M., Clemente J. C., 
Clifton S. W., Conlan S., Crabtree J., Cutting M. A., Davidovics N. J., Davis C. C., 
DeSantis T. Z., Deal C., Delehaunty K. D., Dewhirst F. E., Deych E., Ding Y., 
Dooling D. J., Dugan S. P., Michael Dunne W., Scott Durkin A., Edgar R. C., Erlich 
R. L., Farmer C. N., Farrell R. M., Faust K., Feldgarden M., Felix V. M., Fisher S., 
Fodor A. A., Forney L. J., Foster L., Di Francesco V., Friedman J., Friedrich D. C., 
Fronick C. C., Fulton L. L., Gao H., Garcia N., Giannoukos G., Giblin C., Giovanni 
M. Y., Goldberg J. M., Goll J., Gonzalez A., Griggs A., Gujja S., Kinder Haake S., 
Haas B. J., Hamilton H. A., Harris E. L., Hepburn T. A., Herter B., Hoffmann D. E., 
Holder M. E., Howarth C., Huang K. H., Huse S. M., Izard J., Jansson J. K., Jiang 
H., Jordan C., Joshi V., Katancik J. A., Keitel W. A., Kelley S. T., Kells C., King N. 
P a g e  | 114 
 
 
B., Knights D., Kong H. H., Koren O., Koren S., Kota K. C., Kovar C. L., Kyrpides 
N. C., La Rosa P. S., Lee S. L., Lemon K. P., Lennon N., Lewis C. M., Lewis L., 
Ley R. E., Li K., Liolios K., Liu B., Liu Y., Lo C.-C., Lozupone C. A., Dwayne 
Lunsford R., Madden T., Mahurkar A. A., Mannon P. J., Mardis E. R., Markowitz 
V. M., Mavromatis K., McCorrison J. M., McDonald D., McEwen J., McGuire A. L., 
McInnes P., Mehta T., Mihindukulasuriya K. A., Miller J. R., Minx P. J., Newsham 
I., Nusbaum C., O’Laughlin M., Orvis J., Pagani I., Palaniappan K., Patel S. M., 
Pearson M., Peterson J., Podar M., Pohl C., Pollard K. S., Pop M., Priest M. E., 
Proctor L. M., Qin X., Raes J., Ravel J., Reid J. G., Rho M., Rhodes R., Riehle K. 
P., Rivera M. C., Rodriguez-Mueller B., Rogers Y.-H., Ross M. C., Russ C., Sanka 
R. K., Sankar P., Fah Sathirapongsasuti J., Schloss J. A., Schloss P. D., Schmidt 
T. M., Scholz M., Schriml L., Schubert A. M., Segata N., Segre J. A., Shannon W. 
D., Sharp R. R., Sharpton T. J., Shenoy N., Sheth N. U., Simone G. A., Singh I., 
Smillie C. S., Sobel J. D., Sommer D. D., Spicer P., Sutton G. G., Sykes S. M., 
Tabbaa D. G., Thiagarajan M., Tomlinson C. M., Torralba M., Treangen T. J., Truty 
R. M., Vishnivetskaya T. A., Walker J., Wang L., Wang Z., Ward D. V., Warren W., 
Watson M. A., Wellington C., Wetterstrand K. A., White J. R., Wilczek-Boney K., 
Wu Y., Wylie K. M., Wylie T., Yandava C., Ye L., Ye Y., Yooseph S., Youmans B. 
P., Zhang L., Zhou Y., Zhu Y., Zoloth L., Zucker J. D., Birren B. W., Gibbs R. A., 
Highlander S. K., Methé B. A., Nelson K. E., Petrosino J. F., Weinstock G. M., 
Wilson R. K., White O., The Human Microbiome Project C. (2012) Structure, 
function and diversity of the healthy human microbiome. Nature 486 (7402):207-214. 
doi:10.1038/nature11234 
P a g e  | 115 
 
 
Ibels L. S., Györy A. Z. (1994) IgA nephropathy: analysis of the natural history, important 
factors in the progression of renal disease, and a review of the literature. Medicine 
(Baltimore) 73 (2):79-102 
Imai E., Horio M., Watanabe T., Iseki K., Yamagata K., Hara S., Ura N., Kiyohara Y., 
Moriyama T., Ando Y., Fujimoto S., Konta T., Yokoyama H., Makino H., Hishida 
A., Matsuo S. (2009) Prevalence of chronic kidney disease in the Japanese general 
population. Clinical and Experimental Nephrology 13 (6):621-630. 
doi:10.1007/s10157-009-0199-x 
Imai E., Yamagata K., Iseki K., Iso H., Horio M., Mkino H., Hishida A., Matsuo S. (2007) 
Kidney Disease Screening Program in Japan: History, Outcome, and Perspectives. 
Clinical Journal of the American Society of Nephrology 2 (6):1360-1366. 
doi:10.2215/cjn.00980207 
Imai H., Miura N. (2012) A treatment dilemma in adult immunoglobulin A nephropathy: what 
is the appropriate target, preservation of kidney function or induction of clinical 
remission? Clinical and experimental nephrology 16 (2):195-201. doi:10.1007/s10157-
011-0552-8 
Ito S., Misaki T., Naka S., Wato K., Nagasawa Y., Nomura R., Otsugu M., Matsumoto-
Nakano M., Nakano K., Kumagai H., Oshima N. (2019) Specific strains of 
Streptococcus mutans, a pathogen of dental caries, in the tonsils, are associated with 
IgA nephropathy. Scientific Reports 9 (1):20130. doi:10.1038/s41598-019-56679-2 
Iwasawa K., Suda W., Tsunoda T., Oikawa-Kawamoto M., Umetsu S., Takayasu L., Inui 
A., Fujisawa T., Morita H., Sogo T., Hattori M. (2018) Dysbiosis of the salivary 
microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a 
biomarker. Sci Rep 8 (1):5480. doi:10.1038/s41598-018-23870-w 
P a g e  | 116 
 
 
Jensen A., Fago-Olsen H., Sorensen C. H., Kilian M. (2013) Molecular mapping to species 
level of the tonsillar crypt microbiota associated with health and recurrent tonsillitis. 
PLoS One 8 (2):e56418. doi:10.1371/journal.pone.0056418 
Kabeerdoss J., Jayakanthan P., Pugazhendhi S., Ramakrishna B. S. (2015) Alterations 
of mucosal microbiota in the colon of patients with inflammatory bowel disease 
revealed by real time polymerase chain reaction amplification of 16S ribosomal 
ribonucleic acid. Indian J Med Res 142 (1):23-32. doi:10.4103/0971-5916.162091 
Kawai Y., Masutani K., Torisu K., Katafuchi R., Tanaka S., Tsuchimoto A., Mitsuiki K., 
Tsuruya K., Kitazono T. (2018) Association between serum albumin level and 
incidence of end-stage renal disease in patients with Immunoglobulin A nephropathy: 
A possible role of albumin as an antioxidant agent. PloS one 13 (5):e0196655-
e0196655. doi:10.1371/journal.pone.0196655 
Kawamura T., Yoshimura M., Miyazaki Y., Okamoto H., Kimura K., Hirano K., 
Matsushima M., Utsunomiya Y., Ogura M., Yokoo T., Okonogi H., Ishii T., 
Hamaguchi A., Ueda H., Furusu A., Horikoshi S., Suzuki Y., Shibata T., Yasuda 
T., Shirai S., Imasawa T., Kanozawa K., Wada A., Yamaji I., Miura N., Imai H., 
Kasai K., Soma J., Fujimoto S., Matsuo S., Tomino Y. (2014) A multicenter 
randomized controlled trial of tonsillectomy combined with steroid pulse therapy in 
patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 29 (8):1546-
1553. doi:10.1093/ndt/gfu020 
KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 10: Immunoglobulin A 
nephropathy (2012). Kidney international supplements, vol 2. Nature Publishing Group. 
doi:10.1038/kisup.2012.23 
Khasnobish A., Takayasu L., Watanabe K.-i., Nguyen T. T. T., Arakawa K., Hotta O., Joh 
K., Nakano A., Hosomi S., Hattori M., Suda W., Morita H. (2021) Dysbiosis in the 
P a g e  | 117 
 
 
Salivary Microbiome Associated with IgA Nephropathy—A Japanese Cohort Study. 
Microbes and Environments 36 (2). doi:10.1264/jsme2.ME21006 
Kim S. W., Suda W., Kim S., Oshima K., Fukuda S., Ohno H., Morita H., Hattori M. (2013) 
Robustness of gut microbiota of healthy adults in response to probiotic intervention 
revealed by high-throughput pyrosequencing. DNA Res 20 (3):241-253. 
doi:10.1093/dnares/dst006 
Kiryluk K., Li Y., Scolari F., Sanna-Cherchi S., Choi M., Verbitsky M., Fasel D., Lata S., 
Prakash S., Shapiro S., Fischman C., Snyder H. J., Appel G., Izzi C., Viola B. F., 
Dallera N., Del Vecchio L., Barlassina C., Salvi E., Bertinetto F. E., Amoroso A., 
Savoldi S., Rocchietti M., Amore A., Peruzzi L., Coppo R., Salvadori M., Ravani 
P., Magistroni R., Ghiggeri G. M., Caridi G., Bodria M., Lugani F., Allegri L., 
Delsante M., Maiorana M., Magnano A., Frasca G., Boer E., Boscutti G., Ponticelli 
C., Mignani R., Marcantoni C., Di Landro D., Santoro D., Pani A., Polci R., Feriozzi 
S., Chicca S., Galliani M., Gigante M., Gesualdo L., Zamboli P., Battaglia G. G., 
Garozzo M., Maixnerova D., Tesar V., Eitner F., Rauen T., Floege J., Kovacs T., 
Nagy J., Mucha K., Paczek L., Zaniew M., Mizerska-Wasiak M., Roszkowska-
Blaim M., Pawlaczyk K., Gale D., Barratt J., Thibaudin L., Berthoux F., Canaud 
G., Boland A., Metzger M., Panzer U., Suzuki H., Goto S., Narita I., Caliskan Y., 
Xie J., Hou P., Chen N., Zhang H., Wyatt R. J., Novak J., Julian B. A., Feehally J., 
Stengel B., Cusi D., Lifton R. P., Gharavi A. G. (2014) Discovery of new risk loci for 
IgA nephropathy implicates genes involved in immunity against intestinal pathogens. 
Nat Genet 46 (11):1187-1196. doi:10.1038/ng.3118 
Kistler J. O., Arirachakaran P., Poovorawan Y., Dahlén G., Wade W. G. (2015) The oral 
microbiome in human immunodeficiency virus (HIV)-positive individuals. Journal of 
Medical Microbiology 64 (9):1094-1101. doi:https://doi.org/10.1099/jmm.0.000128 
P a g e  | 118 
 
 
Kittiskulnam P., Kanjanabuch T., Tangmanjitjaroen K., Chancharoenthana W., 
Praditpornsilpa K., Eiam-Ong S. (2014) The beneficial effects of weight reduction in 
overweight patients with chronic proteinuric immunoglobulin a nephropathy: a 
randomized controlled trial. J Ren Nutr 24 (3):200-207. doi:10.1053/j.jrn.2014.01.016 
Kluytmans J., van Belkum A., Verbrugh H. (1997) Nasal carriage of Staphylococcus 
aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol 
Rev 10 (3):505-520. doi:10.1128/cmr.10.3.505 
Koçak G., Huddam B., Azak A., Ortabozkoyun L., Duranay M. (2012) Coexistent findings 
of renal glomerular disease with Hashimoto's thyroiditis. Clin Endocrinol (Oxf) 76 
(5):759-762. doi:10.1111/j.1365-2265.2011.04302.x 
Kodama S., Suzuki M., Arita M., Mogi G. (2001) Increase in tonsillar germinal centre B-1 
cell numbers in IgA nephropathy (IgAN) patients and reduced susceptibility to Fas-
mediated apoptosis. Clin Exp Immunol 123 (2):301-308. doi:10.1046/j.1365-
2249.2001.01431.x 
Komatsu H., Fujimoto S., Hara S., Sato Y., Yamada K., Kitamura K. (2008) Effect of 
tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a 
controlled study. Clinical journal of the American Society of Nephrology : CJASN 3 
(5):1301-1307. doi:10.2215/CJN.00310108 
Kondo Y., Sato K., Nagano K., Nishiguchi M., Hoshino T., Fujiwara T., Nakayama K. 
(2018) Involvement of PorK, a component of the type IX secretion system, in 
Prevotella melaninogenica pathogenicity. Microbiology and Immunology 62 (9):554-
566. doi:10.1111/1348-0421.12638 
Konishi Y., Okada N., Okamura M., Morikawa T., Okumura M., Yoshioka K., Imanishi M. 
(2001) Sodium Sensitivity of Blood Pressure Appearing Before Hypertension and 
P a g e  | 119 
 
 
Related to Histological Damage in Immunoglobulin A Nephropathy. Hypertension 38 
(1):81-85. doi:doi:10.1161/01.HYP.38.1.81 
Koyama A., Igarashi M., Kobayashi M. (1997) Natural history and risk factors for 
immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal 
Diseases. Am J Kidney Dis 29 (4):526-532. doi:10.1016/s0272-6386(97)90333-4 
Koyama A., Sharmin S., Sakurai H., Shimizu Y., Hirayama K., Usui J., Nagata M., Yoh 
K., Yamagata K., Muro K., Kobayashi M., Ohtani K., Shimizu T., Shimizu T. (2004) 
<em>Staphylococcus aureus</em> cell envelope antigen is a new candidate for the 
induction of IgA nephropathy. Kidney International 66 (1):121-132. doi:10.1111/j.1523-
1755.2004.00714.x 
Krishnan K., Chen T., Paster B. (2017) A practical guide to the oral microbiome and its 
relation to health and disease. Oral Diseases 23 (3):276-286. doi:10.1111/odi.12509 
Lai K. N. (2012) Pathogenesis of IgA nephropathy. Nature Reviews Nephrology 8 (5):275-
283. doi:10.1038/nrneph.2012.58 
Lai K. N., Li P. K., Hawkins B., Lai F. M. (1989) IgA nephropathy associated with ankylosing 
spondylitis: occurrence in women as well as in men. Ann Rheum Dis 48 (5):435-437. 
doi:10.1136/ard.48.5.435 
Lai K. N., Tang S. C., Schena F. P., Novak J., Tomino Y., Fogo A. B., Glassock R. J. 
(2016) IgA nephropathy. Nat Rev Dis Primers 2:16001. doi:10.1038/nrdp.2016.1 
Lamm M. E. (1997) INTERACTION OF ANTIGENS AND ANTIBODIES AT MUCOSAL 
SURFACES. Annual Review of Microbiology 51 (1):311-340. 
doi:10.1146/annurev.micro.51.1.311 
Larsen J. M. (2017) The immune response to Prevotella bacteria in chronic inflammatory 
disease. Immunology 151 (4):363-374. doi:https://doi.org/10.1111/imm.12760 
P a g e  | 120 
 
 
Lassalle F., Spagnoletti M., Fumagalli M., Shaw L., Dyble M., Walker C., Thomas M. G., 
Bamberg Migliano A., Balloux F. (2018) Oral microbiomes from hunter-gatherers 
and traditional farmers reveal shifts in commensal balance and pathogen load linked 
to diet. Mol Ecol 27 (1):182-195. doi:10.1111/mec.14435 
Lau W. L., Kalantar-Zadeh K., Vaziri N. D. (2015) The Gut as a Source of Inflammation in 
Chronic Kidney Disease. Nephron 130 (2):92-98. doi:10.1159/000381990 
Le Floch A.-S., Cassir N., Hraiech S., Guervilly C., Papazian L., Rolain J.-M. (2013) 
Haemophilus parahaemolyticus septic shock after aspiration pneumonia, France. 
Emerg Infect Dis 19 (10):1694-1695. doi:10.3201/eid1910.130608 
Lee H., Kim D. K., Oh K.-H., Joo K. W., Kim Y. S., Chae D.-W., Kim S., Chin H. J. (2012) 
Mortality of IgA Nephropathy Patients: A Single Center Experience over 30 Years. 
PLOS ONE 7 (12):e51225. doi:10.1371/journal.pone.0051225 
Levey A. S., Eckardt K. U., Tsukamoto Y., Levin A., Coresh J., Rossert J., De Zeeuw D., 
Hostetter T. H., Lameire N., Eknoyan G. (2005) Definition and classification of 
chronic kidney disease: a position statement from Kidney Disease: Improving Global 
Outcomes (KDIGO). Kidney Int 67 (6):2089-2100. doi:10.1111/j.1523-
1755.2005.00365.x 
Lewy T., Hong B. Y., Weiser B., Burger H., Tremain A., Weinstock G., Anastos K., 
George M. D. (2019) Oral Microbiome in HIV-Infected Women: Shifts in the 
Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV 
Load, CD4 Count, and Antiretroviral Therapy. AIDS Res Hum Retroviruses 35 (3):276-
286. doi:10.1089/aid.2017.0200 
Li H., Limenitakis J. P., Fuhrer T., Geuking M. B., Lawson M. A., Wyss M., Brugiroux S., 
Keller I., Macpherson J. A., Rupp S., Stolp B., Stein J. V., Stecher B., Sauer U., 
McCoy K. D., Macpherson A. J. (2015) The outer mucus layer hosts a distinct 
P a g e  | 121 
 
 
intestinal microbial niche. Nature Communications 6 (1):8292. 
doi:10.1038/ncomms9292 
Li J., Quinque D., Horz H.-P., Li M., Rzhetskaya M., Raff J. A., Hayes M. G., Stoneking 
M. (2014a) Comparative analysis of the human saliva microbiome from different 
climate zones: Alaska, Germany, and Africa. BMC Microbiology 14 (1):316. 
doi:10.1186/s12866-014-0316-1 
Li Y., Jin L., Chen T. (2020) The Effects of Secretory IgA in the Mucosal Immune System. 
BioMed Research International 2020:2032057. doi:10.1155/2020/2032057 
Li Y., Saxena D., Chen Z., Liu G., Abrams W. R., Phelan J. A., Norman R. G., Fisch G. 
S., Corby P. M., Dewhirst F., Paster B. J., Kokaras A. S., Malamud D., Tang Y.-W. 
(2014b) HIV Infection and Microbial Diversity in Saliva. Journal of Clinical Microbiology 
52 (5):1400-1411. doi:doi:10.1128/JCM.02954-13 
Lif Holgerson P., Esberg A., Sjödin A., West C. E., Johansson I. (2020) A longitudinal 
study of the development of the saliva microbiome in infants 2 days to 5 years 
compared to the microbiome in adolescents. Scientific Reports 10 (1):9629. 
doi:10.1038/s41598-020-66658-7 
Lozupone C., Knight R. (2005) UniFrac: a new phylogenetic method for comparing microbial 
communities. Appl Environ Microbiol 71 (12):8228-8235. 
doi:10.1128/aem.71.12.8228-8235.2005 
Lozupone C., Lladser M. E., Knights D., Stombaugh J., Knight R. (2011) UniFrac: an 
effective distance metric for microbial community comparison. The ISME Journal 5 
(2):169-172. doi:10.1038/ismej.2010.133 
Lu M., Xuan S., Wang Z. (2019) Oral microbiota: A new view of body health. Food Science 
and Human Wellness 8 (1):8-15. doi:https://doi.org/10.1016/j.fshw.2018.12.001 
P a g e  | 122 
 
 
Luan S., Zhang S., Zhong H., Zhang Y., Wei X., Lin R., Li C., Zeng P., Wang X., Li W., 
Gao H. (2019) Salivary microbial analysis of Chinese patients with immunoglobulin A 
nephropathy. Mol Med Rep 20 (3):2219-2226. doi:10.3892/mmr.2019.10480 
Macpherson A. J., Harris N. L. (2004) Interactions between commensal intestinal bacteria 
and the immune system. Nat Rev Immunol 4 (6):478-485. doi:10.1038/nri1373 
Markowitz G. (2017) Glomerular disease: Updated Oxford Classification of IgA nephropathy: 
a new MEST-C score. Nat Rev Nephrol 13 (7):385-386. doi:10.1038/nrneph.2017.67 
Marsh P. D. (2018) In Sickness and in Health-What Does the Oral Microbiome Mean to Us? 
An Ecological Perspective. Adv Dent Res 29 (1):60-65. 
doi:10.1177/0022034517735295 
Martin J., Sykes S., Young S., Kota K., Sanka R., Sheth N., Orvis J., Sodergren E., Wang 
Z., Weinstock G. M., Mitreva M. (2012) Optimizing Read Mapping to Reference 
Genomes to Determine Composition and Species Prevalence in Microbial 
Communities. PLOS ONE 7 (6):e36427. doi:10.1371/journal.pone.0036427 
Masakane I., Taniguchi M., Nakai S., Tsuchida K., Wada A., Ogata S., Hasegawa T., 
Hamano T., Hanafusa N., Hoshino J., Goto S., Yamamoto K., Minakuchi J., 
Nakamoto H., on behalf of Japanese Society for Dialysis Therapy Renal Data 
Registry C. (2018) Annual Dialysis Data Report 2016, JSDT Renal Data Registry. 
Renal Replacement Therapy 4 (1):45. doi:10.1186/s41100-018-0183-6 
Matsumoto K., Ikeda Y., Yamaguchi S., Sanematsu M., Fukuda M., Takashima T., Kishi 
T., Miyazono M., Uchiumi S., Yoshizaki M., Nonaka Y., Matsumoto R., Kanaya A., 
Fukunari K., Ikeda Y. (2018) Long-term outcomes of tonsillectomy for IgA 
nephropathy patients: A retrospective cohort study, two-centre analysis with the 
inverse probability therapy weighting method. Nephrology 23 (9):846-854. 
doi:https://doi.org/10.1111/nep.13108 
P a g e  | 123 
 
 
Matsuo S., Kawamura T., Joh K., Utsunomiya Y., Okonogi H., Miyazaki Y., Koike K., 
Yokoo T., Matsushima M., Komura H., Ogura M., Horikoshi T., Suzuki Y., Furusu 
A., Kimura K., Yasuda T., Shirai S., Endo M., Hattori M., Akioka Y., Hirano K., 
Katafuchi R., Hisano S., Shimizu A., Hashiguchi A., Furukawa T., Tomino Y. 
(2011) Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. 
Nihon Jinzo Gakkai Shi 53 (2):123-135 
Matsuzaki K., Suzuki Y., Nakata J., Sakamoto N., Horikoshi S., Kawamura T., Matsuo 
S., Tomino Y. (2013) Nationwide survey on current treatments for IgA nephropathy in 
Japan. Clinical and Experimental Nephrology 17 (6):827-833. doi:10.1007/s10157-
013-0779-7 
MayoClinic (2019) IgA nephropathy (Berger's disease). Mayo Foundation for Medical 
Education and Research (MFMER). https://www.mayoclinic.org/diseases-
conditions/iga-nephropathy/symptoms-causes/syc-20352268. Accessed July 6 2021 
McCarthy D. D., Kujawa J., Wilson C., Papandile A., Poreci U., Porfilio E. A., Ward L., 
Lawson M. A., Macpherson A. J., McCoy K. D., Pei Y., Novak L., Lee J. Y., Julian 
B. A., Novak J., Ranger A., Gommerman J. L., Browning J. L. (2011) Mice 
overexpressing BAFF develop a commensal flora-dependent, IgA-associated 
nephropathy. J Clin Invest 121 (10):3991-4002. doi:10.1172/JCI45563 
McGuire B. M., Julian B. A., Bynon J. S., Jr., Cook W. J., King S. J., Curtis J. J., Accortt 
N. A., Eckhoff D. E. (2006) Brief communication: Glomerulonephritis in patients with 
hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 144 (10):735-
741. doi:10.7326/0003-4819-144-10-200605160-00007 
Meng H., Ohtake H., Ishida A., Ohta N., Kakehata S., Yamakawa M. (2012) IgA production 
and tonsillar focal infection in IgA nephropathy. J Clin Exp Hematop 52 (3):161-170. 
doi:10.3960/jslrt.52.161 
P a g e  | 124 
 
 
Minty M., Loubieres P., Canceill T., Azalbert V., Burcelin R., Terce F., Blasco-Baque V. 
(2020) Gender-associated differences in oral microbiota and salivary biochemical 
parameters in response to feeding. J Physiol Biochem. doi:10.1007/s13105-020-
00757-x 
Morita H., Kuwahara T., Ohshima K., Sasamoto H., Itoh K., Hattori M., Hayashi T., 
Takami H. (2007) An Improved DNA Isolation Method for Metagenomic Analysis of 
the Microbial Flora of the Human Intestine. Microbes and Environments 22 (3):214-
222. doi:10.1264/jsme2.22.214 
Moriyama T. (2019) Clinical and histological features and therapeutic strategies for IgA 
nephropathy. Clin Exp Nephrol 23 (9):1089-1099. doi:10.1007/s10157-019-01735-4 
Moriyama T., Karasawa K., Miyabe Y., Akiyama K., Iwabuchi Y., Ogura S., Takabe T., 
Sugiura N., Seki M., Hanafusa N., Uchida K., Nitta K. (2020) Long-Term Beneficial 
Effects of Tonsillectomy on Patients with Immunoglobulin A Nephropathy. Kidney360 
1 (11):1270-1283. doi:10.34067/kid.0003932020 
Moriyama T., Suzuki K., Sugiura H., Itabashi M., Tsukada M., Takei T., Koike M., Uchida 
K., Horita S., Taneda S., Honda K., Nitta K. (2010) Frequency of renal disease in 
Japan: an analysis of 2,404 renal biopsies at a single center. Nephron Clin Pract 115 
(3):c227-236. doi:10.1159/000313040 
Moriyama T., Tanaka K., Iwasaki C., Oshima Y., Ochi A., Kataoka H., Itabashi M., Takei 
T., Uchida K., Nitta K. (2014) Prognosis in IgA Nephropathy: 30-Year Analysis of 
1,012 Patients at a Single Center in Japan. PLOS ONE 9 (3):e91756. 
doi:10.1371/journal.pone.0091756 
Moutsopoulos N. M., Konkel J. E. (2018) Tissue-Specific Immunity at the Oral Mucosal 
Barrier. Trends in Immunology 39 (4):276-287. doi:10.1016/j.it.2017.08.005 
P a g e  | 125 
 
 
Nagasawa Y., Iio K., Fukuda S., Date Y., Iwatani H., Yamamoto R., Horii A., Inohara H., 
Imai E., Nakanishi T., Ohno H., Rakugi H., Isaka Y. (2014) Periodontal disease 
bacteria specific to tonsil in IgA nephropathy patients predicts the remission by the 
treatment. PLoS One 9 (1):e81636. doi:10.1371/journal.pone.0081636 
Nakajima A., Vogelzang A., Maruya M., Miyajima M., Murata M., Son A., Kuwahara T., 
Tsuruyama T., Yamada S., Matsuura M., Nakase H., Peterson D. A., Fagarasan 
S., Suzuki K. (2018) IgA regulates the composition and metabolic function of gut 
microbiota by promoting symbiosis between bacteria. Journal of Experimental 
Medicine 215 (8):2019-2034. doi:10.1084/jem.20180427 
Nasidze I., Li J., Quinque D., Tang K., Stoneking M. (2009) Global diversity in the human 
salivary microbiome. Genome Res 19 (4):636-643. doi:10.1101/gr.084616.108 
Nihei H., Sakai K., Shishido S., Sibuya K., Edamatsu H., Aikawa A. (2017) Efficacy of 
tonsillectomy for the treatment of immunoglobulin A nephropathy recurrence after 
kidney transplantation. Renal Replacement Therapy 3 (1). doi:10.1186/s41100-016-
0090-7 
Norskov-Lauritsen N. (2014) Classification, identification, and clinical significance of 
Haemophilus and Aggregatibacter species with host specificity for humans. Clin 
Microbiol Rev 27 (2):214-240. doi:10.1128/CMR.00103-13 
Novak J., Julian B. A., Mestecky J., Renfrow M. B. (2012) Glycosylation of IgA1 and 
pathogenesis of IgA nephropathy. Semin Immunopathol 34 (3):365-382. 
doi:10.1007/s00281-012-0306-z 
Nunes T., Fiorino G., Danese S., Sans M. (2011) Familial aggregation in inflammatory 
bowel disease: is it genes or environment? World J Gastroenterol 17 (22):2715-2722. 
doi:10.3748/wjg.v17.i22.2715 
P a g e  | 126 
 
 
Obrișcă B., Ștefan G., Gherghiceanu M., Mandache E., Ismail G., Stancu S., Boitan B., 
Ion O., Mircescu G. (2019) "Associated" or "Secondary" IgA nephropathy? An 
outcome analysis. PLoS One 14 (8):e0221014. doi:10.1371/journal.pone.0221014 
Pabst O., Cerovic V., Hornef M. (2016) Secretory IgA in the Coordination of Establishment 
and Maintenance of the Microbiota. Trends Immunol 37 (5):287-296. 
doi:10.1016/j.it.2016.03.002 
Park J. I., Kim T. Y., Oh B., Cho H., Kim J. E., Yoo S. H., Lee J. P., Kim Y. S., Chun J., 
Kim B. S., Lee H. (2020) Comparative analysis of the tonsillar microbiota in IgA 
nephropathy and other glomerular diseases. Sci Rep 10 (1):16206. 
doi:10.1038/s41598-020-73035-x 
Piccolo M., De Angelis M., Lauriero G., Montemurno E., Di Cagno R., Gesualdo L., 
Gobbetti M. (2015) Salivary Microbiota Associated with Immunoglobulin A 
Nephropathy. Microb Ecol 70 (2):557-565. doi:10.1007/s00248-015-0592-9 
Pontier P. J., Patel T. G. (1994) Racial differences in the prevalence and presentation of 
glomerular disease in adults. Clin Nephrol 42 (2):79-84 
Pozzi C., Andrulli S., Del Vecchio L., Melis P., Fogazzi G. B., Altieri P., Ponticelli C., 
Locatelli F. (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results 
of a randomized, controlled trial. J Am Soc Nephrol 15 (1):157-163. 
doi:10.1097/01.asn.0000103869.08096.4f 
Pozzi C., Bolasco P. G., Fogazzi G. B., Andrulli S., Altieri P., Ponticelli C., Locatelli F. 
(1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353 
(9156):883-887. doi:10.1016/s0140-6736(98)03563-6 
Raju S. C., Lagström S., Ellonen P., de Vos W. M., Eriksson J. G., Weiderpass E., 
Rounge T. B. (2019) Gender-Specific Associations Between Saliva Microbiota and 
Body Size. Frontiers in Microbiology 10 (767). doi:10.3389/fmicb.2019.00767 
P a g e  | 127 
 
 
Rauen T., Fitzner C., Eitner F., Sommerer C., Zeier M., Otte B., Panzer U., Peters H., 
Benck U., Mertens P. R., Kuhlmann U., Witzke O., Gross O., Vielhauer V., Mann 
J. F. E., Hilgers R.-D., Floege J. (2018) Effects of Two Immunosuppressive 
Treatment Protocols for IgA Nephropathy. Journal of the American Society of 
Nephrology 29 (1):317-325. doi:10.1681/asn.2017060713 
Rehnberg J., Symreng A., Ludvigsson J. F., Emilsson L. (2021) Inflammatory Bowel 
Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression 
of ESKD: A Swedish Population-Based Cohort Study. J Am Soc Nephrol 32 (2):411-
423. doi:10.1681/asn.2020060848 
Rodrigues J. C., Haas M., Reich H. N. (2017) IgA Nephropathy. Clin J Am Soc Nephrol 12 
(4):677-686. doi:10.2215/cjn.07420716 
Rosier B. T., Marsh P. D., Mira A. (2018) Resilience of the Oral Microbiota in Health: 
Mechanisms That Prevent Dysbiosis. J Dent Res 97 (4):371-380. 
doi:10.1177/0022034517742139 
Russo D., Pisani A., Balletta M. M., De Nicola L., Savino F. A., Andreucci M., Minutolo 
R. (1999) Additive antiproteinuric effect of converting enzyme inhibitor and losartan in 
normotensive patients with IgA nephropathy. Am J Kidney Dis 33 (5):851-856. 
doi:10.1016/s0272-6386(99)70416-6 
Saha M. K., Julian B. A., Novak J., Rizk D. V. (2018) Secondary IgA nephropathy. Kidney 
Int 94 (4):674-681. doi:10.1016/j.kint.2018.02.030 
Said H. S., Suda W., Nakagome S., Chinen H., Oshima K., Kim S., Kimura R., Iraha A., 
Ishida H., Fujita J., Mano S., Morita H., Dohi T., Oota H., Hattori M. (2014) 
Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with 
oral immunological biomarkers. DNA Res 21 (1):15-25. doi:10.1093/dnares/dst037 
P a g e  | 128 
 
 
Saito A., Komatsuda A., Kaga H., Sato R., Togashi M., Okuyama S., Wakui H., Takahashi 
N. (2016) Different Expression Patterns of Toll-Like Receptor mRNAs in Blood 
Mononuclear Cells of IgA Nephropathy and IgA Vasculitis with Nephritis. The Tohoku 
Journal of Experimental Medicine 240 (3):199-208. doi:10.1620/tjem.240.199 
Sallustio F., Curci C., Di Leo V., Gallone A., Pesce F., Gesualdo L. (2019) A New Vision 
of IgA Nephropathy: The Missing Link. Int J Mol Sci 21 (1). doi:10.3390/ijms21010189 
Schena F. P. (1990) A retrospective analysis of the natural history of primary IgA 
nephropathy worldwide. Am J Med 89 (2):209-215. doi:10.1016/0002-9343(90)90300-
3 
Schena F. P., Nistor I. (2018) Epidemiology of IgA Nephropathy: A Global Perspective. 
Semin Nephrol 38 (5):435-442. doi:10.1016/j.semnephrol.2018.05.013 
Schmalz G., Kauffels A., Kollmar O., Slotta J. E., Vasko R., Müller G. A., Haak R., Ziebolz 
D. (2016) Oral behavior, dental, periodontal and microbiological findings in patients 
undergoing hemodialysis and after kidney transplantation. BMC Oral Health 16 (1):72. 
doi:10.1186/s12903-016-0274-0 
Schmitt R., Carlsson F., Mörgelin M., Tati R., Lindahl G., Karpman D. (2010) Tissue 
deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-
Schonlein purpura. Am J Pathol 176 (2):608-618. doi:10.2353/ajpath.2010.090428 
Schuurhuis J. M., Stokman M. A., Witjes M. J. H., Langendijk J. A., van Winkelhoff A. 
J., Vissink A., Spijkervet F. K. L. (2016) Head and neck intensity modulated radiation 
therapy leads to an increase of opportunistic oral pathogens. Oral Oncology 58:32-40. 
doi:https://doi.org/10.1016/j.oraloncology.2016.05.005 
Segata N., Izard J., Waldron L., Gevers D., Miropolsky L., Garrett W. S., Huttenhower C. 
(2011) Metagenomic biomarker discovery and explanation. Genome Biol 12 (6):R60. 
doi:10.1186/gb-2011-12-6-r60 
P a g e  | 129 
 
 
Selvaskandan H., Cheung C. K., Muto M., Barratt J. (2019) New strategies and 
perspectives on managing IgA nephropathy. Clin Exp Nephrol 23 (5):577-588. 
doi:10.1007/s10157-019-01700-1 
Shaw L., Ribeiro A. L. R., Levine A. P., Pontikos N., Balloux F., Segal A. W., Roberts A. 
P., Smith A. M. (2017) The Human Salivary Microbiome Is Shaped by Shared 
Environment Rather than Genetics: Evidence from a Large Family of Closely Related 
Individuals. mBio 8 (5):e01237-01217. doi:10.1128/mBio.01237-17 
Sibley C. D., Grinwis M. E., Field T. R., Eshaghurshan C. S., Faria M. M., Dowd S. E., 
Parkins M. D., Rabin H. R., Surette M. G. (2011) Culture Enriched Molecular Profiling 
of the Cystic Fibrosis Airway Microbiome. PLOS ONE 6 (7):e22702. 
doi:10.1371/journal.pone.0022702 
Singleton D. R., Furlong M. A., Rathbun S. L., Whitman W. B. (2001) Quantitative 
Comparisons of 16S rRNA Gene Sequence Libraries from Environmental Samples. 
Applied and Environmental Microbiology 67 (9):4374-4376. 
doi:10.1128/aem.67.9.4374-4376.2001 
Stahringer S. S., Clemente J. C., Corley R. P., Hewitt J., Knights D., Walters W. A., 
Knight R., Krauter K. S. (2012) Nurture trumps nature in a longitudinal survey of 
salivary bacterial communities in twins from early adolescence to early adulthood. 
Genome Res 22 (11):2146-2152. doi:10.1101/gr.140608.112 
Stangou M., Alexopoulos E., Papagianni A., Pantzaki A., Bantis C., Dovas S., 
Economidou D., Leontsini M., Memmos D. (2009) Urinary levels of epidermal 
growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as 
predictor markers of renal function outcome in immunoglobulin A nephropathy. 
Nephrology (Carlton) 14 (6):613-620. doi:10.1111/j.1440-1797.2008.01051.x 
P a g e  | 130 
 
 
Sukcharoen K., Sharp S. A., Thomas N. J., Kimmitt R. A., Harrison J., Bingham C., 
Mozere M., Weedon M. N., Tyrrell J., Barratt J., Gale D. P., Oram R. A. (2020) IgA 
Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in 
UK Biobank. Kidney International Reports 5 (10):1643-1650. 
doi:10.1016/j.ekir.2020.07.012 
Suzuki H. (2019) Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin 
Exp Nephrol 23 (1):26-31. doi:10.1007/s10157-018-1582-2 
Suzuki H., Kiryluk K., Novak J., Moldoveanu Z., Herr A. B., Renfrow M. B., Wyatt R. J., 
Scolari F., Mestecky J., Gharavi A. G., Julian B. A. (2011) The Pathophysiology of 
IgA Nephropathy. Journal of the American Society of Nephrology 22 (10):1795-1803. 
doi:10.1681/asn.2011050464 
Suzuki K., Honda K., Tanabe K., Toma H., Nihei H., Yamaguchi Y. (2003) Incidence of 
latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63 
(6):2286-2294. doi:10.1046/j.1523-1755.63.6s.2.x 
Suzuki T., Miyazaki Y., Shimizu A., Ito Y., Okonogi H., Ogura M., Utsunomiya Y., 
Kawamura T., Hosoya T. (2009) Sodium-sensitive variability of the antiproteinuric 
efficacy of RAS inhibitors in outpatients with IgA nephropathy. Clin Nephrol 72 (4):274-
285. doi:10.5414/cnp72274 
Szeto C. C., Lai F. M., To K. F., Wong T. Y., Chow K. M., Choi P. C., Lui S. F., Li P. K. 
(2001) The natural history of immunoglobulin a nephropathy among patients with 
hematuria and minimal proteinuria. Am J Med 110 (6):434-437. doi:10.1016/s0002-
9343(01)00659-3 
Szeto C. C., Li P. K. (2014) MicroRNAs in IgA nephropathy. Nat Rev Nephrol 10 (5):249-
256. doi:10.1038/nrneph.2014.50 
P a g e  | 131 
 
 
Takayasu L., Suda W., Takanashi K., Iioka E., Kurokawa R., Shindo C., Hattori Y., 
Yamashita N., Nishijima S., Oshima K., Hattori M. (2017) Circadian oscillations of 
microbial and functional composition in the human salivary microbiome. DNA 
research : an international journal for rapid publication of reports on genes and 
genomes 24 (3):261-270. doi:10.1093/dnares/dsx001 
Takeshita T., Kageyama S., Furuta M., Tsuboi H., Takeuchi K., Shibata Y., Shimazaki 
Y., Akifusa S., Ninomiya T., Kiyohara Y., Yamashita Y. (2016) Bacterial diversity in 
saliva and oral health-related conditions: the Hisayama Study. Sci Rep 6:22164. 
doi:10.1038/srep22164 
Tashakkorinia N., Muco E., Tudor M. E. (2021) Berger Disease. In:  StatPearls. StatPearls 
Publishing Copyright © 2021, StatPearls Publishing LLC., Treasure Island (FL),  
Tian N., Faller L., Leffler D. A., Kelly C. P., Hansen J., Bosch J. A., Wei G., Paster B. J., 
Schuppan D., Helmerhorst E. J., Dudley E. G. (2017) Salivary Gluten Degradation 
and Oral Microbial Profiles in Healthy Individuals and Celiac Disease Patients. Applied 
and Environmental Microbiology 83 (6):e03330-03316. doi:doi:10.1128/AEM.03330-
16 
Tomino Y. (2016) Diagnosis and treatment of patients with IgA nephropathy in Japan. Kidney 
Res Clin Pract 35 (4):197-203. doi:10.1016/j.krcp.2016.09.001 
Torres P. J., Fletcher E. M., Gibbons S. M., Bouvet M., Doran K. S., Kelley S. T. (2015) 
Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ 
3:e1373. doi:10.7717/peerj.1373 
Trimarchi H. M., Iotti A., Iotti R., Freixas E. A., Peters R. (2001) Immunoglobulin A 
nephropathy and ulcerative colitis. A focus on their pathogenesis. Am J Nephrol 21 
(5):400-405. doi:10.1159/000046283 
P a g e  | 132 
 
 
Tsuda A., Suda W., Morita H., Takanashi K., Takagi A., Koga Y., Hattori M. (2015) 
Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal 
Tract. Clin Transl Gastroenterol 6 (6):e89. doi:10.1038/ctg.2015.20 
Turnbaugh P. J., Ley R. E., Hamady M., Fraser-Liggett C. M., Knight R., Gordon J. I. 
(2007) The human microbiome project. Nature 449 (7164):804-810. 
doi:10.1038/nature06244 
Varis J., Rantala I., Pasternack A., Oksa H., Jäntti M., Paunu E. S., Pirhonen R. (1993) 
Immunoglobulin and complement deposition in glomeruli of 756 subjects who had 
committed suicide or met with a violent death. J Clin Pathol 46 (7):607-610. 
doi:10.1136/jcp.46.7.607 
Wade W. G. (2013) Characterisation of the human oral microbiome. Journal of Oral 
Biosciences 55 (3):143-148. doi:10.1016/j.job.2013.06.001 
Walters W. A., Xu Z., Knight R. (2014) Meta-analyses of human gut microbes associated 
with obesity and IBD. FEBS Letters 588 (22):4223-4233. 
doi:10.1016/j.febslet.2014.09.039 
Wang T., Ye F., Meng H., Zhang L., Jin X. (2012) Comparison of clinicopathological features 
between children and adults with IgA nephropathy. Pediatric Nephrology 27 (8):1293-
1300. doi:10.1007/s00467-012-2139-3 
Watanabe H., Goto S., Mori H., Higashi K., Hosomichi K., Aizawa N., Takahashi N., 
Tsuchida M., Suzuki Y., Yamada T., Horii A., Inoue I., Kurokawa K., Narita I. (2017) 
Comprehensive microbiome analysis of tonsillar crypts in IgA nephropathy. Nephrol 
Dial Transplant 32 (12):2072-2079. doi:10.1093/ndt/gfw343 
Wilharm A., Tabib Y., Nassar M., Reinhardt A., Mizraji G., Sandrock I., Heyman O., 
Barros-Martins J., Aizenbud Y., Khalaileh A., Eli-Berchoer L., Elinav E., Wilensky 
A., Förster R., Bercovier H., Prinz I., Hovav A.-H. (2019) Mutual interplay between 
P a g e  | 133 
 
 
IL-17–producing γδT cells and microbiota orchestrates oral mucosal homeostasis. 
Proceedings of the National Academy of Sciences 116 (7):2652-2661. 
doi:10.1073/pnas.1818812116 
Wyatt R. J., Julian B. A. (2013) IgA nephropathy. N Engl J Med 368 (25):2402-2414. 
doi:10.1056/NEJMra1206793 
Wyatt R. J., Kritchevsky S. B., Woodford S. Y., Miller P. M., Roy S., Holland N. H., 
Jackson E., Bishof N. A. (1995) IgA nephropathy: Long-term prognosis for pediatric 
patients. The Journal of Pediatrics 127 (6):913-919. 
doi:https://doi.org/10.1016/S0022-3476(95)70027-7 
Xie Y., Nishi S., Ueno M., Imai N., Sakatsume M., Narita I., Suzuki Y., Akazawa K., 
Shimada H., Arakawa M., Gejyo F. (2003a) The efficacy of tonsillectomy on long-
term renal survival in patients with IgA nephropathy. Kidney International 63 (5):1861-
1867. doi:10.1046/j.1523-1755.2003.00935.x 
Xie Y., Nishi S., Ueno M., Imai N., Sakatsume M., Narita I., Suzuki Y., Akazawa K., 
Shimada H., Arakawa M., Gejyo F. (2003b) The efficacy of tonsillectomy on long-
term renal survival in patients with IgA nephropathy. Kidney Int 63 (5):1861-1867. 
doi:10.1046/j.1523-1755.2003.00935.x 
Xun Z., Zhang Q., Xu T., Chen N., Chen F. (2018) Dysbiosis and Ecotypes of the Salivary 
Microbiome Associated With Inflammatory Bowel Diseases and the Assistance in 
Diagnosis of Diseases Using Oral Bacterial Profiles. Front Microbiol 9:1136. 
doi:10.3389/fmicb.2018.01136 
Yamabe H., Ozawa K., Fukushi K., Ohsawa H., Chiba N., Onodera K. (1987) Elevated 
Salivary IgA in Patients with IgA Nephropathy. Nephron 45 (2):176-176. 
doi:10.1159/000184111 
P a g e  | 134 
 
 
Yamagata K., Iseki K., Nitta K., Imai H., Iino Y., Matsuo S., Makino H., Hishida A. (2008) 
Chronic kidney disease perspectives in Japan and the importance of urinalysis 
screening. Clinical and Experimental Nephrology 12 (1):1-8. doi:10.1007/s10157-007-
0010-9 
Yamamoto R., Nagasawa Y., Shoji T., Iwatani H., Hamano T., Kawada N., Inoue K., 
Uehata T., Kaneko T., Okada N., Moriyama T., Horio M., Yamauchi A., 
Tsubakihara Y., Imai E., Rakugi H., Isaka Y. (2010) Cigarette smoking and 
progression of IgA nephropathy. American journal of kidney diseases : the official 
journal of the National Kidney Foundation 56 (2):313-324. 
doi:10.1053/j.ajkd.2010.02.351 
Yang Y., Ohta K., Shimizu M., Nakai A., Kasahara Y., Yachie A., Koizumi S. (2005) 
Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus 
angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin 
Nephrol 64 (1):35-40. doi:10.5414/cnp64035 
Yeo S. C., Cheung C. K., Barratt J. (2018a) New insights into the pathogenesis of IgA 
nephropathy. Pediatr Nephrol 33 (5):763-777. doi:10.1007/s00467-017-3699-z 
Yeo S. C., Goh S. M., Barratt J. (2019) Is immunoglobulin A nephropathy different in different 
ethnic populations? Nephrology (Carlton) 24 (9):885-895. doi:10.1111/nep.13592 
Yeo S. C., Liu X., Liew A. (2018b) Complement factor H gene polymorphism rs6677604 and 
the risk, severity and progression of IgA nephropathy: A systematic review and meta-
analysis. Nephrology (Carlton) 23 (12):1096-1106. doi:10.1111/nep.13210 
Yokoyama H., Sugiyama H., Sato H., Taguchi T., Nagata M., Matsuo S., Makino H., 
Watanabe T., Saito T., Kiyohara Y., Nishi S., Iida H., Morozumi K., Fukatsu A., 
Sasaki T., Tsuruya K., Kohda Y., Higuchi M., Kiyomoto H., Goto S., Hattori M., 
Hataya H., Kagami S., Yoshikawa N., Fukasawa Y., Ueda Y., Kitamura H., Shimizu 
P a g e  | 135 
 
 
A., Oka K., Nakagawa N., Ito T., Uchida S., Furuichi K., Nakaya I., Umemura S., 
Hiromura K., Yoshimura M., Hirawa N., Shigematsu T., Fukagawa M., Hiramatsu 
M., Terada Y., Uemura O., Kawata T., Matsunaga A., Kuroki A., Mori Y., Mitsuiki 
K., Yoshida H. (2012) Renal disease in the elderly and the very elderly Japanese: 
analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 16 (6):903-
920. doi:10.1007/s10157-012-0673-8 
Yuzawa Y., Urushihara M., Kagami S., Katafuchi R., Kitamura H., Komatsu H., Goto M., 
Kondo S., Sato M., Takahashi K., Takahara M., Tomita M., Harabuchi Y., Fujigaki 
Y., Yasuda T., Yasuda Y., Yamamoto R., Kimura K., Matsuo S. (2015) Evidence-
Based Clinical Practice Guidelines for IgA Nephropathy 2014 Japanese Society of 
Nephrology,  
Zaura E., Brandt B. W., Mattos M. J. T. d., Buijs M. J., Caspers M. P. M., Rashid M.-U., 
Weintraub A., Nord C. E., Savell A., Hu Y., Coates A. R., Hubank M., Spratt D. A., 
Wilson M., Keijser B. J. F., Crielaard W., Belkum A. v. (2015) Same Exposure but 
Two Radically Different Responses to Antibiotics: Resilience of the Salivary 
Microbiome versus Long-Term Microbial Shifts in Feces. mBio 6 (6):e01693-01615. 
doi:doi:10.1128/mBio.01693-15 
Zenobia C., Herpoldt K.-L., Freire M. (2021) Is the oral microbiome a source to enhance 
mucosal immunity against infectious diseases? npj Vaccines 6 (1):80. 
doi:10.1038/s41541-021-00341-4 
Zhang X., Zhang D., Jia H., Feng Q., Wang D., Liang D., Wu X., Li J., Tang L., Li Y., Lan 
Z., Chen B., Li Y., Zhong H., Xie H., Jie Z., Chen W., Tang S., Xu X., Wang X., Cai 
X., Liu S., Xia Y., Li J., Qiao X., Al-Aama J. Y., Chen H., Wang L., Wu Q. J., Zhang 
F., Zheng W., Li Y., Zhang M., Luo G., Xue W., Xiao L., Li J., Chen W., Xu X., Yin 
Y., Yang H., Wang J., Kristiansen K., Liu L., Li T., Huang Q., Li Y., Wang J. (2015) 
P a g e  | 136 
 
 
The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly 
normalized after treatment. Nat Med 21 (8):895-905. doi:10.1038/nm.3914 
 
  





1 General Introduction ..................................................................................................... 1 
1.1 Overview of IgA Nephropathy .................................................................................. 2 
1.2 Overview of human salivary microbiome ............................................................... 20 
1.3 Salivary microbiome and systemic diseases ......................................................... 23 
1.4 Motivation, objectives and hypotheses .................................................................. 24 
2 Comparison of Salivary Microbiome of Japanese IgA Nephropathy Patients and 
Healthy Controls ................................................................................................................. 28 
Abstract .............................................................................................................................. 29 
2.1 Introduction ............................................................................................................ 30 
2.2 Methods ................................................................................................................. 33 
2.3 Results .................................................................................................................. 38 
2.4 Discussion ............................................................................................................. 53 
3 Comparison of Salivary Microbiome of Japanese IgA Nephropathy Patients versus 
Chronic Tonsillitis Patients, Ulcerative Colitis Patients and Healthy Controls ..................... 61 
Abstract ........................................................................................................................... 62 
3.1 Introduction ............................................................................................................ 64 
3.2 Methods ................................................................................................................. 67 
3.3 Results .................................................................................................................. 73 
3.4 Discussion ............................................................................................................. 86 
4 Summary ...................................................................................................................... 95 
ACKNOWLEDGEMENT ....................................................................................................100 
References ........................................................................................................................104 
 
 
